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ABSTRACT
The nucleus contains a variety of morphologically distinct substructures called nuclear 
bodies, which include the promyelocytic leukemia oncogenic domains (PODs) also 
known as PML-NDIO, PODs are macromolecular multiprotein complexes that are 
present in all cultured cell lines as well as in vivo. The major component of PODs is the 
PML protein, which was originally identified as the fusion partner of retinoic acid 
receptor alpha (RARa) in the chromosomal translocation t(15;17) in patients with acute 
promyelocytic leukaemia (APL) (Kakizuka et a l, 1991; Lavau et a l, 1991; Goddard et 
a l, 1992).
The minor capsid proteins L2 of BPV-1, HPV-11 and HPV-33 have been shown to 
localise to PODs in the absence of other viral components (Day et a l, 1998) and co­
expression of BPV-1 L2 with BPV-1 E2TA recruits E2 to PODs (Lambert et a l, 2000). 
The presence of L2 in PODs also appears to be associated with the recmitment of the 
major capsid protein LI. The association of PODs with E2 is dependent on L2 but is 
independent of LI The effect of HPV-16 L2 on the functions of HPV-16 E2 and the 
implications of this interaction to the virus life cycle are discussed.
This study showed that HPV-16 L2 has a selective effect on the functions of HPV-16 E2. 
L2 was able to down regulate the transcription transactivation function of E2 in HaCaT, 
U20S and C33a cells. No effect of L2 on E2 mediated DNA replication was observed. 
L2 was also able to reduce the level of E2 expression in HaCaT and U20S cells but not in 
C33a cells. The effect of L2 on E2 expression in HaCaT cells was further investigated by
XXI
examining E2 mRNA levels and protein half-life. No difference in E2 mRNA or protein 
half-life was detected in the presence of L2.
A series of L2 amino and carboxyl terminal deletion mutants were constructed as GST 
fusion proteins and GST binding assays were performed which showed that the amino 
terminus of L2, even just the first 50 amino acids, was capable of binding with E2. GFP 
fusion forms of each L2 deletion mutant were also constructed and cellular localisation 
detected by immunofluorescence. GFP-L2 and all C-terminal deletion mutants localised 
and were retained in the nucleus while the N-terminal deletion mutants localised to both 
the nucleus and the cytoplasm.
Investigation of the effect of L2 deletion mutants on the transcription transactivation 
function of E2 showed that mutants expressing 1-200 and 150-473 amino acids of L2 do 
not down regulate function in HaCaT and C33a cells. In HaCaT cells, mutants expressing 
amino acids 1-50 and 1-100 also did not inhibit E2 function indicating that binding to E2 
did not correlate with down-regulation of transcription transactivation. Furthermore, only 
full-length L2 was able to reduce the level of E2 expression.
XXII
Chapter One_________________  Introduction
CHAPTER 1: INTRODUCTION
1.1. Viruses and Cancer
Viruses and cancer have a long history in animal studies. Leukemia in chickens was 
experimentally transmitted by an agent that passed through a filter by Danish researchers 
in 1908. Soon aftemards Peyton Rous, in New York, showed the same for chicken 
sarcoma. In 1936, Bittner showed that predisposition to breast cancer in C3H mice was 
passed through the milk to their offspring; this milk factor was later shown to be 
mammary tumour viras (Lyons and Moore., 1962; Lyons and Moore., 1965) . In 1964, 
three scientists Epstein, Achong and Barr working on Burkitfs lymphoma cells 
discovered the first human tumour viras, today known as the Epstein-Bara viras (Epstein 
et al., 1964). Since then the link between viral infections and human cancer has been well 
established. Today, viral infections have been associated with 10 to 15% of all cancers 
worldwide. In most cases, cancer is an infrequent consequence of infection by the 
causative virus (usually as a by-product of viral replication) and often occurs years after 
the initial infection has taken place. As tumour progression is regarded as a multistep 
process, virases may be an essential step but alone might not cause cancer. Certain 
factors must be considered for a virus to be implicated in tumor progression such as the 
introduction of a viral oncogene into a cell or insertion of viral genome into the genome 
of the host cell, thus disrapting the noraial regulation of cell division. Also the viras 
should usually persists during the disease, prevent reinfection and be located
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appropriately to account for disease. Today a variety of DNA and RNA virases have 
now been associated with various malignancies in both humans and animals.
1.1.1. Human T-cell Leukemia virus Type 1 (HTLV-1)
Shortly after its discoveiy in 1980, HTLV-1 was found to be the etiologic agent of both
adult T cell leukamia (ATL) and HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP), a neurologic disease characterised by demyelinating lesions in 
both the brain and the spinal cord. Approximately 5-10% of HTLV-1 infected individuals 
develop either ATL or HAM/TSP. Recent research has suggested that the route of 
primary viral infection may dictate the course of disease pathogenesis associated with 
HTLV-1 infection. Specifically, mucosal exposure to HTLV-1 has been associated with 
cases of ATL. ATL is an aggressive lymphoproliferative disease that develops in 
approximately 1-5% of seropositive individuals. The leukemic cells in ATL are almost 
exclusively CD4^ T cells, likely reflecting the fact that HTLV-1 displays an in vivo 
cellular tropism for this cell population within the peripheral blood. It has been 
demonstrated that 90-99% of HTLV-1 proviras segregates with CD4^ T cells within the 
peripherial blood of ATL patients infected with the viras (Richardson et a l, 1990). The 
genesis of ATL has been linked to the effects of the viral protein TAX (Franchini., 1995; 
Uchiyama., 1997). Tax is a 40-kDa phosphoprotein essential for both viral replication 
and cellular transformation. It is a transcriptional transactivator and can dramatically 
increase viral gene expression through its interaction with cellular factors and the 5' long 
terminal repeats (LTR) of the proviral genome (Marriott et al., 1989). HTLV-1 has been 
found primarily in populations in southern Japan, Brazil, the Caribbean, and regions of 
central Africa. HTLV-2 has been linked with haiiy cell leukaemia although its connection
2
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with the disease is weak because it has been identified in cells from only a few patients 
with the disease (For review) (Bannak et ciL, 2003; Uchiyama., 1997).
1.1.2. Hepatitis B virus (HBV)
HBV causes hepatitis B and plays a major role in the development of liver cancer known 
as hepatocellular carcinoma (HCC) (Brechot et a i, 2000; Buendia., 1998; Buendia., 
2000). HBV is a small-enveloped DNA viras, which replicates in paraenchymal cells of 
the liver. During acute and chi'onic infections, the liver produces empty viral envelopes 
organized in spherical or filamentous particles that cany the HBV surface antigen. In 
endemic regions, young children are usually infected at birth by their infected mothers or 
by contact during early yeai*s of life. In non-endemic regions, HBV-infected individuals 
usually develop adequate cellular and humoral immune responses, produce antibodies 
against HBV and recover. In 5-10% of patients, failure of the immune system to clear the 
virus results in a chronic HBV carrier state (Hollinger., 1996). These individuals usually 
develop persistent infections and an increased risk of liver ciiriiosis and liver cancer 
(HCC). Integration of the viral DNA and deregulation of cell growth control by 
inappropriate expression of viral transactivators have been implicated in HBV induced 
oncogenesis (Brechot., 1998).
1.1.3. Kaposi’s sarcoma-associated herpesvirus (KSHV)
KSHV is a member of the gammaherpesviras subfamily, Rhadinoviras genera. They are
double-stranded DNA virases approximately 165kbp in size. A characteristic of KSHV 
and other gammaheipesvirases is the similarity of a large number of the ORFs to known 
cellular genes suggesting that some of these genes may be pirated from the host
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cliromosome during the process of viral evolution. KSHV latently infects predominantly 
B-cells and endothelial cells. Infected cells retain the virus from one generation to the 
next and can also transform (Ganem., 1997). Strong evidence now exists to establish 
KSHV as the etiologic agent of Kaposi sarcoma (KS) (Boshoff et ciL, 1995; Chang et al., 
1994). KS is an unusual multifocal neoplasm characterised by dark puiple lesions, which 
differs from most other common tumours in that the lesions contain multiple cell types 
(polyclonal), with the dominant cell being the spindle cell derived from endothelial 
origins. In addition, the KS lesions contain numerous infiltrating inflammatory cells 
(Verma and Robertson., 2003). KS is more wide spread in patients who are 
immunocompromised such as people with AIDS. In such cases it can become detrimental 
to the patient and even fatal.
1.1.4. Epstein-Barr virus (EBV)
EBV is a member of the gammaheipesvims family that infects 94% of adult populations 
worldwide and following primaiy infection the individual remains a lifelong earner of the 
virus. The viras is generally spread to and between young children tlirough salivary 
contact. Cancer usually develops in cases of clinical illness, where primaiy infection is 
delayed until adolescence or beyond, or when an intense immunopathological reaction 
leads to the symptoms of infeetious mononucleosis (a lymphoproliferative disorder). The 
virus is found in neaiiy all Burkitt’s lymphoma tumours from patients in central Africa, 
where the disease is most common. EBV has a pronounced tropism for human B- 
lymphocytes, which are readily infected and immortalized in vitro (Kaye et al., 1999; 
Rickinson et al., 1984). By influencing B-cell suiwival mechanisms, EBV may induce 
tumours such as B Lymphoproliferative disease and Hodgkins disease. EBV contributes
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to the immortalization/transformation of infected cells through the activity of viral 
proteins that interfere with cellular pathways controlling growth and/or suiwival. These 
viral proteins act cooperatively and may induce different biological effects in different 
cellular backgrounds (Kaye etaL, 1993; Wang et ciL, 1985).
1.1.5. Viruses and Breast Cancer
The mouse mammary tumour virus (MMTV) is a B-type retro vims. MMTV causes 
mammary cancer in mice thiough a process called inseitional mutagenesis. Reseai’chers 
have long sought a human homologue of MMTV. Recent reports from a group in Sydney 
suggest a link between a new vims and a large percentage of breast cancer cases (Ford et 
ai, 2003). They found that 40% of breast cancer samples taken from Australian- 
Caucasian women had MMTV-like gene sequences although it was found in only two 
percent of noimal breast samples taken from cosmetic surgeiy. The vims was found in 
the cancerous tissue and not in the normal breast tissue from women with breast cancer. It 
may also play an important role in male breast cancer, with over 50% of male samples 
testing positive for the vims. Previous studies have also found MMTV-like gene 
sequences in 38% of breast cancer tissue from United States women (Wang et al., 1995).
Chapter One Introduction
PATHOGEN MALIGNANCY
HTLV-I Adult T-cell leukaemia/lymphoma
HTLV-II Hairy cell leukaemia
HBV Liver cancer
KSHV Kaposi’s sarcoma
EBV Lymphoproliferative disorders
EBV Nasopharyngeal carcinomas
EBV Burkitt’s lymphoma
HPV Anogenital carcinoma, cervical 
cancer, skin cancer
Table 1.1. Showing some known viral-cancer associations.
HTLV=human T-cell leukaemia/lymphoma vims, HHV= human herpes vims, EBV= Epstein- 
Barr vims, HBV= hepatitis B virus, HPV= human papillomavirus
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1.2. Papillomaviruses
Papillomavirases are nonenveloped icoshedral, double-stranded DNA vimses that belong 
to the family of Papoviridae. They are found in many species, including humans, rabbits, 
cows, and dogs (Campo., 2002). They are highly species specific and are not known to 
cross the species barriers, with the exception of Bovine papillomavimses, which can 
infect horses and induce equine sarcoid (Chambers et al., 2003). There aie over 90 
different types of Human papillomavimses (HPVs) identified based upon degree of 
relatedness of viral genome, Papillomavimses induce tumours in skin and mucosa, thus 
explaining the name of this vims group (from the Latin papilla, nipple, pustule and the 
Greek suffix oma to denote tumour). In some tumours, the vimses occur in large amounts 
(up to 10^  ^physical particles per gram tumour). Certain types of HPVs may cause warts 
or papillomas, which are benign (non cancerous) tumours that grow on hands and feet 
and or in the mouth and genital area. HPVs are divided into low-risk vimses such as 
HPV-6, HPV-11 associated with skin warts and high-risk vimses such as HPV-16, HPV- 
18 and HPV-31, which are recognised as the major cause of cervical cancer. HPVs that 
lead to the development of cancer are referred to as “cancer associated types” (Campo., 
1998).
1.2.1. Papillomavirus Genome Organisation
HPVs are DNA vimses with double-stranded circular DNA enclosed in a protein coat, the 
capsid. The protein stmctural units of the capsid are capsomeres. HPVs contain 72 
capsomers and measure 52-55 imi in diameter. The genome of HPVs can be divided into 
three regions, the early and late open reading frames separated by a long control region 
(LCR) (Fig 1.1). The LCR is a Ikb sequence containing many of the viral transcriptional
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regulatory signals as well as origin of replication (Fig 1.2). The early region contains 
those ORFs expressed primarily in non-productively infected cells expressing genes 
designated El to E7. The late region contains the ORFs for the capsid proteins LI and L2 
(Fig 1.1).
The El ORE encodes a 68-76kDa protein essential for viral DNA replication. The full- 
length El product is a phosphoiylated nuclear protein that binds to the origin of 
replication in the LCR of papillomavimses. E 1 binds to the E2 protein enhancing viral 
replication. Binding to E2 also strengthens the affinity of El for the origin of DNA 
replication. The E2 ORE encodes a 42-48kDa protein that regulates viral DNA 
transcription. BPV-1 encodes three E2 proteins, the major transcription transactivator 
(E2TA) which activates viral promoters by binding to E2 responsive elements. The 
function of the E2TA is repressed by two other E2 proteins; the E2 transcriptional 
repressor (E2TR) and E8/E2 transcriptional repressor (E8/E2TR) (Choe et al., 1989; 
Lambert et al., 1990). The E2 protein is described in further detail in section 1.2.7.
The Human Papillomavirus type 16 Genome
LCR
Figure 1.1. Schematic representation of the HPV-16 genome showing the 
early and late open reading frames. The early region contains those ORFs 
expressed primarily in non-productively infected cells expressing genes 
designated El to E7. The late region contains the ORFs for the capsid 
proteins LI and L2.
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The E4 gene product is found primarily in the cytoplasm of kératinocytes, where it is 
extremely abundant. It is expressed from spliced mRNA (EKE4) transcripts from a 
differentiation inducible promoter that lies within the E7 open reading frame. It was first 
detected in naturally occumng lesions in cells in which vegetative viral DNA replication 
is occuiTing. It persists during the late stages of infection and is modified by proteolytic 
processing and phosphorylation. The role of E4 in the viral life cycle is described in more 
detain section 1.2.3.
The E5 ORE encodes a 4.6-9.2kDa cell-transforming protein. It is one of the more poorly 
conserved ORFs among the papillomaviruses and often lacks an initiation codon. The E5 
gene product is a very small hydrophobic transforming protein that is expressed in the 
deep layers of the epithelium (Anderson et ah, 1997; Burnett et al., 1992), localising in 
the endomembrane compartments of the endoplasmic reticulum and Golgi apparatus 
(Burkhardt et al., 1989; Pennie et a l, 1993). E5 from both animal and human 
papillomavimses can transfoim mammalian cells with vai ying degrees of efficiency. The 
transforming activity of BPV-1 E5 is shared by other fibropapillomvimses; in contrast, 
E5 proteins of HPVs show only weak transforming activity. E5 cell transformation is 
brought about by the activation of several kinases, from growth factor receptors to 
cyclins-cdks. BPV-1 E5 has been shown to stimulate the transforming activity of EGF 
and CSF-1 receptors associated with the inhibition of receptor degradation and 
persistence of activated receptors on the cell surface (Martin et al., 1989). E5 interacts 
with the 16 kDa subunit of the vacuolar H^ATPase usually resulting in the inhibition of 
the acidification of the endosomes (Straight et al., 1995). Failure to acidify endosornes
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may be responsible for the inliibition of the EGF receptor degradation, thereby allowing 
increased receptor recycling to the membrane. BPV E5 also activates the platelet derived 
growth factor receptor (PDGFR) for the platelet-derived growth factor in cells stably 
transfoiTned with E5 (Petti et al., 1991).
E5 has also been implicated in viral immune evasion with recent observations that in E5 
expressing cells, the major histocompatability complex (MHC I) is not present on the cell 
surface but is retained in the Golgi apparatus. The treatment of E5-transformed cells with 
interferon which increases the synthesis of MHC I, did not prevent E5 from inhibiting 
MHC I transportation to the cell surface (Ashrafi et al., 2002; Marchetti et al., 2002). 
Preventing MHC I transport to the cell surface would have immense consequences for 
presentation of viral peptides to the immune system.
The E6 ORF encodes a 16-19kD cell transforming protein. Although small, E6 induces 
several important changes in the host cell that impact both on the normal viral life cycle 
and the process of immortalisation. The E6 protein contains four Cys-X-X-Cys motifs, 
indicating a potential for zinc binding. It may also act as a nucleic acid binding protein. 
E6 alone is not capable of immortalising primary human foreskin kératinocytes (HFK) 
but can efficiently immortalise human mammary epithelial cells (HMEC) (Kiyono et al., 
1997; Liu et al., 1999). In high-risk HPVs such as HPV-16 however, E6 and E7 proteins 
are necessary and sufficient to immortalize their host squamous epithelial cells. The E6 
proteins of high-risk HPVs have been shown to complex with p53 and to promote its 
degradation (Scheffner et al., 1990) via the ubiquitin pathway, while low risk HPV E6
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protein binds p53 less efficiently. In addition to interacting with p53, E6 may impact on 
apoptosis through p53-independent pathways. E6 can interact and inhibit Bak, a 
proapaototic protein expressed at high levels in the upper layers of differentiating 
epithelium (Thomas and Banks., 1998).
The E7 ORF encodes a I0-14kD cell-transfonning protein. E7 proteins are approximately 
100 amino acids in size and divided into domains with sequences homologous to the Ad5 
El A sequence with conserved region 1 (CRl) consisting of amino acids 1-20, CR2 
containing residues 21-39 and CR3 composed of amino acids 40-100. The protein 
contains two Cys-X-X-Cys zinc-finger DNA-binding motifs, a pRB-binding domain, a 
casein kinase II (CKII) phosphorylation site, and regions that show homology to other 
viral oncoproteins. The role of E6 and E7in cell transformation is described in section 
1.2.4.
LI and L2 late gene products are estimated to be in a molar ratio of 30 to 1. The LI ORF 
encodes the 56-60kD major capsid protein. The carboxy-terminus of the LI protein of 
HPV-16 contains two basic sequences believed to be responsible for the nuclear 
localisation of the LI protein. The minor capsid protein L2 has a molecular weight of 76- 
78kD. The N-terminal domain of the L2 protein is highly conserved among different 
papillomavimses. Differentiation of the epithelium triggers a coordinate increase in the 
replication of the viral genome and expression of the LI major and L2 minor stmctural 
viral proteins leading to the assembly of infectious viral particles in the nucleus. When 
LI alone is expressed in eukaryotic cells by recombinant baculovirus or vaccinia vims
13
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(Hagensee et a i, 1993b; Kirnbauer et al., 1993; Rose et al., 1993), it can self-assemble to 
form icosahedral particles or vims-like particles (VLP). When L2, which is not required 
for assembly, is coexpressed with LI, both LI and L2 are incorporated into the particles 
(Hagensee et al., 1993b; Kirnbauer et al., 1993). Restriction of HPV late gene expression 
to terminally differentiated cells and differences in level of expression of late gene 
products from various HPV types may be due to the presence of negative regulatory 
elements in the HPV late mRNAs (Gumming et al., 2002; Kennedy et al., 1990; Kermedy 
et al., 1991; Koffa et al., 2000). L2 is described in further detail in section 1.2.8.
1,2.2. Epithelial Differentiation
The complete HPV replication cycle resulting in the production of infectious progeny 
(virions) is tightly linked to the differentiation state of infected cells (Meyers et a i, 
1997). Epithelial cells are tightly bound together in sheets called epithelia which line all 
cavities and free surfaces of the body forming baniers to the movement of water, solutes 
and cells from one compartment to another. The differentiation of epithelial cells such as 
in the skin epithelium (i.e. the epidermis) is characterised by a series of coordinated 
biochemical and morphological changes resulting in a highly organised stratified 
epithelium. The epidermis is a dynamic epithelium that is constantly renewed throughout 
life. Its turnover is estimated at about 7days in mice and about 60 days in humans 
(Ghazizadeh and Taichman., 2001; Potten., 1981). Maintenance of the epidermis is 
accomplished by the presence of stem cells that self renew and generate progeny, which 
then undergo terminal differentiation (Watt., 2001).
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Stem cells are not the only cells within the epidermis capable of proliferation. Stem cell 
progeny that are destined to undergo terminal differentiation can divide a small number 
of times before they irreversibly exit the cell cycle; these are known as transit amplifying 
cells (Fig 1,3b) (Lavker and Sun., 2003; Watt., 2001). Divisions of transit amplifying 
cells increase the number of tenninally differentiated cells that are produced by each stem 
cell division. In normal undamaged epidermis, stem cells divide infrequently, whereas 
transit-amplifying cells are actively recycling but have a low self-renewal capacity and a 
high probability of undergoing terminal differentiation (Taylor et al., 2000).
The layers of the stratified epithelium begin with a basal layer of cells anchored to a 
basement membrane. The basal layer contains proliferating cells, which expand by cell 
division, some cells then detach from the basement membrane and begin to move 
upwards towards the surface and activate a programme of teiminal differentiation. As the 
cells move up towards the surface, they progress thiough thi ee distinct stages; spinous, 
granular and stratum corneum (Fig 1.3a). As basal cells enter the spinous layer, they 
strengthen their cytoskeletal and intracellular connections, gaining resilience to 
mechanical stress. Once this task is completed, the cells enter the granular layer, where 
they produce the epidermal barrier. The barrier precursors consist of two major 
components: (i) glutamine- and lysine-rich comifled envelope precursor proteins, which 
are synthesized and deposited beneath the plasma membrane and (ii) lamellar granules, 
which are filled with lipid bylayers. As the cells enter the final phases of teiminal 
differentiation, a flux of calcium activates the enzyme transglutaminase, which 
biochemically cross-links the cornified envelope proteins through s-(Y-glutamyl)lysine
15
Chapter One_______________________________  Introduction
isopeptide bonds and which activates extmsions of the lipid bylayers onto this scaffold. 
Cell death ensures, leaving dead, flattened squames at the skin surface, the end process of 
teiTninal differentiation (Fig 1.3a).
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As the cells progress thi ough the different layers of the epithelium, unique sets of genes 
are turned on and off in a growth and differentiation specific manner. These include 
genes encoding stmctural cytoskeletal proteins, transcription factors and products that are 
necessary for the barrier function of the skin. Basal cells transcribe genes encoding 
keratins K5 and K14, while cells in the spinous layer switch off these genes and induce 
K1 and KIO, required for the marked mechanical resistance of these cells (Fuchs, 1995). 
In the granular layer, cells express loricrin, filaggrin and transglutaminase, which are 
involved in the assembly of the cornified envelope. The cornified envelope plays a 
critical role in barrier function of the tissue and for the organism. Several other proteins 
have been identified to be components of the epidermal cornified envelope, they include 
involucrin, cystatin a, elafin and several small proline rich proteins (SPRl and SPR2) 
(Steinert and Marekov., 1995). This stmcture foims a sac to contain the keratin filaments 
and to provide a scaffold upon which specialized lipids are extruded and organized 
(Fuchs., 1993; Fuchs., 1997). Once the barrier is in place, kératinocytes cease their 
metabolic activity becoming dead squames that are eventually sloghed off the skin 
surface, continually being replaced by stems cells transiting outward and differentiating.
Several molecular networks and cellular signalling pathways regulate the balance 
between epithelial growth and differentiation. In cultured epideimal cells, the 
concentration of extracellular Ca^ "^  can select for a basal or differentiation phenotype 
(Hemiings et al., 1980; Yuspa et al., 1983). Under conditions were Ca^ "^  is <G.lmM, 
kératinocytes proliferate rapidly, express a basal cell phenotype and do not cornify, while 
higher Ca^  ^ induces terminal differentiation in basal kératinocytes (Yuspa et al., 1982).
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Also physical analyses of tissue sections from mouse and human epidermis have 
demonstrated the existence of a gradient of Ca^ "^  in which basal layer Ca^  ^content is low 
(<0.1 mM) while granular layer Ca^  ^ content is much higher (Malmquist et a l, 1984; 
Menon et al., 1985).
Adhesion mediated by pi integrins have also been known to regulate terminal 
differentiation of epidermal kératinocytes and when mouse or human kératinocytes are 
placed in suspension they withdraw rapidly from the cell cycle and initiate teiminal 
differentiation (Watt., 2000). Other regulators of teiminal differentiation are 14-3-3a 
(Dellambra et al., 2000) and a-catenin (Vasioukhin et al., 2001). a-Catenin links 
adherens junctions to the actin cytoskeletion, targeted ablation of a-catenin in mouse 
epidermis results in epideimal hypeiproliferation and sustained activation of the 
Ras/MAPK cascade (Vasioukhin et al., 2001). 14-3-3o binds to phosphoserine motifs in 
a variety of cellular proteins and can thus contribute to the regulation of a range of 
signalling pathways, including Ras/MAPK cascade; expression of 14-3-3o antisense 
mRNA blocks exit from the stem cell compartment in cultures of human kératinocytes 
(Dellambra et a i, 2000).
19
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1.2.3. HPV LIFE CYCLE
The productive life cycle of papillomavimses usually begins in epithelial stem cells 
located in the basal layers of the stratified epithelium. The vims enters the epithelium 
through microlesions and infects the basal epithelial cells. As these cells keep dividing, 
they produce daughter cells, which withdraw from the cell cycle, migrate away from the 
basal layer and become committed to differentiation. As HPVs infect proliferating 
undifferentiated kératinocytes, the HPV genome becomes established as 
extrachromosomal elements in the nucleus and copy number is increased to 
approximately 50-100 copies per cell. As infected cells divide, viral DNA is distributed 
between both daughter cells. One of the daughter cells migrates away from the basal 
layer and initiates a program of differentiation. The other daughter cell continues to 
divide in the basal layer and provides a reseivoir of viral DNA for further cell divisions. 
Since production of HPV is restricted to suprabasal cells, the cells in the basal layer 
continue to proliferate (Fig 1.4). This differentiation dependence allows the infected cells 
to persist in the basal layers for periods as long as several years (For reviews see 
Desaintes and Demeret., 1996; Phelps et aL, 1998; Stubemauch and Laimins., 1999).
All HPV genomes contain approximately eight open reading frames, which are 
transcribed as polycistronic messages from a single DNA strand. Regulatory sequences 
for early viral transcription and DNA replication are concentrated in a small non-coding 
region teimed the long control region (LCR). In basal cells, transcripts from high-risk 
types are initiated from a promoter in the LCR such as p97 for HPV-16. The maintenance 
and establishment of HPV genomes are associated with expression of the early HPV 
transcripts that encode the oncoproteins E6, E7 and E5 as well as the replication proteins
20
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El and E2. Viral replication is intimately tied to the differentiation programme of the 
host tissue. As the cells of the basal layer divide, one of the daughter cells migrates away 
from the basal layer and initiates a program of differentiation. The other daughter cell 
continues to divide in the basal layer and provides a reseivoir of viral DNA for further 
cell divisions. Since production of HPV is restricted to suprabasal cells, the cells in the 
basal layer continue to proliferate (Fig 1.4). This differentiation dependence allows the 
infected cells to persist in the basal layers for periods as long as several years (For 
reviews see (Desaintes and Demeret., 1996; Phelps et al., 1998; Stubenrauch and 
Laimins., 1999).
Cell proliferation poses a problem for the virus which needs the replicative machinery of 
the cell for viral DNA synthesis, and a terminally differentiated cell will contain little or 
no replicative enzymes. Therefore the vims needs to stimulate G1 to S phase progression 
in the face of a cell programmed to terminally differentiate, in order to produce the 
conect environment for viral DNA amplification. The virus is still dependent on cellular 
differentiation as the late promoter, which regulates the mRNA coding for the capsid 
proteins LI and L2, is only switched on in partially differentiated cells. HPV-infected 
cells, contrary to normal epithelial cells, continue cycling also in the subrabasal layers 
(Doorbar et al., 1997b) resulting in amplification of the viral genomes to 1000-10000 
copies per cell (Lambert., 1991) (Fig 1.4).
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Transcription of papillomavims genes is dependent upon epithelial specific 
transcriptional enhancers present in the viral long control region (LCR). Multiple 
promoters direct transcription of subsets of viral genes. These promoters are differentially 
regulated by viral and cellulai' transcription factors. Promoters directing transcription of 
early genes are active throughout the epithelial layers, while those directing expression of 
the late genes are preferentially active in highly differentiated cells. Viral proteins are 
expressed from differentially spliced mRNA at different times during the migration of the 
infected cell towards the epithelial surface. With the exception of the virion stmctural 
proteins and E4, viral gene products are not readily detected in vivo (Doorbar et aL, 
1986; Doorbar et al., 1988). The onset of HPV-31b early transcription following 
epithelial cell infection was examined by detecting newly synthesized, spliced viral 
transcripts by reverse transcription and PCR (Ozbun., 2002). El and E2 transcripts were 
detected as early a 4 hours post-infection, whereas the other major viral transcripts such 
as E6, E1^E4 were detected by 8 to 10 hour post-infection.
E7 is expressed in lower epithelial layers as determined by the presence of E2F-activated 
gene products such as MCMs (Middleton et aL, 2003). In HPV-16 infected epithelial raft 
tissues prepared using NIKS cells harbouring HPV-16 episomes, cells expressing both E4 
and E7 were found in the intenuediate epithelial layers. Cells expressing E7 in the 
absence of E4 were oecasionally apparent in the upper epithelial layers (Middleton et aL, 
2003). In lesions caused by HPV 16, E7 is expressed from the early promoter (p97), 
which also directs expression of E6. Very low E6/E7 transcripts are detected in basal 
cells in low-grade dysplastic lesions, while an increase in their levels is observed in
23
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differentiated upper layers of the epidermis (Durst et aL, 1991). In contrast, high-grade 
lesions and squamous cell carcinoma (SCC) show high levels of E6/E7 transcripts 
throughout all layers of the epithelium, including the basal layers (Durst et aL, 1991; 
Stoler 1992). Staining of ceiwical section for E2 showed detection in CIN I and II grade 
lesions. E2 expression was confined to the superficial layers of the epithelium, 
specifically to the koilocytic nuclei with little immunoreactivity obseiwed in the 
inteimediate or basal layers. Weak detection of E2 was observed in CIN III lesions, 
while no E2 was detected in SCC lesion (Stevenson et aL, 2000).
E4 proteins expressed from the spliced mRNA E1^E4 was first detected in naturally 
occurring lesions in cells in which vegetative viral DNA replication is occumng (Doorbar 
et aL, 1997a). The E4 proteins persist throughout the late stages of infection and are 
modified by proteolytic processing and phosphoiylation (Grand et aL, 1989). E4 proteins 
localise in part to cytoplasmic intermediate filaments in low grade squamous 
intraepithélial lesions caused by HPV-16 but are also diffusely cytoplasmic and 
perinuclear. As infected cells near the epithelial surface, E4 proteins localize to 
perinuclear bundles (Doorbar et aL, 1997b). Although its function in the viral life cycle is 
still unclear, expression of the HPV E1^E4 protein in kératinocytes in monolayer cultures 
leads to a collapse of cellular intermediate filament network (Doorbar et aL, 1991). E4 
has been implicated in viral genome amplification with the obseiwation of a coirelation 
between initiation of E4 expression and the onset of viral DNA amplification in 
suprabasal epithelial cells (Breitburd et aL, 1987).
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Expression of E4 precedes the synthesis of vims structural proteins and the assembly of 
infectious particles. The production of HPV late-gene products, LI and L2 are detected 
primarily in the terminally differentiated cells in the upper layers of the epithelium 
(Hagensee et aL, 1993a; Turek., 1994). In addition to promoter switch, one reason for the 
restriction of HPV late gene expression to teraiinally differentiated cells is due to the 
presence of negative regulatoiy elements in the HPV late mRNA identified as an 
inhibitoiy sequence in the 3’ untranslated region (UTR) which acts by reducing mRNA 
stability in vitro (Kennedy et aL, 1990; Kennedy et aL, 1991). This post-transcriptional 
regulation of late mRNA may also be responsible differences observed in the levels of 
expression of late gene products from various HPV types.
1.2.4. HPV and Cell Transformation
The association of HPV infection and squamous cell precancer lesions of the uterine 
ceiwix has been established since the late 1970s. Today, oncogenic HPV types are 
regarded as the most important etiological factors of ceiwical squamous cell cai'cinoma. 
HPV types cause a variety of lesions in the genital tract of males and females (Schiffman 
and Brinton., 1995). Some types cause benign warts and low-grade premalignant lesions 
and are not found in malignant tissues. HPV-6 and HPV-11 are the most common isolates 
from these lesions. The high-risk viruses such as HPV-16 and HPV-18 are found in 
premalignant and malignant tissues. Initial infection with high-risk types causes low- 
grade disease, which is manifested by inhibition of the noiuial differentiation in the lower 
third of the epithelium. The lesions may remain low grade, regress, or progress to severe 
dysplasia. This later stage may persist or may start to penetrate the basement membrane 
leading to invasive disease. During progression from premalignant to malignant phases of
25
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the disease, the relationship between the HPV genome to the host cell chromosomal DNA 
may change. Most metaplastic cells have been shown to have integrated HPV sequences 
(McCance et aL, 1986; zur., 2002) with integration occurring randomly in cellular 
chromosomes. All viral DNA integration events associated with malignant disease allow 
for the expression of E6 and E7.
Due to their limited coding capacity, HPYs have to use the cellular DNA synthesis 
machinery in order to replicate their genomes. However, while low-risk HPYs begin 
replication in cells that are still proliferating, the replicative phase of high-risk HPY 
infection is confined to more differentiated cells that have already exited the cell cycle 
and are non-permissive for DNA synthesis (Doorbar et aL, 1997a). In order to overcome 
the problem, the high-risk HPY E7 protein tai'gets a number of cell cycle regulatory 
proteins, including the pocket protein family of pRb, p i07 and p i30, thereby 
upregulating genes required for G 1/S transition and DNA synthesis (Fig 1.5a,b). 
However, the noimal response of the host cell to this unscheduled induction of 
proliferation would be to trigger apoptosis and/or growth anest. To overcome these 
obstacles, the high-risk E6 protein targets a variety of cellular proteins involved in 
regulating these defence mechanisms (Fig 1.6, Table 1.2).
The tumour suppressor protein p53 is a transcription factor that stimulates the expression 
of genes involved in cell-cycle anest and apoptosis such as the cyclin-dependent kinase 
inhibitor p21. E6 binds to p53 and leads to ubiquitin-mediated degradation of the latter 
(Scheffher et aL, 1990). E6 mediated degradation of p53 involves an E3 ubiquitin ligase
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E6AP. Under normal circumstances, viral replication would then continue resulting in 
production of infectious virions. On rai'e occasions, however, the viral life cycle is 
inteiTUpted and processes are initiated that lead to immortalization and ultimately to full 
transformation of the cell. E6 alone is not capable of immortalising primary human 
foreskin kératinocytes (HFK) but can efficiently immortalise human mammary epithelial 
cells (HMEC) (Kiyono et aL, 1997; Liu et aL, 1999). In high-risk HPVs such as HPV-16 
however, E6 and E7 proteins are necessaiy and sufficient to immortalize their host 
squamous epithelial cells. Both in vitro and in vivo studies have show that the function of 
both proteins, particularly the high-risk types are essential for cellular transformation 
(Herber et aL, 1996; Song et aL, 1999). E6 and E7 from low risk types are weakly 
transfoiming proteins (Mansur and Androphy., 1993). The contribution of E6 and E7 to 
tumour progression is shown in fig 1.7.
Although targeting p53 for degradation is the major route by which E6 overcomes its 
effects, several reports indicate that E6 makes use of additional pathways to abrogate 
p53’s growth suppressive activities. The capacity of high-risk E6 proteins to abrogate 
transactivation of p53 target genes does not depend only on p53 destabilization, as E6 
mutants defective for degradation retain the ability to abrogate transcriptional activation 
by p53 in vivo (Pim et aL, 1994). This could be due to E6 interfering with binding of p53 
to its DNA recognition site (Lechner and Laimins., 1994; Thomas et aL, 1995) or due to 
the interaction of E6 with the transcription coactivator p300/CBP (Patel et aL, 1999; 
Zimmermann et aL, 2000). Reports also indicate that other activities other than targeting 
p53 for degradation are required for the full transfoimation potential of E6 (Liu et aL,
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1999; Nakagawa et aL, 1995; Pim et aL, 1994). Moreover, cutaneous HPVs mainly rely 
on their E6 proteins, which do not interact with p53, for their transfoimation ability 
(Elbel etaL, 1997).
The high-risk HPV E6 oncoproteins have been implicated in activating telomerase, a 
potential mechanism for HPV-induced immortalisation (Klingelhutz et aL, 1996). 
Telomerase adds repeat sequences to chromosome ends and is believed to play a role in 
cellular immortalisation. E6-induced telomerase activity alone cannot result in 
immortalisation without coexpression of E7. E6 protein has also been shown to interact 
with cellular minichi’omosome maintenance proteins, which are believed to play a key 
role in regulating cellular DNA replication (Kuhne and Banks., 1998). E6 can also 
interact and inliibit Bak, a proapaototic protein expressed at high levels in the upper 
layers of differentiating epithelium (Thomas and Banks., 1998).
E6 has been shown to interact with a vaiiety of PDZ domain-containing proteins. PDZ 
domains consist of approximately 90 amino acid long protein-protein interaction units 
often found within cellular proteins located at areas of cell-cell contact such as synaptic 
junctions in neurons and tight junctions in epithelial cells (Fanning and Anderson, 1999). 
PDZ domain containing proteins shown to interact with E6 include liDlg (Kiyono et aL, 
1997, Lee et aL, 1997), MUPPl (Lee et aL, 2000) and hScrib (Nakagawa and Huibregtse. 
2000). HPV E6 proteins possess PDZ domain-binding motifs at their extreme carboxyl- 
tennini (Lee et aL, 1997) (Fig 1.6). Binding of high-risk HPV E6 proteins to these PDZ 
proteins results in E6AP mediated ubiquitination and proteolysis (Gardiol et aL, 1999;
28
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Nakagawa and Huibregtse, 2000). The cellular tai’gets of E6 have been summarised in 
table 1.2.
29
Structure and cellular targets of HPV E7
Recruits
HDAC
+
Mi2p
CRl CR2 AP-1
R b A
1 20 38 IA  j 981 N -T e r . I R b  b rn d ln iÜ Z n  y  y  F in a e r  I
LXCXE ^  ^ cxxc cxxc
casein kinase (OKU) 
domain 30-35aa
Associated Cellular Proteins Functional consequences
pR B ,p l07 ,p l30 Disruption of E2F transcription factor complexes 
Degradation
p21c'P' Inactivation of cdk and replication inhibitory activity
p27k'P' Inactivationof cdk inhibitory activity
TBP Transcription ?
TAFllO Transcription ?
AP-1 Activation of c-jun transcriptional activity function
Mi2(3 (HDAC) Chromatin remodelling ?
IGFBP-3 Inhibition of IGFBP-3 mediated apoptosis
M2 Pyruvate kinase 7
a-Glucosidase ?
hTid-1 ?
p48 component of 1SGF3 Inhibition of interferon-a stimulation
F-actin ?
Forkhead transcription factor MPP2 Activation of MPP2 transcriptional activity
S4 subunit of proteasome ?
Figure 1.5. (a) A schematic representation of the HPV E7 protein showing CRl HD, CR2 HD denoting conserved 
regions of 1 and 2 of the Adenovirus El A protein respectively. CR2 HD contains the core pRB binding domain 
(LXCXE) and a consensus sequence for casein kinase II phosphorylation (CKll). The metal binding domain 
consists o f two C-X-X-C sequences in the carboxyl terminus. From McCance J., ed. Human Papillomaviruses. Perspectives in medical virology 8. Elsevier 2002. (b) Table 1.2. Showing known cellular proteins which interact 
with E7. Data complied from Munger and Howley 2002. Virus Res. (8) 9:213-228.
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The ability of E7 to bind to the retinoblastoma (Rb) protein is perhaps the most 
characterized property of this viral oncoprotein. Evasion of cell cycle arrest by binding 
Rb is a property common to various viral oncoproteins, such as adenovims El A and 
simian vims SV40 large T antigen (Munger., 1995), this underscores the importance of 
Rb binding in the natural history of vims infection. Hypophosphorylated Rb binds to E2F 
transcription factor, repressing the transcription of cell cycle genes. During progression 
from GO through G1 to S-phase, Rb gets hypeiphosphorylated by G1 cyclin-cyclin 
dependent kinases, releasing E2F, which in turn activates genes involved in DNA 
synthesis and cell cycle progression (Dyson., 1998). E7 binds to hypophosphoiylated Rb 
and thereby induces cells to enter into premature S-phase by dismpting Rb-E2F 
complexes (Huang etaL, 1993; Wu etaL, 1993).
Binding to Rb is primarily mediated through amino acid sequences contained in the 
consei’ved amino acid terminal of CR2 region of E7 (Barbosa et al., 1990). The CR2 
region of E7 binds to Rb and its family members p i07 and p i30, through sequence 
motifs LXCXE. The LXCXE motif of E7 has been shown to specifically bind to the Rb 
pocket region, between 649 and 772 amino acids (Huang et aL, 1993). The E7 proteins of 
HPV-16 and HPV-18 bind hypophosphorylated Rb with higher affinity than HPV- 6  and 
HPV-11 (Griffiths and Mellon., 1999). E7 has also been associated with histone 
deacetylases (HDAC), AP-1 transcription factors, cyclins, cyclin-dependent kinases 
(cdks), and cdk inhibitors. These associations contribute to the ability of E7 to induce 
cellular proliferation, immortalisation and transformation.
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Cyclin E-cdk2 is essential for initiation of DNA synthesis and can activate cell cycle 
progression in the absence of cyclin D-cdk4 underlining this complex as a potential target 
by which E7 propels cell cycle re-entry. E7 expressing cells have been shown to maintain 
cyclin E-cdk2 activity in the presence of growth arrest signals such as epithelial 
differentiation, semm deprivation, and anchorage-independent growth (Ruesch and 
Laimins., 1998). E7 has been detected in complex with pl07-cyclin E-cdk2, suggesting 
that E7 may affect cyclin E-cdk2 through physical interaction (McIntyre et aL, 1996).
To determine whether E7 plays a role in the HPV-16 life cycle, Flores et aL, (2000), 
created an E7-defrcient HPV-16 genome by inserting a translational termination linker in 
the E7 gene of the full-length genome (Flores et aL, 2000). This DNA was transfected 
into an immortalized human foreskin keratinocyte cell line, BCl-Ep/SL, which support 
the full viral life cycle. Cells hartouring the wild type or E7 deficient HPV-16 were 
grown using raft cultures and also suspended in methylcellulose to induce differentiation, 
which promotes the productive phase of the HPV-16 life cycle. The loss of E7 resulted in 
lack of viral DNA amplification and reduced LI expression. In contrast, cells harbouring 
wild type HPV-16 genome induced the host cell DNA replication machinery and 
inhibited the differentiation of the host cell in the suprabasal layers of the raft.Concluding 
that E7 is important for the full viral life cycle.
The link between dismption of E2F/pRB binding and cell transfoimation by E7 is still 
under investigation. Interaction of pRB with E7 is mediated through the amino terminal 
domain containing the LXCXE pRB binding motif. Although this region of E7 mediates
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high affinity binding to pRB, it is not sufficient to displace E2F from pRB (Huang et aL, 
1993; Wu et aL, 1993). The carboxyl region of E7 has been shown to bind pRB and is 
required for displacement of E2F from pRB. Chimeric E7 proteins with carboxyl 
terminus replaced with stmcturally related HPV E6  derived domains were impaired for 
dismption of E2F/pRB complexes but retained transformation competence (Braspenning 
et aL, 1998; Mavromatis et aL, 1997). This suggests that the ability of E7 to dismpt 
pRB/E2F complexes and cellular transfonnation are not necessarily linked. This is further 
supported by evidence that several non-transforming HPV-16 E7 mutants retain the 
ability to interact with pRB and efficiently activate transcription of E2F-responsive 
promoters (Banks et aL, 1990; Edmonds and Vousden., 1989; Phelps et aL, 1992). Jewers 
et al (1992) showed that mutations in HPV-16 E7, which eliminate binding to pRB, do 
not alter the ability of the constmcts to immortalize primary kératinocytes (Jewers et aL,
1992). Therefore these results suggest that the transfoimation ability of E7 is not 
primarily linked to its interaction with pRB but could result with interaction with other 
cellular proteins.
1.2.5. HPV and Cervical Cancer
The ceivix is the naiTow lower portion of the female utems that extends into the vagina. 
Cancer of the ceivix is the second most common malignant disease among women 
coming only second to cancer of the breast. In many developing countries, it is the most 
common cause of cancer and death. The primary cause of ceivical cancer is HPV as more 
than 90% of squamous cervical cancers contain HPV DNA (Herzog., 2003; Waggoner., 
2003). Infection is believed to be primarily by sexual activity. Only high risk HPVs such 
as types 16, 18, 31 and 33 promote the development of ceivical cancer to any appreciable
36
Chapter One_____________________________________________________ Introduction
extent (Campo., 1998; Waggoner., 2003). The variation in carcinogenic potential among 
HPVs is governed by the E6  and E7 proteins; specifically the capacity of these proteins to 
interact with and alter or destroy key cell cycle regulatory molecules. Factors associated 
with the development of ceivical cancer include the age of onset of sexual activity, 
number of sexual partners as well as histoiy of genital warts. Immunocompromised 
patients such as HIV positive ones and smokers are also at increased risk.
Ceivical intraepithélial neoplasia (CIN) associated with infections of high-risk HPV types 
typically begins as flat or inverted condylomas (CIN I). Grades of CIN identify 
increasing numbers of undifferentiated malignant cells and a decrease in noimal 
epithelial cell differentiation. CIN III therefore morphologically describes severe 
dysplasia and carcinoma in situ (Fig 1.8). In most cases progression of CIN lesions to 
carcinoma takes a few years of continuous presence of high-risk HPVs. The prognosis for 
patients with cervical cancer is dependent on the stage of disease at diagnosis. Routine 
Pap screening is able to detect precancerous lesions in the ceivix and carcinoma in situ. 
Preinvasive disease is generally managed thiough ablative or excisional procedures. 
Radical hysterectomy or radiotherapy can be used for early invasive stages while more 
advanced stages are treated with radiotherapy or combined chemotherapy and 
radiotherapy (For review see Herzog., 2003).
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1.2.6. Other HPV Associated Diseases
A small but significant number of patients present with papillomas of the mucosa of the 
respiratory tract. Although laryngeal papillomas are associated with low-risk HPV- 6  and 
HPV-11, these usually benign infections can cause life-threatening disease by obstmction 
of the aiiways, and from the debilitating effects of frequent treatments for recuiTences. 
Squamous cell carcinoma of some oral and head and neck cancer contain high-risk HPV- 
16, HPV-18 and HPV-31, and occasionally, low-risk HPV- 6  and HPV-11 (Schwartz et 
aL, 1998). Epidemiological and experimental data suggest that some chemicals, 
nutritional deficiencies, physical factors and infectious agents are associated with the 
development of oesophageal squamous cell carcinoma (Syijanen, 2003). One of the 
earliest evidence for the involvement of papillomavimses in oesophageal carcinogenesis 
has been obtained from studies from cattle in Scotland, which have a high incidence of 
upper alimentary tract papillomas and carcinomas (Campo et aL, 1981; Campo, 1987; 
Campo et aL, 1990). Bracken fern is a cmcial factor in malignant conversion of these 
papillomas. Bracken fern contains carcinogenic agent that can induce damage to DNA 
and immunosuppresants that inhibit the ability of the animal to mount an immune 
response against the vims (Jackson et aL, 1993). Experimental data suggests that similar 
mechanisms to those that occur in ceivical carcinogenesis may also be involved in 
oesophageal carcinogenesis with both E6  and E7 interfering with cell-cycle regulation 
(Syijanen., 2003).
Epidermodysplasia vermciformis (EV) is a rare recessive autosomal disease associated 
with cutaneous flat papillomas known as macular lesions. Some lesions progress to
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malignant squamous cell carcinomas (Jablonska et al., 1972; McGregor and Rustin., 
1994). EV carcinomas harbor high copy numbers of episomal HPV genomes (usually 
HPV5 or occasionally HPV8 , 14, 17, 20, or 47) and abundant transcripts of the E6  and E7 
open reading frames (Orth., 1986). Patients with EV tend to have depressed cell-mediated 
immunity. A susceptibility locus for EV has been mapped to chi'omosome 17q25, with 
the identification of nonsense mutations in two adjacent genes, EVERl and EVER2 
(Ramoz et aL, 2002). The gene products EVERl and EVER2 have features of integral 
membrane proteins and are localized in the endoplasmic reticulum.
The viral and cellular molecular mechanisms leading to the early development of skin 
malignancies in EV patients are still poorly understood. HPV-5 and HPV- 8  E7 proteins 
have been shown to associate with retinoblastoma (Rb) protein, though with reduced 
binding affinities compared to HPV-16 and HPV-18 E7 proteins (Schmitt et aL, 1994; 
Yamashita et aL, 1993). In addition, the E6  proteins of oncogenic EV HPV do not 
possess the ability to interact with p53 protein and ubiquitin-protein ligase E6 -AP, which 
would promote p53 degradation and inhibit p53-mediated transactivation of cellular 
genes (Elbel et aL, 1997; Kiyono et aL, 1994; Steger and Pfister., 1992). Analyses of the 
p53 status in EV carcinogenesis from lesion specimens from two PIPV5-infected EV 
patients showed a dysfunction of the p53 gene in EV tumours with mutations detected at 
different stages of tumour progression (Padlewska et aL, 2001). The role of p53 in EV 
carcinogenesis is supported with the report that expression of HPV-5 E6  inhibits 
ultraviolet (UV) radiation-induced G1 arrest and apoptosis, in spite of increased levels of 
transcriptionally active p53 protein (Jackson and Storey., 2000). This is particularly
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relevant as malignant transformation of EV lesions usually occurs on sun-exposed areas 
of the skin, suggesting that UV radiation may act as a cofactor in the carcinogenesis 
process (Majewski and Jablonska., 1995; Orth., 1986).
1.2.7. The Transcription Regulator E2
The E2 protein belongs to a family of proteins that form dimeric p-ban els and use surface 
a-helices for DNA interaction. The E2 protein has three domains; the well-conseived N- 
teiminal/trans-activating and C-tenninal DNA-binding/dimerisation domains are 
connected thiough a variable hinge region (Giri and Yaniv., 1988). The activation 
domain is involved in interactions with the replication protein El and the cellular proteins 
TFIIB and AMF-1. E2 activates transcription in a cell type dependent manner (Morgan et 
aL, 1998; Vance et aL, 1999). The DNA-binding domain of E2 has been shown to make 
functional interactions with the replication protein El and the transcription factor TBP 
(Fig 1.9). E2 facilitates efficient binding of El to its target DNA sequence (Seo et aL,
1993). The El binding site is juxtaposed with an E2 DNA binding site. The transcription 
and replication functions of E2 can be separated by point mutations within the amino- 
teiTninal 200 amino acids (Ferguson and Botchan., 1996; Sakai et aL, 1996; Winokur and 
McBride., 1992). The ciystal structure of BPV-1 E2 DNA binding domain revealed that 
the protein forms a dimeric (3-barrel with surface recognition a-helices. BPV-1 E2 
undergoes a subtle reaiTangement in subunit orientation upon DNA binding while 
maintaining the overall stmcture of each monomer (Hegde and Androphy., 1998). The 
DNA wraps around the E2 |3-barrel enclosing both recognition helices in successive 
major groves (Fig 1.10).
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The transcriptional regulation and replication functions of E2 are mediated thiough its 
interaction with a palindromic consensus sequence ACCGN4 CGGT in the viral LCR. 
Multiple E2 binding sites that differ in the sequences of the central N4  “spacer” 
nucleotides are present in the viral LCRs (17 in BPV-1 and 4 in HPV-16). Although all 
E2 proteins recognise the same consensus palindromic DNA sequence, proteins from 
different viral types differ in their abilities to discriminate among their specific DNA- 
binding sites. The LCR of HPV-16 as well as other mucosal epitheliotropic 
papillomavimses such as HPV-18 or BPV-4 has four E2 binding sites. Two immediately 
upstream from the TATA box separated by 3 or 4bp, the most proximal of which to the 
TATA box mediates transcriptional down-regulation at high levels of E2 (Morgan et aL, 
1998). Further upstream there are two other sites, one juxtaposed with the El DNA 
binding site while the other is some 300 or 400bp further upstream (Fig 1.2).
The role of the hinge domain of E2 is less well defined, although it is generally 
considered a flexible linker between the two functional domains (Gauthier et al., 1991). 
In a recent study, Zou et aL, (2000) used green fluorescent protein (GFP) as a tracer to 
delineate the domains of HPV-11 E2 responsible for its nuclear localization (Zou et aL,
2000). Mutational analysis identified in the hinge a cluster of basic amino acids critical 
for nuclear localisation signalling and for nuclear matrix association. Phosphorylation of 
the hinge domain has been associated with the stability of BPV-1 E2 protein (Lehman et 
aL, 1997; McBiide et aL, 1989). However studies with HPV-18 have shown that the 
hinge region is not involved in controlling the stability of the protein (Bellanger et aL,
2001).
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The major role of E2 in HPV DNA replication is to target El to the HPV origin of 
replication as El has a weak affinity for it’s binding sequence. Once viral replication has 
been initiated, E2 is no longer required for DNA synthesis. E2 has been shown to bind 
the cellular replication factor RPA (Li and Botchan, 1993). It has also been shown that 
El-mediated replication of bovine papillomavims type 1 is repressed by nucleosomal 
assembly. E2 counteracts this repression, suggesting that E2 might have additional 
functions during viral replication (Li and Botchan, 1994). Analyses of various deletion 
mutants of E2 demonstrate that in most cases, an intact transactivation domain and an 
intact DNA binding domain are required for DNA replication (Ustar and Ustar 1998). 
However some mutants which lack regions in the C-tenninal DNA-binding dimerization 
domain have been shown to support replication (Winoker and McBride 1992). Mutational 
analysis has also shown that the role of the hinge region of E2 in replication is to provide 
a flexible linker function, which comiects the N-teiminus transactivation domain and the 
C-teiminus DNA binding-dimerization domain. The particular amino acid sequence of 
the hinge region is not important for the ability of E2 to bind DNA or initiate replication 
(Allikas et al., 2001).
1.2.8. The Minor Capsid Protein L2
The exact role of the L2 minor capsid protein in the viral life cycle is still unclear 
although its importance in viral capsid assembly has been well documented. It is 
speculated to be involved in encapsidation of the viral DNA, generation and infectivity of 
PV virions as well as interaction with cell surface receptors (Kawana et aL, 2001; Okun 
et aL, 2001). The exact location of the L2 in the viral capsid is unclear although the 
ability of an antibody to L2 to neutralise infectivity demonstrates that a portion of the
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protein is exposed on the surface of the capsid (Heino et aL, 1993). It is speculated that 
L2 molecules are located in the centre of the twelve pentavalent capsomeres in the capsid 
(Tms et aL, 1997).
Differentiation of epithelium triggers the expression of LI and L2, leading to the 
assembly of infectious viral particles in the nucleus. Studies on the regulation of late gene 
expression have resulted in the detection of negative regulatory elements in the HPV late 
mRNA and factors binding to these elements have been identified. Analysis of HPV-16 
late poly (A) sites showed the presence of a negative regulatory element (NRE) in the late 
RNA 3’ untranslated region (Dietrich-Goetz et aL, 1997).
The L2 protein of HPV-16 is 473 amino acids long with groups of positively charged 
residues at the N (from amino acids 1-12) and C teiminus amino acids (456 to 461) 
corresponding to classic nuclear localisation signals (NLS). The amino acid sequence of 
the N teiTuinus is MRHKRSAKRTKR with four charged amino acid clusters important 
for DNA binding (Zhou et aL, 1994). Retention of at least one charged amino acid is 
necessary for DNA binding. Both the N- tenninus DNA binding domain and C-terminus 
NLS sequence of HPV-6 b L2 function in nuclear transport and contribute to the L2 
translocation into the nucleus (Sun et aL, 1995). The sequence 286-306aa which is 
relatively conseiwed among HPV types has been found to be responsible for HPV6 b L2 
nuclear accumulation and retention (Fig 1.11).
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BPV-1 L2 is 469 amino acids long, with groups of positively charged residues at the 
extreme C and N termini. With the goal of assessing the role of these positively charged 
teimini in the generation of infectious virions, Roden et al (2001) constmcted BPV-1 L2 
deletion mutants of amino acids 2 to 9 (L2A2-9) and the final nine amino acids (L2A461- 
469) (Roden et aL, 2001). Coexpression of LI and L2 mutants lacking either the eight N- 
teiminal or nine C- terminal amino acids resulted in wild-type levels of viral genome 
encapsidation; the resulting mutant virions, despite binding to the cell surface with 
similar efficiency of wild type virions, were not infectious. As L2 interacts in vitro 
through positively charged side chains with DNA independently of nucleotide sequence 
(Mallon et aL, 1987; Zhou et aL, 1991), and is associated with viral episomes in vivo 
(Stauffer et aL, 1998), it is possible to speculate that L2 may function in the delivery of 
the viral genome to the nucleus (Kawana et aL, 2001). Characterisation of L2 mutants has 
identified two L2 domains independently interacting with LI (Becker et aL, 2004; Okun 
et aL, 2001). Wild type L2 is able to interact with LI in the nucleus and cytoplasm with 
VLP assembly occurring in the nucleus as the L1-L2 complex is translocated from the 
cytoplasm to the nucleus.
Recent studies have identified several cellular L2 interacting proteins (Table 1.4). Using 
the HPV-16 L2 protein as bait, Gomemann et a l, (2002) used a yeast two-hybrid system 
to isolate putative interacting partners. Their work suggests that L2 can interact with 
several cellular host proteins, has the ability to recmit such proteins to the nucleus and the 
property of complexing with at least three cellular proteins in specific nuclear domains. 
Two of the proteins, the previously identified PATZ and a novel protein designated
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PLINP, were localized in PODs and colocalised with L2. PATZ in a transcriptional 
regulator and member of the zinc finger proteins originally identified as an interactor for 
the androgen receptor, a nuclear homione receptor (Fedele et aL, 2000; Pero et aL, 2002). 
The third protein designated PMSP, is a newly identified cytoplasmic protein, which was 
recmited to PODs when coexpressed with L2. The functional outcome of these 
interactions is unknown. The relationship between L2 and PODs is discussed in further 
detail in section 1.3.2.
L2 has also been shown to bind p-actin, Yang et aL, (2003) demonstrated that a 
conserved domain comprising residues 25-45aa of HPV 16 L2 was sufficient for this 
interaction. The 25-45 L2 residue fused to green fluorescent protein co-localized with 
actin and caused cell retraction and dismption of the microfilament network possibly 
assisting in the release of mature vims.
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Cellular proteins shown to interact with HPV 16 L2
PATZ (POZ-AT-Zn-finger 
Tip60 (tat interacting protein) 
AUPl (ancient ubiquitous protein) 
TIN-Ag-RP
c-myc-modulating protein 
Creatine-transpoiter (CRTR) 
Serine-threonine-kinase 11 
G-protein, p-subunit 
Lysosomal a-Mannosidase 
P-actin
Table 1.4. Table showing HPV-16 L2 interacting partners identified using a yeast two-hybrid system. Data from Gornemann et al, 2002. Virology, 303, 69-78 and, from Yang et aL, 2003. J Biol Client. 278(14) 12546-53
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1.3. Promyelocytic Leukemia (PML) Oncogenic Domains 
‘TO Ds”
The cell nucleus contains a variety of moiphologically distinct substructures called 
nuclear bodies, which include the sphere organelles, colloid bodies and the PML nuclear 
bodies or PODs. PODs (also known as PML-NDIO) are maeromolecular multiprotein 
complexes that are present in all cultured cell lines as well as in vivo. They were initially 
visualised using sera horn autoimmune patients with primary biliary cinhosis. 
Immunofluorescence studies have demonstrated that depending on the cell type and other 
factors such as homional exposure and cell cycle (Doucas et a i, 1996), the number of 
PODs per nucleus can vary between 10 and 20. A major component of PODs is the PML 
protein, which was originally identified as the fusion partner of retinoic acid receptor 
alpha (RARa) in the chromosomal translocation t(15;17) in patients with acute 
promyelocytic leukaemia (APL) (de The et al., 1991; Goddard et al., 1991; Kakizuka et 
al., 1991; Lavau et al., 1995a). In leukemic cells from patients with APL that cany the 
translocation t(15;17), the expression of the PML-RARa fusion protein disrupts the 
structural integrity of PODs. In fact PML-RARa forms heterodimers in vivo, which 
results in dismption of noimal POD integrity and may contribute to the oncogenic state in 
APL patients. The POD stmcture is reformed in leukemic cells following treatment with 
a\\-trans retinoic acid (RA), a process that is associated with RA therapy (Dyck et al., 
1994; Grignani et a l, 1993; Weis et a l, 1994).
During mitosis, PODs seem to disappear until early Gi phase where they seem to 
reappear as small sites of low frequency. A cell-cycle dependent regulation of POD
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frequency has been reported (Terris et al., 1995). PML appears to be essential for POD 
assembly. Using cells that lack SplOO or PML, Ishov et al demonstrated that the lack of 
SplOO did not affect the structure of PODs. In contrast, cells lacking PML exhibited 
dispersion of all POD-associated proteins. PODs eould be reconstmcted by the 
introduction of PML into PML -/- cells either by transfection or at more physiological 
concentrations of PML through fusion with PML containing cells (Ishov et al., 1999). 
This reconstmction includes the recruitment of all POD proteins including SplOO.
The central function of PML in POD formation seems to suggest that interaction of PML 
is a key factor in the accumulation of proteins (Fig 1.7 and 1.8). Studies of other POD 
associated proteins such as Daxx (a DNA-binding protein) showed that its localisation to 
PODs depended on the presence of a PML interaction domain located at the same region 
of Daxx as the interaction domain with Fas (Ishov et al., 1999). PML has several SUMO- 
1 modification sites (Kamitani et al., 1998a; Kamitani et a l, 1998b) and it has been 
obseiwed that Daxx accumulation at PODs is dependent on SUMO-1 modification of 
PML. SUMO-1 is a small ubiquitin-related modifier, which binds to PML at three lysine 
residues (Fig 1.7) (Duprez et al., 1999; Muller et al., 1998; Stemsdorf et al., 1997). 
Testing PML constmcts with decreasing numbers of SUMO-1 modification sites suggests 
less Daxx binding at PODs. SplOO can also be SUMO-1 modified, but SUMOylation is 
not essential for its localization to the nuclear body.
52
eou
P m
CQs
0 ^
CQ
3
o
o
Bok
P h
pC
H
oU
% )
" 6U
XoOQ
bûC
GO
PQ -0
GO
X0OQ1OQ
OQ
oB3CO0
a>00c o
00 1c'C ‘5ca U
*c5oeg
c x:oo «
c&c.y -S Ü
t iî
ê f 1ii<
l ê u
o —
o
0 0c
S
X
Ic/5
<S
II,S “  
1 1
JÎ§ ,4U
ill
COIf)
(X)
oo
P n
«woet
ASo
^  3  — -O
6  s
iîilo0  zDc/5
2
1
QOa.
Ef i  
l §f 2
_)
2  — s;
£
<u
3
CT
1
3
Ol l  =tei s  c/5
m
Chapter One ______  Introduction
To date several components of the nuclear body have been identified; these include pRB, 
p53, Daxx, GBP, SplOO (transcription regulation), BLM (DNA helicase), elF-4 (initiation 
of translation), SUMO-1 (SUMOylation) and HAUSP (De-ubiquitination). An 
understanding of common biological and biochemical features shared by these molecules 
may reveal the function of the nuclear body. However the various nuclear body 
components seem to posses multiple biological functions and as such do not appear to act 
in a common pathway or share stmctural features.
SplOO is an acidic protein with a molecular mass of 54kDa, which has a highly abeiTant 
electrophoretic mobility in SDS-polyacrylamide gel electrophoresis of approximately 
lOOkDa (Szostecki et al., 1990). SplOO is an autoantigen that was originally identified in 
patients suffering from the auto-immune disease, primary biliary cinhosis. The SplOO 
gene located on the human chromosome 2  gives rise to a number of alternatively spliced 
SplOO variants, some of which contain a domain with high sequence similarity to an 
interferon-inducible human nuclear phosphoprotein HNPPl/2 (Grotzinger et al., 1996; 
Guldner et al., 1999; Seeler et al., 1998). SplOO has been described to exhibit 
transcriptional modulatoiy effects under certain experimental conditions possibly due to 
its interaction with the heterochromatin protein 1 (HPl), which has been shown to 
interact directly with SplOO (Lehming et al., 1998; Seeler et a i, 1998). Both HPl and 
SPlOO concentrate in PODs and overexpression of SPlOO leads to enhanced 
accumulation of endogenous HPl in these stmctures (Seeler et al., 1998). The molecular 
domains of SplOO for interaction with HPl is located in the C-tenninal region and the 
SplOO homo-dimerization domain in a rather long sequence at the N-terminal end
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(Sternsdorf et a l, 1999), suggesting that a three dimensional stmcture is responsible for 
the oligomerization of SplOO at PODs.
1.3.1. Association of Viruses with PODS
The association of POD bodies with viral infection was first explored by Gerd Maul 
(Maul et al., 1993) when he observed that HSV-1 infection led to the dismption of these 
nuclear bodies. Since then, there has been a great interest in the field of virology to 
understand the exact role of POD during viral infection. Today, a large number of vimses 
have been linked with POD alteration in one foiTn or the other. At present, the functional 
consequence of this alteration of PODs is still not known. It is possible that this alteration 
could be a result of nuclear reorganisation in response to infection or a specific viral 
strategy to block cellular systems that may hamper viral replication.
1.3.1.1. Interferon
Interferons (IFNs) are a large family of multifunctional secreted proteins that regulate 
cellular antiviral, antitumour and immunological responses thi'ough IFN-stimulated gene 
expression. They consist of two different types, type I IFNs (i.e. IFN-a/|3) that are 
produced in virally infected cells, and type II IFN (i.e. IFN-y) that is not virus inducible 
and is restricted to mitogen or cytokine-activated lymphoid cells such as T lymphocytes 
and natural killer cells.
It has been obseiwed that upon treatment of cells with interferon, PML is induced and the 
number of nuclear bodies increases dramatically (Gaboli et al., 1998; Lavau et al., 
1995b), possibly suggesting a role for PML and the nuclear bodies as part of the anti-viral
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defence mechanism. Apart from PML, other POD associated proteins such as SplOO, 
Sp40, Spl 10 and PA28 also have increased expression as a result of IFN treatment. Type 
I (a,(3) and type II (y) IFNs strongly enhance SplOO and PML gene expression both at the 
RNA and protein level (Chelbi-Alix et al., 1995); (Grotzinger et al., 1996; Guldner et al., 
1992; Lavau et al., 1995b) with very similar kinetics (Grotzinger et a l, 1996).
The IFNs a, p and IFNy-inducible gene promoters are characterised by the presence of 
consensus elements known as IFN-stimulated response elements (ISRE) and IFN-y 
activation sites (GAS), which mediate primary transcriptional induction in response to 
IFN-a/p and IFN-y, respectively (Darnell, Jr. et al., 1994). In the case of SplOO, elevated 
RNA levels are mainly due to an IFN-enhanced transcription rate of SplOO gene. 
Identification and analysis of ISRE and GAS in the SplOO promoter region (Grotzinger et 
al., 1996) demonsti'ated that both elements aie neeessary for long term transcriptional 
IFN-a/p induction of the SplOO gene and that the Spl 00-GAS site suffices to render a 
heterologous promoter IFN-y-inducible. Since promoters of IFN-inducible genes usually 
contain either an ISRE or a GAS element, it appears that this seems to be a unique 
characteristic of the SplOO promoter.
The PML promoter also contains an ISRE and GAS (Stadler et al., 1995). In contrast to 
SPlOO, the PML-ISRE alone is sufficient to mediate type I and II IFN-enhanced gene 
expression. Expression is usually upregulated with a noticeable swelling of POD bodies. 
Different types of PML, aiising from alternative splicing of a single gene are induced by 
IFN in different cell lines. Probably due to sequence differences the SplOO- and PML-
57
Chapter One_____________________________________________________ Introduction
ISRE bind transcription factors with strikingly different affinities (Grotzinger et al., 
1996; Stadler et al., 1995; Stemsdorf et a l, 1997). Deletion of the ISRE motif in the 
PML promoter abolishes the response to type I and diminishes induction by type II IFN, 
whereas deletion of the GAS element only modestly alters the response to IFNy. This is 
due to the binding of IFN signal transducers and activators of transcription (STATs), 
which have been shown to be weak for the GAS, but strong for the ISRE, which also 
seemed to contribute substantially to the IFN-gamma response (Stadler et al., 1995).
1.3.12. Herpes Simplex virus type one (HSV-1)
A variety of vimses target the PODs and often cause their dismption. HSV-1 carries out 
gene expression, DNA replication, and DNA encapsidation in globular nuclear domains 
designated replication compartments (Puvion-Dutilleul et al., 1995; Quinlan et al., 1984). 
These domains contain the essential viral DNA replication proteins (the origin-binding 
protein, the single-stranded DNA-binding protein, the helicase-primase subunits, and the 
polymerase subunits (Liptak et a l, 1996) (Lukonis and Weller., 1997; Quinlan et a l, 
1984)and are usually visualised by antibodies either against ICP8 , the single-stranded 
DNA-binding protein, or UL42, the polymerase processivity subunit. The formation of 
replication compartments is mediated by interactions with PODs. HSV-1 DNA 
accumulates in the periphery of the nuclear bodies (Ishov and Maul., 1996), within 
minutes of infection, the immediate early protein ICPO (VmwllO) also localizes to the 
nuclear bodies and rapidly induces their disruption (Everett et al., 1998; Everett and 
Maul., 1994). Specifically, the expression of ICPO, which like PML is a RING finger 
protein, causes a decrease in the amounts of SUMOylated PML and SplOO (Muller and 
Dejean., 1999). ICPO is a potent and promiscuous activator of gene expression and plays
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a role in lytic growth of the vims as well as in viral latency. ICPO is also a co-activator of 
ICP4 (Vmwl75), the major transcriptional regulator of HSV-1. The loss of POD staining 
after HSV-1 infection seems not to be due to degradation of the conesponding proteins 
but to relocalisation of POD proteins into vims-induced stmctures (Maul et a i, 1993; 
Puvion-Dutilleul et al., 1995). The proposal that HSV-1 induces either the degradation of 
PML and SplOO or their de-SUMOylation (Chelbi-Alix and de The., 1999) (Everett et 
al., 1998)is still widely debated. ICPO has been postulated to be a derepressing agent for 
HSV-1 viral genome; this suggests that dismption of the nuclear bodies can be a critical 
event for expression of viral genes (Everett et al., 1998).
Everett et al identified a 135kDa protein HAUSP (herpes simplex-associated ubiquitin- 
specific protease), so named because it binds strongly to the C-terminal region of ICPO 
(Everett et al., 1997). HAUSP is a member of a family of proteins that removes ubiquitin 
adducts from proteins, thus protecting them from degradation by the ubiquitin-protease 
pathway. It is distributed in the nucleus in a micropunctate pattern with a limited number 
of larger discrete foci, some of which co-localize with PML in PODs. At early stages of 
viral infection, the presence of ICPO increases the proportion of PODs, which contain 
HAUSP. The interaction of HAUSP and ICPO implicates ICPO in a ubiquitin-protease 
pathway. Deletion of the region of ICPO which binds to HAUSP reduced significantly 
its ability to stimulate gene expression and viral lytic growth (Everett et al., 1997; 
Meredith et al., 1995), and a deletion which overlaps this region eliminates the ability of 
ICPO to reactivate latent vims in an in vitro latency system (Zhu et al., 1990). Varicella 
zoster vims, type I bovine and equine herpesviruses as well as pseudorabies virus, all
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members of the alpha herpesvirus sub-family express proteins similar to ICPO which 
disrupt PODs to varying degrees (Parkinson and Everett., 2000).
1.3.1.3. Epstein-Barr virus
EBV initially replicates within epithelial cells in the oropharynx and subsequently infects 
B cells trafficking thiough the pharynx. In B cells, the vims usually converts to a latent 
form and persists indefinitely in the host (Li et ah, 1992; Sixbey et ciL, 1984). During 
latency, only a small subset of EBV-encoded proteins is expressed. The first EBV genes 
expressed during the lytic form of viral replication are the immediate-early genes BZLF-1 
and BRLFl (Kieff et ctL, 1996; (Adamson and Kenney., 2001). Both proteins function as 
transcriptional activators and induce expression of the next group of EBV genes, the early 
genes that encode the viral proteins required for EBV DNA replication (Kieff et al., 
1996). Induction of the lytic fonn of EBV infection using either expression vectors for 
BZLF-1 or BRLFl or an adenovims vector that expresses BZLF-1 leads to dispersion of 
PODs in EBV-positive cells (Adamson and Kenney., 2001). In EBV negative cells, 
expression of BZLF-1 alone but not BRLFl is sufficient to disperse PODs. The first 8 6  
amino acids of BZLF-1, which encode the transcriptional activation domain as well as 
replication function, are required for PML dispersion (Adamson and Kenney., 2001). 
EBV also expresses a protein, EBNA-5 that associates with PODs (Szekely et a l, 1996). 
EBNA-5 is one of the earliest of six nuclear proteins expressed by EBV and is nuclear 
matrix associated. EBNA-5 is homogeneously distributed throughout the nucleus within 
the early phase of infection but associates with PODs at the end of the first day of 
infection.
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1.3.1.4. Human Cytomegalovirus (HCMV)
Infection by HCMV abolishes POD staining by anti-SplOO and PML antibodies both 
during the early and late phase of infection. HCMV early proteins lEl and IE2 
accumulate in the nuclear bodies and induce their dismption (Ishov et al., 1997). 
Interestingly, lEl, like ICPO, can act as a de-SUMOylating agent for PML (or induce its 
degradation) (Maul et al., 1996). IE2 interacts with Ubc and SUMO-1,-2 and -3 
(probably through a specific SUMO-interaction domain), and can be modified by both 
SUMO-1 and SUMO-2. Mutation of the two modification sites on IE2 does not affect its 
interaction with PODs (Ahn and Hayward., 2000). The HCMV protein IE72 includes a 
potential zinc-binding motif in a region that is also required for its ability to dismpt 
PODs.
1.3.1.5. Adenovirus
Adenovims infection also results in the redistribution of PODs into fibrous stmctures of 
elongated tracks within 4 hours of infection. This redistribution of PODs into nuclear 
tracks is mediated by E4orI3 which itself co-localizes with PML in the nuclear tracks. 
The El A oncoprotein of Adenovims also concentrates in PML-containing fibres 
(Caivalho et al., 1995), which becomes visible after extraction of soluble El A from cells. 
Although E4orf3 does not affect SUMO-1 conjugation to exogenous PML in co­
transfected cells, there is a gradual change in PML during adenovims infection that 
results in an additional modification of many of the endogenous PML isoforms. This is 
followed by loss of the SUMO-1 modified PML species.
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1.3.1.6. Other viruses and PODs
As seen, viral infections appear to target and dramatically alter the composition of PODs. 
Disruption of the PODs function can in turn favour transformation by oncogenic vimses, 
or allow expression of viral genes, or aid viral replication by triggering the cell 
replication machinery though inactivation of the growth/tumour suppressive role of the 
PML nuclear body. Rabies vims genome encodes a phosphoprotein, which is amino- 
teiTninally tmncated to give four other products known as P2, P3, P4 and P5. GFP-P3 has 
been shown to localise to PODs. In Lymphocytic choriomenengitis vims (LCMV) 
infection, PML is redistributed to the cytoplasm (Borden et ciL, 1998). In the case of 
HTLV-1, the tax protein alters POD associated Int- 6  protein localisation. The binding of 
Tax to Int- 6  eauses its redistribution from PODs (Desbois et al., 1996). Hepatitis delta 
vims (HDV) large antigen (L-HDAg) colocalises with PODs during infeetion. PML is 
found in the rims with L-HDAg and viral RNA while the other POD components Sp 100 
and Daxx were found in the centre of the PODs (Bell et al., 2000).
1.3.2. Papillomavirus proteins and PODs
It has been obseived that the minor capsid protein L2 of BPV has an intrinsic capacity to 
localize to PODs in the absence of other viral components (Day et al., 1998). The 
presence of L2 in PODs appeared to be associated with the recmitment of the major 
eapsid protein LI and E2 (the transcriptional activator). L2 has been shown to also recmit 
the E2 transcriptional repressor E2TR of BPV 1 to PODs as well as the ftill-length E2TA 
(Heino et al., 2000). The association with E2 is dependent on L2 but is independent of 
LI. The reason why L2 localizes to PODs still remains unclear but one may speculate 
that E2 (which is capable of binding DNA with high-affmity at multiple sequence-
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specific sites) is recmited to PODs by L2, suggesting that L2 may hmction to facilitate 
virion production by inducing the co-localization of other components required for virion 
assembly. Alternatively association with PODs can also be speculated to play a positive 
role in viral replication. The localisation of L2 might result in an increase of the local 
concentration of viral products and as such promote viral assembly and packaging. It 
could also result in access to cellular transcription and/or replication factors promoting 
processing of viral products.
1.4, Project Aims
The role of PODs during viral infection has not been clearly defined. Viruses have been 
implicated in a variety of different ways with these discrete nuclear domains within the 
nucleus. Ai’e they part of the hosts natural defence mechanism to fight off viral infection 
or are they utilised by the vims as sites of viral replication and virion assembly?
Previous studies have shown that BPV-1, HPV-11 and HPV-33 L2 localises to PODs and 
co-expression of BPV-1 L2 with BPV-1 E2TA sees the recmitment of E2 by L2 to PODs. 
The aim of this thesis was to define the relationship between HPV-16 E2 and HPV-16 L2 
proteins. As such, the consequence of the co-localisation of E2 and L2 at PODs on viral 
transcription was studied. A number of HPV-18 LCR derived E2-responsive promoters 
with mutations in one or more E2 binding sites and two synthetic E2 responsive 
promoters linked to the tk or HPV-18 TATA were used. The effect of L2 on E2 mediated 
viral DNA replication in transient replication assays was also studied.
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HaCaT, U20S and C33a cells were used in most experiments. HaCaT are spontaneously 
immortalised kératinocytes (Boukamp et a l, 1988) while U20S are osteosarcoma cell 
lines. C33a are ceiwical carcinoma derived cells, which have no HPV DNA. The effect of 
L2 on E2 protein expression and stability was examined in all tlnee cell lines.
To further characterise the interaction of L2 with E2, the sequence domains of L2 
required for its association with E2 were investigated. Amino and carboxyl teiminus 
deletion mutants of L2 were generated. The L2 mutants were cloned into pCDNA 3.1 
expression plasmids and their effect on E2 mediated viral transcription and E2 protein 
expression was studied. Fusion forms of these mutants were constmcted with Glutathione 
S-transferase (GST) and Green Fluorescence Protein (GFP). Deletion-mutants of L2 
fused with GFP were transfected in HaCaT cells to analyse by confocal microscopy their 
localisation. This enabled conelation between the intracellulai* localisation of these 
proteins and their effects on E2 mediated transcription transactivation. GST binding 
assays were done using in vitro translated E2 labelled with ^^S-methionine to determine 
domains of L2 that bind to E2.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
2.1.1. Antibodies
SUPPLIER ANTIBODY
CalbioChem- Novabiochem corporation 
San Diego, USA
Anti-mouse IgM horseradish peroxidase 
linked whole antibody (raised in goat)
CalbioChem- Novabiochem corporation 
San Diego, USA
Anti-Actin (Ab-1). Mouse monoclonal IgM 
antibody (clone JLA20).
Amersham International pic, Amersham, 
Bucks, England
Anti-rabbit IgG horseradish peroxidase 
linked whole antibody (raised in sheep)
Amersham Pharmacia Biotech, 
Amersham, Bucks, England
Anti-mouse IgG horseradish peroxidase 
linked whole antibody (raised in sheep)
Amersham Pharmacia Biotech UK Ltd. 
Amersham, Bucks, England
Anti-GST goat polyclonal antibody 
horseradish peroxidase conjugated
Sigma Chemical Co., Ltd., Poole, 
Dorset, UK
Anti-Rat IgG (whole molecule) peroxidase 
conjugate (raised in rabbit)
Sigma Chemical Co., Ltd., Poole, 
Dorset, UK
Anti-Rabbit IgG (whole molecule) 
peroxidase conjugate (raised in goat)
Santa Cruz Biotechnology, Inc 
California, USA
Anti-GFP (FL) rabbit polyclonal IgG 
antibody (Sc-8334)
Santa Cruz Biotechnology, Inc. 
California, USA
Anti-HA Rabbit polyclonal IgG antibody (Y- 
11: Sc-805)
A gift from Dr. M. Hibma, ICRF 
Tumour Virus Group, University of 
Cambridge
TVG261, a monoclonal antibody directed 
against amino acids 2-17 in the amino 
terminus of HPV-16 E2.
Roche Diagnostics GmbH, Germany Anti-HA high affinity rat monoclonal 
antibody (clone 3FI0)
A gift from Dr. M. Muller, Deutsches HPV-16 L2 polyclonal rabbit serum (No. 20)
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Krebsforschungszentrum, Angewandte 
Tumorirologie, Heidelberg, Germany.
2.1.2. Bacterial Hosts
SUPPLIER BACTERIAL HOSTS
Invitrogen Life Technologies, Ltd., 
Paisley, Scotland
E. coli DH5a competent cells
Amersham International pic, Amersham, 
Bucks, England
E. coli BL21 competent cells
2.1.3. Buffers
TE lOmM Tris-HCl pH 8.0, ImM EDTA pH 
8.0
lOx TBE buffer 900mM Tris base, 900mM boric acid, 
25mMEDTA, pH8.0
1 X ligase buffer 50mM Tris HCL pH7.6, lOmM MgClz, 
ImM ATP, ImM DTT, 5% (w/v) 
polyethylene glycol-8000
Phosphate buffered saline (PBS) 137mM NaCl, 44mM KCl, 1.4 mM 
KH2 PO4 , 8.5 mMNa2 HP0 4
10 X loading buffer 0.45% (w/v) Bromophenol blue, 1% (w/v) 
SDS, lOOmM EDTA, 2.5% (w/v) Ficoll 
400 in TE
SDS-PAGE Lysis buffer IM Tris-HCl (pH 6.8), 10% (w/v) SDS, 
20% (v/v) glycerol
SDS-PAGE Resolution gel buffer 0.5M Tris (pH8.8), 0.4% (w/v) SDS
Tris-glycine electrophoresis buffer 25mM Tris, 250mM glycine and 0.1% 
(w/v) SDS
2x SDS gel loading buffer 4% (w/v) SDS, 0.2% (w/v) bromophenol
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blue, 20% (v/v) glycerol and lOOmM Tris,
2.1.4. Cells
Cell types Description Growth Medium
HaCaT Spontaneously immortalised 
kératinocytes
Dulbecco’s Modified Eagles 
Medium,
10% Foetal Calf Serum 
ImM sodium pyruvate 
4mM L-glutamine 
100 lU penicillin 
lOOpg streptomycin
HaCaT-E2 HaCaT derived cell line 
expressing HPV-16 E2 
constitutively kindly 
provided by Dr Pablo 
Cordano, ICM, Glasgow.
Dulbecco’s Modified Eagles 
Medium,
10% Foetal Calf Serum 
ImM sodium pyruvate 
4mM L-glutamine 
100 rU penicillin 
lOOgg streptomycin 
Geneticin G418 sulphate
C33a Human cervical carcinoma 
cells with no HPV DNA
Dulbecco’s Modified Eagles 
Medium with GlutaMAX-1 
4500mg/L D-Glucose with 
sodium pyruvate 
10% Foetal Calf serum 
100 lU penicillin 
lOOpg streptomycin
U20S Osteosarcoma cell line Dulbecco’s Modified Eagles 
Medium with GlutaMAX-1 
4500mg/L D-Glucose with 
sodium pyruvate
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10% Foetal Calf serum 
100 lU penicillin 
lOOpg streptomycin
2.1.5. Cell Culture Materials
SUPPLIER MATERIAL
Cadisch and Sons, Finchley, UK 70|im filter nylon gauze
Invitrogen Life Technologies, Ltd., 
Paisley, Scotland
Foetal Calf Serum
Invitrogen Life Technologies, Ltd., 
Paisley, Scotland
10% Dulbecco s Modified Eagles Medium
200 mM glutamine
Geneticin, G418 sulphate
100 mM sodium pyruvate
2.5% Trypsin
2.1.6. Chemicals and Enzymes
Supplier- Amersham International pic. Amersham, Bucks. England
ECL Western detection agent
ECL Plus Western detection agent
Redivue [a^^PJdATP
Amplify™ Fluorographic reagent
Glutathione Sepharose® 4B
Supplier- BDH Chemicals Ltd.. Poole. Dorset. England.
Calcium chloride
D-glucose
Glycerol
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Supplier- Beta Lab.. East Moslev. Surrey. England.
Yeast Extract
Supplier- Boehringer Mannheim UK Ltd.. Lewes. East Sussex. England.
DNase 1, RNase-free 
Protease K
Supplier- Calbiochem (Merck)
MG-101; Calpain Inhibitor 1
MG-132; Carbobenzoxt-L-leucyl-L-leucyl-L-leucinal
ALLM; Calpain Inhibitor 11
Lactacystin, synthetic
Leupeptin hemisulfate
Supplier- Difco laboratories. Detroit. Michigan. USA.
Bacto-Agar
Bactotryptone
Supplier- Fisons Scientific Equipment. Loughborough. England.
Acetic acid 
Butan-l-ol 
Chloroform
di-potasium hydrogen orthophosphate anhydrous 
Ethylene diamine tetra acetate (EDTA) disodium salt 
Dimethyl sulfoxide (DMSO)
Hydrochloride acid 
Magnesium chloride 
Magnesium sulphate 
Methanol 
Potassium chloride
Potassium dihydrogen orthophosphate 
Propan-2-ol
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Sodium acetate
Sodium carbonate
Sodium chloride
Sodium dodecyl sulphate (SDS)
Sodium hydroxide
Supplier- Invitrogen Life Technologies. Ltd.. Paisley. Scotland.
All DNA restriction enzymes and appropriate buffer concentrates were obtained from 
Invitrogen Life Technologies unless otherwise stated. The following reagents were also 
obtained from Invitrogen:
Agarose (ultrapure electrophoresis grade)
Tris Base
LIPOFECTAMINE™ Reagent 
LipofectAMINE PLUS™ Reagent 
Superscript™ One-Step RT-PCR with PLATINUM® Taq 
Deoxyribonuclease 1, Amplification Grade
Supplier- James Burrough Ltd.. Witham. Essex. England.
Ethanol
Supplier- NBL Gene Sciences 
Alkaline phosphatase 
T4 DNA ligase
Supplier- New England Biolabs
NEB buffer 2
Xmnl
Dpnl
Bovine Serum Albumin
Supplier- Novagen. Inc USA 
BugBuster™ Protein Extraction Reagent
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Supplier- Promega. Southampton. England
Deoxynuclease Triphosphates (dNTPs); dATP, dCTP, dGTP, dTTP
Rnasin ® Ribonuclease Inhibitor
Pfu DNA Polymerase
AMV Reverse transcriptase
Supplier- Sigma Chemical Co.. Ltd., Poole. Dorset. England.
Arabinose 
(3-mercaptoethanol 
Bicinchoninic Acid solution 
Bovine Serum Albumin 
Bromophenol Blue 
Coomassie Brilliant Blue R
Copper(II) sulphate (pentahydrate 4% (w/v) solution)
DEPC
Dithiothreitol (DTT)
Ethidium Bromide
Kanamycin
Leupeptin
Nonidet P-40 (NP40)
Phenol:Chloroform;Isoamyl Alcohol (25:24:1 (v/v))
PMSF
Ponceau S solution
TEMED (N,N,N’ ,N’ -tetramethylethylenediamine)
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
Supplier- Roche Diagnostics GmbH. Germanv 
Protease Inhibitor Cocktail tablets
Supplier- Stratagene.
QuickHyb® Hybridization Solution 
Prime it 11 Random primer labelling kit
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Supplier-Qiagen, Dorking. Surrey. England 
Superfect Transfection Reagent™
Supplier- Vector Laboratories. Burlingame, USA. 
Vectashield™ Mounting Medium
2.1.7. Equipment and Plasticware
SUPPLIER EQUIPMENT
Alpha Laboratories Ltd., Eastleigh, 
Hampshire, England
Microfuge tube 
Pastettes
Amersham International pic, Amersham, 
Bucks, England
Hybond-C extra 
Hybond-N
Becton Dickinson Lab ware, Plymouth, 
England
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes 
Falcon 2097 polypropylene tubes 
Falcon 2098 polypropylene tubes 
Sterile Plastipak syringes 
18 gauge sterile syringe needles 
60, 90 and 140 mm tissue culture dishes
Greiner Sterile bijou tubes 
Sterile universal tubes 
Cell scrapers 
Filter tips
60 and 100mm bacteriological petri dishes 
Sterile plastic universal containers
Corning B V, High Wycombe, Bucks, 
England
25ml, 10ml 5ml pipettes 
24 well tissue culture plates 
96 well tissue culture plates 
Cryogenic vials
Eastman Kodak Co., Rochester, New 
York, USA
X-ray film (XAR-5)
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VMR (MERCK/BDH) Sterile syringes 
Needles 
Saran wrap 
Foil
Ilford Ltd., Mobbrrley, Cheshire, England Ilford PANF 50 black and white film
Scientific Laboratory Supplies T25, 80, and 175 cm^ tissue culture flasks
Sartorius Sterile 0.2gm filter 
Sterile 0.45p.m filter
Labco Cin Bins
Whatman International Ltd., Maidstone, 
Kent, England
Whatman 3MM filter paper
2.1.8. Kits
SUPPLIER KIT
Perkin Elmer Cetus, Norwalk, USA. Gene Amp PCR core kit
Gene Amp thinwalled reaction tubes
BigDye™ Terminator Cycle Sequencing
Promega Ltd., Chilworth Research Centre, 
Southampton, England
Luciferase Assay System 
Reporter Lysis 5 X Buffer 
TNT® Quick Coupled 
transcription/translation system
Qiagen Ltd., Dorking, Surrey, England QIA prep Spin plasmid miniprep kit 
QIA quick gel extraction kit 
RNeasy Mini RNA purification kit 
Omniscript RT Kit 
HotStar Taq PCR Kit
Applied Biosystems Big dye 3 
Big dye 3 buffer 
HI-DI formamide
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2.1.9. Molecular W eight Markers
SUPPLIER MARKER
Invitrogen Life Technologies, Ltd., 
Paisley, Scotland
Rainbow™ coloured protein molecular 
weight markers
Invitrogen Life Technologies, Ltd., 
Paisley, Scotland
Bacteriophage X DNA (Hindlll digested) 
lOObp DNA ladder 
1Kb DNA Ladder
2.1.10. Other Materials
SUPPLIER MATERIALS
Veterinary Pathology Central Services LB-Medium (Luria-Bertani Medium) 
TSS (Transformation storage solution) 
YTA medium 
Sterile distilled water 
Sterile glycerol
Sterile phosphate-buffered saline (PBS)
Merck Ltd., Poole, England Silicone grease
Johnson and Johnson Medical Limited, 
Berks, UK
PRESEPT* effervescent disinfectant 
tablets
Premier Beverages., Adbaston, Stafford, 
UK
Marvel (Dried Skimmed milk)
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2.1.11. Plasmids
pCMV is an expression vector which contains the cytomegalovirus (CMV) immediate- 
early promoter/enhancer, pCDNA 3.1+ is a 5.4kb vector derived from pcDNA3 and 
designed for high-level stable and transient expression in mammalian hosts. It also contains 
CMV promoter and a multiple cloning site, which facilitates cloning.
pCMV-Elie is a construct that consists of the HPV-16 DNA fragment nt 865 to 2813 
encoding the E l protein, amplified by PCR to add the Kozak consensus sequence, inserted 
into the Xbal-Smal sites of pCMV4 .
p C M V - E 2 i6  contains the HPV-16 DNA fragment from nt 2725 to 3852 encoding the 
viral transcription regulator E2, excised from pSK-E2i6 and cloned into the Xbal-Smal 
sites.
pGL3 is a luciferase reporter vector obtained commercially from Promega
pGL3 CONT contains the SV40 enhancer-promoter driving expression of the luciferase 
gene. This reporter plasmid is commercially available from Promega.
pBPV-4LCR contains the BPV-4 LCR from nucleotide 6710-331 cloned into the BamHl 
site of the pOluc luciferase plasmid.
pl8LCR-BSl is a pGL3 luciferase reporter plasmid that contains the full length HPV-18 
LCR with four point mutations in the E2 binding site 1 introduced by PCR.
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pl8LCR-BSl-3 contains the HPV-18 LCR with mutations in the E2 binding sites 1-3. It 
was derived from CAT reporter plasmid, generously provided by F. Thierry.
pl8-6E2 is a luciferase reporter plasmid which contains six E2 binding sites linked to the 
HPV-18 TATA box promoter element.
ptkluc contains the tk promoter from HSV-1 cloned into the pGL2 luciferase vector.
ptk6E2 is a ptkluc with six E2 binding sites linked to the tk promoter.
pl6ori contains the HPV-16 origin of replication (nucleotides 7838-130 of the HPV-16 
genome) cloned into pBSII SK(-)(Stratagene). This plasmid was a gift from Prof. Peter 
Howley (Harvard University).
pl6ori-m, is a pl6ori plasmid with a point mutation at nt 115 from C to A to create a 
Dpnl restriction enzyme site.
pCDNA-L2 is a construct that consists of the HPV-16 DNA fragment nt 4135 to 5560 
encoding the minor capsid protein L2, amplified by PCR and inserted into the BamHl- 
EcoRl sites of pCDNA 3.1 under the control of cytomegalovirus promoter.
pl6-HAL2 contains the HPV-16 L2 DNA sequence from nt 4135 to 5656 inserted into 
pHAl between the Xhol and Xbal sites under the transcriptional control of a CMV 
promoter. pHAl was a kind gift from C.W. Lee. It contains three copies of the HAl 
epitiope cloned in pcDNA3 (Invitrogen, UK).
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pEG FP-Cl is a eukaryotic expression plasmid for the Green Flourescent Protein (GFP). 
GFP expression is driven by the CMV promoter and the multiple cloning site is between 
the GFP sequences and SV40 poly A site. It is commercially available from Clontech Lab. 
This plasmid was a kind gift from Dr M. Roberts (ICM, Glasgow).
pEGFP-L2 is a pEGFP plasmid expressing the GFP protein fused amino terminally to the 
full-lenght HPV-16 L2 protein.
pGEX-4T-2 contains a GST domain and the recognition sequence for thrombin cleavage. 
This plasmid is commercially available from Amersham Pharmacia Biotech.
pGEX-L2 expresses the GST protein fused to wild type HPV-16 L2 under the control of 
the tac promoter.
A series of L2 deletion mutants were designed generating amino and carboxyl terminal 
deletions of the HPV-16 L2. All mutants of L2 were cloned into pCDNA 3.1+, pEGFP- 
N1 and pGEX-4T-2. A summary of all deletion mutants is given in the table below.
Mutant
l-400aa Encoding HPV-16 L2 from amino acids 1- 
400
l-300aa Encoding HPV-16 L2 from amino acids 1- 
300
l-200aa Encoding HPV-16 L2 from amino acids 1- 
200
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1-lOOaa Encoding HPV-16 L2 from amino acids 1- 
100
l-50aa Encoding HPV-16 L2 from amino acids 1- 
50
25-473aa Encoding HPV-16 L2 from amino acids 25- 
473
50“473aa Encoding HPV-16 L2 from amino acids 50- 
473
150-473aa Encoding HPV-16 L2 from amino acids 
150-473
250-473aa Encoding HPV-16 L2 from amino acids 
250-473
350-473aa Encoding HPV-16 L2 from amino acids 
350-473
390-473aa Encoding HPV-16 L2 from amino acids 
390-473
2,1,12. W ater
Distilled water for the preparation of buffer stocks was obtained from a Millipore MilliRQ 
15 system, and for protein, enzyme, RNA or recombinant DNA procedures was further 
purified on a Millipore MilliQ System to 18MiQ/cm.
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2.2. Methods
2.2.1. Molecular biology
2.2.1.1. DNA Extraction
DNA samples were purified by extraction with phenol;chloroform in order to remove 
contaminants, such as residual enzyme activities from a restriction reaction or detergent 
which might otherwise interfere with subsequent cloning steps. In the first round of 
extraction the DNA sample was mixed with an equal volume of phenol:chloroform. The 
aqueous DNA and organic phase were mixed thoroughly by vortexing, and then separated 
by centrifugation in a microcentrifiige at 14000 rpm for 5 minutes at room temperature. 
The upper aqueous phase was transferred in a clean eppendorf tube, care was taken not to 
transfer any of the interphase to the tube, and the extraction process repeated. The 
aqueous phase was then extracted with an equal volume of chloroform 
(chloroform: isoamyl alcohol, 24:1 v/v) by vortexing and centrifugation as described 
above. This was repeated to remove any traces of phenol from the aqueous phase. The 
aqueous phase was transferred to a fresh eppendorf for ethanol precipitation.
Ethanol precipitation was used to concentrate DNA samples and also to remove solute 
contaminants such as salt. The aqueous DNA solution was mixed with one-tenth volume 
of 3M sodium acetate pH 5.2 and 2-2.5 volumes of ice-cold ethanol. The sample was then 
mixed well by inversion several times and then stored at -20°C or, alternatively, placed on 
dry ice for 15-30 minutes to facilitate DNA precipitation. The precipitated DNA was 
collected by centrifugation in a microcentrifuge at 14000 rpm for 15 minutes at 4°C. The 
supernatant was discarded, the pellet was washed with 70 % ethanol to remove any trace
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of salt and dried under vacuum before resuspension in distilled water at an appropriate 
concentration. The DNA concentration was determined as described below.
2.2.1.2. Quantification of Nucleic Acids
The concentration of nucleic acid in a solution was determined spectrophotometrically in a 
WPA UVl 101 Biotech spectrophotometer. Samples were diluted in dH20 and transferred 
to a quartz cuvette with a pathway of 1cm. The spectrophotometer was initially calibrated 
using dH20 only as a blank. The optical density reading were obtained at 260nm and 
280nm; an O.D, reading of 1 at 260nm (A2 6 0  -  1) corresponds approximately to a 
concentration of 50p,g/ml of double stranded DNA, for oligonucleotides an A2 6 0  of 1 was 
taken to correspond to ~35p,g/ml, and for RNA an A2 6 0  of 1 was taken to correspond to 
40|ug/ml. The ratio between readings at 260nm and 280nm (A2 6 o:A2 8 o) provided an 
estimate of the sample purity; a ratio of -1,8 indicated that preparations contained 
essentially no protein or phenol contamination.
2.2.1.3. Restriction Enzyme Digestion of DNA
Restriction digests were carried out in small reaction volumes using enzymes and their 
appropriate concentrated buffer solutions according to the manufacturer’s instructions. 
Plasmid DNA was incubated with 5-10 units enzyme/|ug DNA in a buffered solution 
ensuring that the total volume of enzyme added did not exceeded one tenth of the final 
reaction volume. Small quantities of plasmid DNA (<5pg) were routinely digested in a 
20|ul reaction volume as specified by the manufacturer for 1 hour at 37“C. Large digests 
were carried out in proportionally larger reaction volumes. The digestion fragments were 
analysed by agarose gel electrophoresis as described below.
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2.2.1.4, Agarose Gel Electrophoresis
In general, 1% (w/v) agarose gels were used, but smaller fragments (100-400) were 
separated on 2-4% gels. Low melting point agarose was used at a concentration of 1% 
(w/v) in order to isolate and purify required DNA restriction fragments. Gel mixes 
containing the appropriate amount of agarose were dissolved in 0.5 x TBE buffer by 
heating the solution in a glass conical flask in a microwave until all the particles of agarose 
gel had dissolved. The gel was poured when the agarose was hand hot and a comb with 
the required number and size of teeth placed immediately into the gel to form the sample 
wells. The gel was submerged in 0.5 x TBE buffer. The samples containing 1 x loading 
buffer were loaded in each well along with an appropriate size marker (e.g. 100b ladder, 
1Kb ladder) into the first and/or last well in the gel and run at 70-100 constant voltage 
usually until the samples’ blue dye front was 1-3 cm from the end of the gel. Once run, 
the DNA fragments were visualised by staining the gel in running buffer containing
0.5p,g/ml ethidium bromide with gentle agitation for 10 minutes at room temperature. The 
separated DNA was visualised by illumination with short wave (312nm) UV light and 
photographed through a red filter onto video print paper using an UVP gel documentation 
system.
2.2.1.5. Southern Blotting
The DNA fragment to be used was digested with the appropriate restriction enzymes as 
described in section 2.2.1.3 and run on an agarose gel with the appropriate DNA size 
markers (2.2.1.4). The gel was stained with ethidium bromide and photographed with a 
ruler laid alongside the gel so that band positions can be identified on the membrane. The 
following procedure was then undertaken:-
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1. The gel was rinsed in distilled water and placed in a clean glass dish containing -10 
gel volumes of dénaturation solution (1.5MNaCl, O.SMNaOH) and shaken slowly 
on a platform shaker for 30 minutes at room temperature. This was done twice.
2. The dénaturation solution was poured off and the gel rinsed with distilled water 
washed twice with -10 gel volumes of neutralisation solution (1.5M NaCl, 0.5M 
Tris-HCi pH 7.0) shaking slowly on a platform shaker for 30 minutes at room 
temperature.
3. To transfer the DNA from the gel to the membrane, a solid support was placed in a 
glass dish with wicks made out of Whatman 3MM filter paper. Three pieces of 
Whatman 3MM paper the same size as the gel was then cut and stacked onto the 
solid support.
4. The gel was rinsed in distilled water and placed on the filter paper stack and air 
bubbles were removed by rolling a glass pipette over the surface.
5. Four strips of plastic wraps were cut and placed over the edge of the gel so that 
the buffer flows through rather than around the gel.
6. A piece of Hybond-N nylon membrane just large enough to cover the exposed 
surface of the gel was immersed in distilled water for -5  minutes. The wet 
membrane was then placed on the surface of the gel. Air bubbles were removed by 
rolling a glass pipette over the surface of the membrane.
7. The surface of the membrane was then flooded with 20 x SSC (3M NaCl, 0.3M 
C^HsO^Nas (tri-sodium citrate)). Five sheets of Whatmann 3MM filter paper cut to 
the same size of the gel were placed on top of the Hybond-N membrane.
8. Paper towels were then cut the same size as the membrane and stacked on the top 
of the Whatmann 3MM paper to a height of-4cm.
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9. A glass plate was placed on top of the structure and a weight placed on top to hold 
everything in place and left overnight.
The next day, the paper towels and filter paper were removed and the Hybond-N 
membrane recovered. The membrane was rinsed in 2 x SSC and placed on a sheet of 
Whatmann 3MM paper to dry. The membrane was then placed in a Spectrolinker 
XL1500 (Spectronics Corperation) and irradiated with 1600 J/m^ of UVC at 254nm to 
crosslink the DNA. The membrane was then baked for >60 minutes at 80“C in a 
Hybaid mini-oven MKII hybridisation oven.
2.2.1.6. Isolation and Purification of DNA Restriction Fragment from  
Agarose Gel
The DNA fragment to be used for cloning was recovered from low melting point agarose 
gel and visualised as described in section 2.2.1.4. The fragment was cut out of the gel 
with a clean scalpel blade and the gel slice placed in an eppendorf tube. Extraction of the 
DNA fragment from the agarose was achieved using a Qiagen Qiaquick gel extraction kit 
following the manufacturer’s instructions.
2.2.1.7. Ligation of DNA Fragments
Both vector DNA and the DNA fragment to be inserted into the vector were separately 
digested with restriction enzymes and purified as described above and then isolated by gel 
electrophoresis as described in section 2.2.1.4. The vector DNA was dephosphorylated at 
its termini to prevent re-ligation. After the vector DNA had been linearized by digestion, 
the reaction mixture was adjusted by adding dephosphorylation buffer and 1 unit of Calf 
Intestinal Alkaline Phosphatase (CIAP) was added to the reaction mixture and incubated 
at 37°C for 1 hour. The reaction was stopped by heating to 90‘’C for a further 5 minutes.
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All enzyme activity in the reaction was finally stopped by heating to 90°C for a further 5 
minutes.
The DNA was phenol:chloroform extracted, ethanol precipitated and then resuspended in 
appropriate volume of distilled water and stored at -20°C. The DNA fragment was 
incubated with dephosphorylated vector (lOOng) at a ratio of 3:1 respectively in a reaction 
containing 1 x ligase buffer and 1 unit of T4 ligase at 16”C for 1 hour or overnight. 
Dilutions of this reaction volume were used to transform competent bacterial cells (section 
2 .2 . 1.8).
2.2.1.8. Preparation of competent cells
E. coli BL21 (Amersham Pharmacia Biotech) were made competent according to the 
manufacturers instructions. A sterile streak technique was used to streak bacteria from a 
glycerol stock onto an LB medium plate and incubated overnight. A single colony was 
isolated and used to inoculate 50ml of LB broth at 37°C with shaking at 225rpm until cells 
grew to an absorbance measurement of 0.4-0.5 at 600 nm. Cells were sedimented at 
approximately 2500xg for 15 minutes at 4“C, then gently resuspended in 1/10 volume (5- 
10ml) of ice-cold TSS (l.Og tryptone, 0.5g yeast extract, 0.5g NaCl, lOg polyethylene 
glycol, 5ml dimethylsulfoxide [DMSO], and 5ml MgCb [1ml] in 70ml sterile dHzO) and 
placed on ice. Cells were transformed within 2-3 hours.
2.2.1.9. Transformation o f  E  c o l i  BL21 cells
GST expression plasmids were transformed and expressed in E  coli BL21 made 
competent as described above (2.2.1.8). For transformation, 1 ml of freshly prepared 
competent bacteria was added to pre-chilled 50ml sterile disposable centrifuge tubes and
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stored on ice. Ing of plasmid was added to the cells, and swirled gently to mix and placed 
on ice for 45 minutes. The cells were heat shocked in a 42”C water bath for 2 minutes then 
chilled briefly on ice. lOOpl of transformed cells were then transferred to 17x100mm tubes 
(Falcon) containing 900pl of LBG medium (LB + 20mM glucose) pre-warmed to 37"C 
and incubated for Ihour at 37‘’C with shaking at 225rpm. lOOpl of the diluted transformed 
cells were plated onto LB AG plates (LBG + lOOpg/ml ampicillin). The plate was inverted 
and incubated overnight at ?>TC to allow colony formation. Frozen glycerol stocks 
cultures were prepared as described below in section 2.2.1.11.
2.2.1.10. Transformation o f  E  c o l i  D H 5a cells
Plasmids were propagated in commercially available E. coli DH5a competent cells 
supplied as frozen stocks (Invitrogen) kept at -70°C until use. Bacteria were transformed 
following manufacturer s instructions. Competent cells were thawed slowly on ice, and 
20gl of aliquots put into prechilled 1.5ml eppendorf tubes. 1-2 ng of the appropriate 
plasmid DNA was added to each aliquot and mixed by gently moving the pipette tip 
trough the cells while dispensing. The cells were then incubated on ice for 30 minutes 
before being heat shocked for 45 seconds at 42”C. The tube was then immediately placed 
on ice for 3 minutes. 180 p.1 of room temperature SOC Media (2% Bactotryptone, 0.3% 
Yeast Extract, lOmM NaCl, 2.5mM KCl, 20mM Mg^' Stock (equimolar ratio of 
MgCli.ôHzO & MgS0 4 .7 H2 0 ) and 20mM Glucose) was then added to each 
transformation reaction. The tube was then transferred to a shaking 37°C incubator 
(approximately 225rpm) for 1 hour to allow expression of the antibiotic resistant marker.
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2.2.1.11. Glycerol Stocks
Host strains, and their derivatives containing useful plasmids, were stored as glycerol 
stocks for future retrieval. 800 p,l of an overnight culture was mixed gently with 200 p,l 
sterile glycerol in a 1.5 ml Nunc Ciyotubes and stored at -70°C. A sterile plastic loop was 
used to retrieve an aliquot of cells as and when required.
2.2.1.12. Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were extracted from transformed bacterial colonies to
identify correct clones. Single colonies of bacteria carrying the required plasmid were 
picked using a sterile yellow pipette tip and grown in 5 ml culture of L-Broth (1% w/v 
Bactotryptone, 0.5% w/v yeast extract, 1% w/v NaCl) containing antibiotic (lOOpgAnl 
Ampicillin) at 37“C in a shaking incubator (225rpm) overnight. 10 separate colonies were 
generally picked for screening at any one time. Bacteria were pelleted from 1.5ml of 
overnight culture by spinning in a micro centrifuge (MOOOrpm) for 30 seconds at room 
temperature. DNA was prepared using the QIA prep Spin plasmid miniprep kit following 
the manufacturer’s instructions.
2.2.1.13. Large Scale Preparation of Plasmid DNA (Maxiprep)
Bacteria containing the plasmid of interest were streaked onto an L-agar plate containing
the appropriate antibiotic and the plate inverted and incubated overnight at 37°C to allow 
colony formation. A single colony was picked, using a sterile yellow tip, from this plate 
and used to inoculate a sterile universal tube containing 5 ml of L-Broth medium and the 
appropriate antibiotic (100|ug/ml Ampicillin) which was then put in a shaking incubator at 
225rpm overnight at 37°C. This culture was then added to 500 ml of broth, containing 
100|Lig/ml Ampicillin in a 1 litre glass conical flask (to allow good aeration), then returned
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to the shaking incubator for 48 hours. DNA was prepared using the QIA prep Spin 
plasmid maxiprep kit following the manufacture’s instructions,
2.2.2. Cell Culture and Transfection
2.2.2.1. Cell Culture
All cell culture work was performed following strict aseptic techniques inside a laminar 
flow hoods (Class II Microbiological safety Cabins; Gelaire BSB4), Cells were incubated 
in dry 37°C incubators containing 5% (v/v) CO2  (Napco Model 5410 Genetic Reseach 
Instrumentation LTD).
2.2.2.2. Maintenance of cells in culture
Cells were fed twice weekly, old medium was aspirated from sub-confluent flasks and 
fresh medium added. Replating was performed as follows: for T150 cm^ tissue culture 
flask medium was aspirated off and the cells washed once with 10 ml phosphate-buffered 
saline (PBS). The PBS was removed and 1 ml of trypsin solution (0.25% trypsin in Ix PE 
buffer; PBS with the addition of EDTA to 1 mM), which had been pre-warmed to 37°C, 
was added to cells. Flasks were transferred to the 37“C incubator until the cells had 
detached from the flasks. Complete medium was added and the cell suspension transferred 
to a sterile universal tube. The cells were pelleted by centrifugation at lOOOrpm for 5 
minutes at room temperature. The pellet was then resuspended in fresh growth medium 
and the cells reseeded at a 1:10 density.
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2.2.2.3. Long Term Cell Storage
To freeze cell stocks for storage, confluent cultures were trypsinised, and pelleted as 
described above (section 2.2.2.2). The pellet was then resuspended at a concentration of 
approximately 10^  cells/ml in growth medium containing 10% (v/v) DMSO. The DMSO 
in the medium acts as a cryoprotectant but all solution must be chilled, as DMSO is toxic 
to cells at room temperature. Suspensions were divided into 1 ml aliquots in 1-2 ml Nunc 
cryotubes and placed in a polystyrene box and frozen, well insulated, at -70°C overnight to 
ensure a slow rate of cooling. The ampoules were then transferred to a liquid nitrogen 
bank containing labelled storage rack until required. Frozen stocks were recovered by 
removing the ampoules from liquid nitrogen and placing them into a small, covered bucket 
of water at 37”C. Once thawed, the cells were added to 10ml of the appropriate pre- 
warmed growth medium, centrifuged, resuspended in fresh growth medium and 
transferred to 175 cm  ^flasks.
2.2.2.4. Transient Transfection of HaCaT and C33a cells
C33a cells were transiently transfected using a standard calcium phosphate precipitation
technique. Cells were plated out at ôxloVôOmm tissue culture dish. The following day a 
solution of calcium phosphate containing the DNA was added to the cells. This was 
carried out as follows, for each 60mm cell monolayer; 250gl of a solution containing the 
plasmid DNA in 250 mM CaClz was added dropwise with gentle mixing to 250pl to 2x 
HEPES buffered saline (280mM NaCl, lOmM KCl, 1.5mM Na2HP0 4 .2 H2 0 , 50mM 
HEPES). The mixture was left for 30 minutes to allow a fine precipitation to form and 
added directly into the medium above the cell monolayer. 16-18 hours later, the cells were 
washed twice with PBS and refed with fresh growth medium. The cells were harvested
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24-32 hours later. HaCaT cells were transfected using LIPOFECTAMINE PLUS™ 
Reagent (Invitrogen) according to the manufacturer’s instructions.
2.2.2.5. Luciferase Assays
Transfected C33a and HaCaT cells were lysed directly on 60mm tissue culture plates. 
Cells were washed twice with PBS. The PBS then was completely removed by aspiration 
and 200p.l of 1 x reporter lysis buffer (Promega) added to each plate. Following 10 
minutes incubation at room temperature, cells were scraped off the culture plate and each 
lysate transferred to a 1.5ml eppendorf. Cell debris was pelleted by spinning lysates at 4°C 
in a microcentrifuge at MOOOrpm for 5 minutes. The supernatant was transferred to a 
second eppendorf tube taking care not to disrupt the cell pellet. The lysate were either 
assayed for reporter enzyme activity immediately or stored at -20°C.
Luciferase activity was determined using a luminometer with automatic injection 
(Luminoskan Ascent-Thermo Labsystems). For each sample, 80pl of lysate and 80pl of 
Luciferase assay buffer (Promega) were used. Luciferase activity was normalised for 
protein content determined using the BCA assay (Sigma).
2.2.2.6. Transient DNA replication assay
Transient DNA replication assays were performed in C33a cells, as first described by 
Sakai et al., (1996) and as modified by Boner et al., (2002). Cells were set up in 100mm 
plates at 6x10^ per plate and transfected with Igg pl6ori-m, 5gg pCMV-Elie, lOng or 
lOOng pCMV-E2i6 with or without Ipg pl6-HAL2 using calcium phosphate precipitation 
method for C33a cells or LIPOFECT AMINE PLUS™ Reagent method for HaCaT cells, 
respectively. Low molecular weight DNA was extracted using the Hirt protocol (Hirt B.,
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1967) modified as described below. On day two after transfection, cells were washed with 
PBS and 800pl of Hirt solution (0.6% SDS, lOmM EDTA) was added per plate. After 5 
minutes the cell lysate was transfered into 1.5ml tubes and 200pl of 5M NaCl was added 
to each tube. The tubes were mixed by inverting gently to allow efficient precipitation of 
genomic DNA and left overnight at 4°C. The next day samples were centrifuged at 15000g 
for 30 minutes at 4°C and the supernatant, containing low molecular weight DNA, was 
retained while the pellet was discarded. DNA in the supernatant was phenol-chloroform 
extracted and ethanol precipitated. To create linearised plasmid, 25gl of each sample were 
digested with 2OU Xmnl for 3 hours at 37“C. Linearised plasmid was further digested 
with 2OU Dpnl overnight at 37°C. Xmnl linearises pl6ori-m while Dpnl digests only 
unreplicated -methylated DNA. Replication was assayed after Xmnl and Dpnl 
digestion. DNA was electrophoresed in a 1% agarose gel in 0.5x TBE and transferred to a 
Hybond-N nylon membrane (Amersham Pharmacia Biotech, UK) by Southern blotting as 
described in section 2.2.1.5. Hybridisation was done using QuikHyb hybridisation solution 
(Stratagene, UK) according to the manufacturer’s instructions. A Molecular Dynamics 
Storm 840 phosphoimager (Amersham Pharmacia Biotech, UK) was used to scan the 
Southern blot and quantify hybridised signals. The extent of replication was calculated by 
measuring the ratio of double cut/single cut bands. This method of measurement controls 
for variation in transfection efficiency between experiments.
2.2.2.7. Probe for Hybridisation
The pl6ori-m (2pg) plasmid was digested with Pvull. The digestion was electrophoresed 
in a 1% agarose gel and a band of ~700bp, corresponding to the sequence of HPV 16-ori, 
was cut out. It was purified using the QIAquick™ Gel Extraction kit (QIAGEN, UK) and 
eluted in 60pl dH20. A Prime-it II Random labelling kit (Stratagene) with [a-P^^]dCTP
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was used to generate the probe according to the manufacturer’s instruction and purified 
using a NICK Column (Amersham Pharmacia Biotech, UK).
2.2.2.8. Beta-Galactosidase Assay
The plasmid pCHllO was used in all transient transfections as an internal control against 
which the efficiency of transfection could be normalised. (3-galactosidase catalytically 
converts colourless o-nitrophenyl-p-D-galactopyranoside (ONPG) to yellow o- 
nitrophenol. The level of activity of this enzyme can be assayed by measuring changes in 
light absorbance at 420nm. Cells were lysed as detailed in section 2 23 .1 . To 80jul of 
each cell lysate, 1ml of solution I (60mM Na2 HP 0 4 , 40mM NaH2 P 0 4 , lOmM KCl, ImM 
MgCl2 , 50mM P-mercaptoethanol) and 0.2ml of solution II (60mM Na2 HP0 4 , 40mM 
NaH2 P 0 4 , 2mg/ml ONPG) was added. After mixing, all samples were incubated at 37°C 
for 30-60 minutes or until a yellow colour change could be seen. Samples were 
transferred to plastic disposable cuvettes and the reactions stopped by the addition of 
0.5ml IM sodium carbonate. The absorbance was read at 420nm using a Beckman DU 
650 spectrophotometer.
2.2.3. DNA and RNA analysis
2.2.3,1, Total RNA Extraction from Cell Lines
Cells were grown in a 175cm^ (T175) flask to approximately 80% confluency. Total RNA 
was then extracted by use of the RNAeasy Kit (Qiagen). The cells were washed once with 
pre-warmed sterile PBS and trypsinised and counted. 1x10^ cells of all cell lines were 
subjected to the RNA extraction method as per manufacturer’s details. For all RNA
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extractions the concentration of RNA was measured spectrophotometrically as described 
in section 2.2.1.2. RNA samples were aliquoted and stored at -70°C.
2.2.3.2. Polymerase Chain Reaction (PCR)
2.2.3.2.I. Amplification of DNA
All reagents were provided in the HotStarTaq PCR Kit with the exception of dNTP’s, 
which were obtained from the Perkin-Elmer Core DNA PCR kit. Primer sequences are 
described in table 2.1.
Table 2.1 Oligonucleotide PCR primers
Primer Name Primer Nucleotide Sequence Purity
HPV-16 L2 BamHl 
AT G forward
tgcaggatccatgcgacacaaacgttctgc Tm 81 
%GC 53
HPV-16 L2 BamHl 
forward
tgcaggatcccgacacaaacgttctgc Tm 77 
%GC 38
HPV-16 L2 EcoRl 
reverse
tgcagaattcggcaagtagacagtggc Tm 81 
%GC 53
25-473 atgL2 
forward
tgcaggatccatggcaggtacatgtccacct Tm 82 
%GC 54
50-473 atgL2 
forward
tgcaggatccatgagtatgggtgtatttttt Tm 76 
%GC 38
150-473atgL2
forward
tgcaggatccatgaatactgttactactgttact Tm 76 
%GC 38
250-473 atg forward tgcaggatccatgattacatatgataatcct Tm 74 
%GC 35
350-473atg forward tgcaggatccatgactaccccttcacatgca Tm 81 
%GC 51
92
Chanter Two Materials & Methods
390-473 atg forward tgcaggatccatgttatcaggttatattcct Tm 76 
%GC 38
GST-L2 1-50 
reverse
tgcagaattcctaacttccatattgtaatat Tm 72 
%GC 29
GST-L2 1-100 
reverse
tgcagaattcctaagggcccacaggatctac Tm 81 
%GC 51
GST-L2 1-200 
reverse
tgcagaattcctatgtatccataggaatttc Tm 74 
%GC 35
GST-L2 1-300 
reverse
tgcagaattcctagccagtacgcctagaggt Tm 81 
%GC 51
GST-L2 1-400 
reverse
tgcagaattcctaaattgttgtatttgcagg Tm 74 
%GC 35
GST-L2 25-473 
forward
tgcaggatccgcaggtacatgtccacct Tm 81 
%GC 57
GST-L2 50-473 
forward
tgcaggatccagtatgggtgtatttttt Tm 74 
%GC 39
GST-L2 150-473 
forward
tgcaggatccaatactgttactactgtt Tm 74 
%GC 39
GST-L2 250-473 
forward
tgcaggatccattacatatgataatcct Tm 72 
%GC 35
GST-L2 350-473 
forward
tgcaggatccactaccccttcacatgca Tm 79 
%GC 53
GST-L2 390-473 
forward
tgcaggatccttatcaggttatattcct Tm 74 
%GC 39
RT-L2
forward
caggcggacgcactgggt Tm 74 
%GC 72
RT-L2
reverse
gtcaggatctggtgctat Tm 65 
%GC 50
Actin
forward
gcgtctggacctggctggccgggacct Tm 87 
%GC 74
Actin
reverse
ggaaggctggaagagtgcctcagggcag Tm 84 
%GC 64
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The reaction mixture comprised 200pM of each dATP, dGTP, dCTP and dTTP, 1 x PCR 
kit buffer, 0.2p,M of each primer, 2.5 units HotStarTaq polymerase (a modified 
thermostable DNA polymerase from Thermus aquaticus) and lp,g of DNA sample. It was 
aliquoted into 0,5ml GeneAmp PCR reaction microfuge tubes in a final volume of lOOjul. 
Each cycle of PCR amplification consists of a number of steps which produce two 
oligonucleotide-primed single-stranded DNA templates, set up the polymerisation reaction 
and synthesize a copy of each strand of the template being targeted. The tubes were 
placed into the PCR machine (MJ Research PTC-200 Peltier Thermal Cycler) and heated 
to 95”C for 15 seconds to inactivate DNase and ensure all DNA duplexes were melted, in 
addition to activating the HotStarTaq.
The DNA was amplified for 35 cycles at 94°C for 60 seconds, then between 55-65°C for 
60 seconds, to allow the primers to anneal to the template DNA. The sequences of the 
primers are a major consideration in determining the temperature of the PCR amplification 
cycles. For primers with a high Tm, a higher annealing temperature is usually 
advantageous. The higher temperature minimizes non-specific primer annealing, increasing 
the amount of specific product produced and reducing the amount of primer-dimer 
formation. The annealing temperatures for all primers were determined by optimising the 
annealing conditions by performing the reaction at several temperatures starting at 5“C 
below any calculated Tm. The annealing temperature for each PCR reaction was dependent 
on the primer with the lowest Tm. The melting temperature for oligonucleotides can be 
calculated with the formula below.
Tm- 81.5 + 16.6 (logio[Na1) + 0.41 (%G+C) -  675/n
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Where [Na^] is the molar salt concentration; [K'^]=[Na^] and n= number of bases in the 
oligonucleotide. Primers are usually designed with a 40-60 G+C%.
The extensions of the primers were performed at 12°C for 60 seconds. After completion of 
the cycles, the reaction was incubated at 72”C for a further 7 minutes to ensure full 
extension and then cooled to 4°C. 5p,I of each sample was analysed by agarose gel 
electrophoresis (as described in section 2.2.1.6) to check the correct product was 
amplified.
2.2.3.2.2. Amplification from RNA: Reverse Transcriptase-PCR (RT- 
PCR)
RNA was prepared (see section 2.2.4.2) and used as the template for reverse transcription 
and PCR amplification of cDNA. Firstly cDNA was synthesised from RNA by reverse 
transcription using the Omniscript RT kit (Qiagen). The reaction was carried out 
according to the manufacturer’s instructions, to the following final concentrations: Ix RT 
buffer, 5mM of each of dATP, dGTP, dTTP, dCTP, 10 unit RNase inhibitor, Ipg RNA, 4 
units Omniscript reverse transcriptase, 1 p-M of Oligo-dT primer, and DEPC-treated water 
to a final volume of 20 \x\. Control reactions using no Omniscript reverse transcriptase 
were carried out, in addition to assaying suitable negative cell lines for each experiment.
All samples were placed in the thermocycler and further incubated at 37°C for 60 minutes, 
and then incubated at 4°C for 5 minutes. The above reaction was then stored at -20°C 
until use. Typically 2p,l of the RT reaction was carried forward to the amplification step. 
PCR reactions were carried out as per manufacturer’s guidelines (Qiagen) for HotStarTaq 
amplification. Briefly final reaction volumes were lOOgl consisting of 2p.l of RT reaction
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mixture combined with a final concentration of Ix PCR Buffer, 200p,M of each dNTP, and
0.2jj,M of the forward and reverse primers, 2.5 Units of the HotStarTaq made up to 98|ul 
with distilled water. To activate the HotStarTaq an initial incubation of 95°C was carried 
out for 15 minutes. Amplification proceeded for 35 cycles of 94°C for 60 seconds, 59“C 
for 60 seconds, plus a 60 second extension at 72 °C. PCR was carried out in a MJ 
Research PTC-200 Peltier Thermal Cycler. The samples were then analysed by agarose 
gel electrophoresis as described in section 2.2.1.6 to ensure correct amplification.
2.2.3,2.3. Real Time Quantitative PCR.
Cells were seeded and transfected with 4|ug plasmid and total RNA was isolated with 
RNeasy®MiniKit (QIAGEN, UK) and resuspended in RNase-free water following the 
instructions of the supplier. Thirty-two nanogram total RNA was digested with 0.5U 
Dnase I (Invitrogen™, UK) according to the manufacturer’s protocol. The reverse 
transcription was primed in duplicate with Random Primers (Promega, UK) at a 
concentration of 0.5|Lig in a 25p.l reaction mixture with or without 3U AMV-RT 
(Promega, UK) and 0.5mM each dNTP (Promega, UK), 20U rRNAsin (Promega, UK), 
and IX AMV-RT buffer (Promega, UK) following the instructions of the supplier. As a 
preliminary screening, cDNA was amplified by PCR with 2.5U Taq Polymerase (Gibco 
BRL®, UK) in a final volume of 50pl containing IX PCR buffer (Gibco BRL®, UK), 
125p,M of each dNTP (Promega, UK) and 0.5|uM of each primer (sense: 5’CGA TGG 
AGA CTC TTT GCC AA; antisense: 5’TAT AGA CAT AAA TCC AGT) for 30 cycles at 
94°C 1 minute, 50°C 1 minute and 72°C for 2 minutes and 1 cycle at 72°C for 10 minutes 
and the PCR products were electrophoresed in a 1% agarose gel. Once checked that the 
RNA was free from DNA contamination, cDNA was amplified in triplicate with the
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primers Tql6E2f 5’CCT GAA ATT ATT AGG CAG CAC TTG and Tql6E2r 5’GCG 
ACG GCT TTG GTA TGG at a concentration of 300mM each in a 50p,l reaction that 
contained in final concentration: IX PCR Buffer II, 200pM dATP, dCTP, dGTP, and 
400p,M dUTP, 5.5mM MgCl2  and 1.25U AmpliTaq® DNA Polymerase with GeneAmp®. 
The reaction also contained the detection probe TaqMan® Probe: 5’ CAA CCA CCC 
CGC CGC GA, at a concentration of 300nM. The thermal cycling conditions were 2 
minutes at 95°C, followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. All 
reactions were performed in the model 7700 Sequence Detector (PE Applied Biosystems), 
which contains a GeneAmp PCR System 9600. As control cDNA was amplified with 
primers for actin: p-actin Forward Primer and P-actin Reverse Primer (PE Applied 
Bio systems, Foster City, Ca, USA) at a concentration of 60nM each in a reaction mix with 
the same cycling conditions, with p-actin Probe (PE Applied Bio systems, Foster City, Ca, 
USA) at a concentration of 40nM.
2.2.3.3. DNA Sequencing
The sequence of all new plasmids was checked using Taq terminator sequencing on an
Applied Bio systems Prism 3100 Genetic Analyzer DNA sequencer. The region to be
sequenced first underwent PCR amplification. The sequencing reaction mix was prepared
by adding 500ng of template DNA (~6gl of standard miniprep), 2|ul 5x sequencing buffer,
3.2pmoles the appropriate primer, 4 |l i 1 of BigDye™ Terminator Ready Reaction Premix
(Applied Biosystems) made up with distilled H2 O to a total reaction volume of 20|il in
200jil thin walled eppendorf tubes. The samples were placed in a MJ Research PTC-200
Peltier Thermal Cycler and exposed to 25 cycles of 96°C for lOseconds, 50°C for
5seconds and 60°C for 4 minutes. The PCR products were purified using PERFORMA®
DTR Gel Filtration Cartridges. The columns were first spun at 3000rpm for 2 minutes to
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remove buffer. The columns were then transferred to sample collection tubes. The PCR 
sequencing reaction mix was then loaded onto the centre of the gel column. The column 
was spun for 3000rpm for 2 minutes. The sample was then dried under vacuum for 15-20 
minutes and then resuspended in 25|ul formamide.
Table 2.2 Sequencing primers
Primer Name Position Primer Nucleotide Sequence
T7 forward 5’-3’ 864-882 5’ - attaatacgactcactataggga -3’
BGH reverse 5’-3’ 1018-1249 5’ - ctagaaggcacagtcgaggc -3’
PGEX forward 5’-3’ 869-891 5’ - gggctggcaagccacgtttggtg -3’
PGEX reverse 5’-3’ 1042-1020 5’ - ccgggagctgcatgtgtcagagg -3’
pEGFP-Cl sequencing 
Primer
679-658 5’ - cctaggagcactaagcga -3’
2.2.4. Protein Analysis
2.2.4.1. Protein Preparations from Cells for W estern Blot Analysis
Cells were lysed by aspirating the culture medium off, washing the cell monolayer once
with ice-cold PBS, the PBS was completely removed by aspiration. For lysis with NP-40 
lysis buffer (150mM NaCl, 0.5% NP-40, 50mM Tris-HCI and one tablet protease inhibitor 
cocktail), 1ml of trypsin was added to cells until they detached. Cells were collected in 
universal tubes using 6ml of serum containing medium to inactivate trypsin. Cells were 
pelleted by spinning for 5 minutes at lOOOrpm. The pellet was washed once with ice cold 
PBS and repelleted. The supernatant was removed and 200pl of NP-40 lysis buffer was
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added to the pellet and kept on ice for 10 minutes. Cell debris was pelleted at 14000 rpm 
and the supernatant transferred to a new micro centrifuge tube.
For lysis with SDS-lysis buffer (lOOmM Tris-HCl pH6.8, 2% SDS, 2% glycerol and one 
tablet protease inhibitor cocktail), the cells were lysed by aspirating the culture medium 
off, washing the cell monolayer once with PBS. The PBS was completely removed by 
aspiration. 200|l i 1 of SDS lysis buffer was added to the plates and cell debris was scraped 
off and transferred to microcentrifuge tubes. The cells were further disrupted using either 
a sonicator or repeated aspiration with a syringe. The cell debris was pelleted at 14000 
rpm and the supernatant transferred to a new microcentrifuge tube.
2.2.4.2. Protein Concentration Assays
The BCA/CuS04 Protein assay was used to spectrometrically determine the protein 
concentration of dilute solutions following the manufacturer’s instructions. Proteins 
reduce alkaline Cu(II) to Cu(I) in a concentration-dependent manner. Bicinchoninic acid is 
a highly specific chromogenic reagent for Cu(I), forming a purple complex with an 
absorbance maximum at 562nm. lOpl of protein solution was placed in separate wells in 
96 well plate. 200p,l of developing solution (5ml BCA (Biocinchoninic acid) solution, 
lOOjul of 4% (w/v) CuS04 (copper II sulphate pentahydrate solution) was added to the 
protein samples and incubated at 37°C for 30 minutes.
The absorbance of each sample was read at 590nm using a WPA UVl 101 Biotech 
photometer plate reader. The absorbance reading was converted to concentration in |ug/ml 
for each sample using a standard curve generated from a series of control BSA solutions
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of known concentration. The actual concentration of each protein sample was calculated 
after multiplying by the relevant dilution factor.
2.2.4.3. SDS-Polyaciylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were resolved according to the molecular weight using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). All Western blot analysis was 
performed using Nu PAGE^^ pre cast gel system. lOpg of each protein sample were 
electrophoresed on Nu PAGE™ 4-12% Bis-Tris gel (Invitrogen, UK) under denaturing 
conditions. Prior to loading, equivalent amount of each protein samples (lOfig) was mixed 
with 5 pi of 4x SDS gel loading buffer (Invitrogen, UK) and 2pi of 2x reducing agent 
(Invitrogen, UK) made up to 20pl with dHzO. Samples were then boiled for lOminutes at 
70°C. The prepared protein samples were then loaded into consecutive wells and 15pl 
Rainbow™ protein molecular weight marker mix (molecular weight range 6KD-188KD) 
added to the first and/or last well on the gel. The gel was run by electrophoresis at a 
constant voltage of 200V for 45minutes. The running buffer (Nu PAGE™ MES buffer, 
Invitrogen, UK) was used with 5 00pi antioxidant (Invitrogen, UK) added to 200ml of the 
running buffer for the inner tank. Once the dye front was approximately 5-10cm from the 
bottom of the gel, the gel was removed and used for western blot analysis.
2.2.4.4. W estern Blotting
Separated protein samples were transferred to a nitro-cellulose membrane using the Nu 
PAGE™ wet blotting tank. For this purpose the gel was removed from the electrophoresis 
tank and transferred onto a nitrocellulose membrane (Invitrogen, UK). Before transferring 
the membrane, the Nu PAGE™ gel sandwich was pre-soaked with transfer buffer with 
500pl antioxidant added to 1ml of transfer buffer (with 10% or 20% methanol depending
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on the number of gels being transferred). The gel sandwich contains a pre-cut 
nitrocellulose membrane sandwiched between two filter papers. The gel tank was set up as 
follows
1. The first sheet of filter paper, soaked in transfer buffer was placed neatly on to 
the gel avoiding any air bubbles.
2. Then the nitro-cellulose membrane was laid on the gel, and then a further sheet of 
filter paper, all soaked in transfer buffer was added to the top.
3. The sandwich was rolled with a glass pipette to eliminate any air bubbles
4. The sandwich was placed into the transfer tank and run at 30V for approximately 
60 minutes, the time taken for the pre-stained marker proteins to be completely 
transferred.
Once the transfer was completed, the membrane was blocked by shaking for a minimum of 
1 hour in 50 ml of block buffer (5% Marvel [dried milk] in PBS-0.01% Tween) at room 
temperature. The nitro-cellulose filter was washed in wash buffer (PBS-T) for 10 minutes. 
The filter was then placed in 7ml blocking buffer containing suitable primary antibody and 
incubated at room temperature for 1 hour with gentle shaking. The primary antibody 
solution was removed and the filter rinsed in blocking buffer then washed 1x15 minutes 
and 2x 5minutes in 100ml volumes of fresh PBS-T. The filter was then incubated in 20 ml 
blocking buffer containing a 1/5000 dilution of the applicable HRP-linked secondary 
antibody for 1 hour at room temperature with gentle shaking. The filter was washed Ix for 
15 minutes and 4x for 5 minutes with PBS-T buffer. Excess surface liquid was removed 
from the filter by briefly blotting with a piece of Whatman 3MM paper. The detection 
consisted of incubating the filter in an equal volume of an Amersham Enhanced
101
Chapter Two______________________________________________________ Materials & Methods
chemilluminescence (ECL) detection reagents 1 and 2 for 1 minute at room temperature. 
The excess detection solution was drained off the nitro-cellulose filter and this was then 
wrapped in Saran wrap and exposed to Amersham ECL film for 30 seconds and up to 30 
minutes (depending on the strength of the signal).
2.2.4.5. Stripping W estern Blot Membranes
If a western blot membrane was required for multiple analyses with different probe 
antibodies then the initial primary and secondary antibodies were removed from the 
membrane by stripping. The membrane post exposure to the Amersham ECL film was 
washed for 10 minutes three times in PBS before being incubated for 1 hour at room 
temperature in Stripping Buffer (0.2M Glycine pH 2.5, 0.2% SDS). The membrane was 
then washed with copious amounts of PBS until all traces of the SDS were safely 
removed. The membrane was then blocked as per protocol for the next probing primary 
antibody.
2.2.4.6, Immunoprécipitation
For immunoprécipitation assays, O.lg of protein-A sepharose beads (Sigma) was pre­
swollen in NP40 lysis buffer overnight at 4^C. The next day, the beads were centrifuged at 
14000rpm at 4°C for 1 minute and washed three times with lysis buffer and finally 
resuspended in 1 volume lysis buffer (~300pl). Then lOpl of beads was added to SOpl 
protein extract plus 50pl lysis buffer for 1 hour with rotation at 4®C. The mixture was 
centrifuged and the supernatant was transferred to new microcentrifuge tubes. The 
antibody was diluted 1:10 and lp.1 added to supernatant and incubated with rotation at 4°C 
for 1 hour. Then lOpl of beads was added and further incubated for another 1 hour with 
rotation at 4°C. The mix was centrifuged and pellet washed 5x with 0.5ml lysis buffer. To
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load onto a gel, traces of lysis buffer were removed and samples prepared for loading onto 
SDS-PAGE gel as described in section 2.2.4.3 above.
2.2.4.7. Expression and Purification of GST Proteins
Individual bacterial colonies {E coli BL21) containing recombinant pGEX-GST fusion 
expression vectors were used to inoculate 5 ml 2x YTA medium and grown overnight at 
37°C with shaking at 225rpm. 1ml of culture was used to inoculate 50ml of pre-warmed 
2x YTA medium and grown at 37°C with shaking until an A^ oo of 0.6-0.8 was reached. 
Expression was induced by the addition of IPTG (final conc. 0.1 mM) and the culture was 
incubated with shaking at 37°C for a fiarther 5 hours. Bacteria were pelleted by 
centrifugation at 2500g for 30 minutes. The pellets were resuspended in 5ml (1/10 
volume) of BugBuster^^ Protein Extraction Reagent (Novagen) containing 1 tablet 
protease inhibitor cocktail (per 10ml reagent) and incubated for 30 minutes with rotation. 
The cell extracts were centrifuged at 2500g for 30 minutes. 1ml aliquots of the 
supernatant were transferred to fresh tubes and stored at -70°C. Fusion proteins were 
purified on glutathionine-Sepharose beads by incubating 1ml supernatant (crude extract) 
with 50pl beads for 30 minutes at room temperature with rotation. The beads were 
pelleted in a microfuge (14000 rpm, 20 seconds) and washed 3x 0.5 ml NETN (20mM 
Tris-HCL, pH 8.0), lOOmMNaCl, ImMEDTA, 0.5% Nonidet P-40 (NP-40) containing 1 
tablet protease inhibitor cocktail per 10ml buffer. The beads were resuspended in 50pl 
NETN and purified proteins were analysed by 10% SDS-PAGE (Section 2.2.4.3) before 
subsequent manipulations.
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2.2.4.S. I n  v i tr o  Transcription Translation and GST-Pull Down Assays
HPV-16 E2 was subcloned from pCMV-HPV16 E2 into the BamHl site of pBluescript
SKII under control of the T7 promoter using standard molecular biology techniques. 
HPV-16 E2 was in-vitro transcribed-translated using TNT Quick Coupled 
Transcription/Translation System (Promega) as instructed by the manufacturer to produce 
^^ S labelled E2. The efficiency of transcription-translation was checked using a luciferase 
control plasmid construct to produce ^^ S labelled luciferase. 5pi of each reaction was 
analysed by SDS-PAGE and proteins were fixed in 7% methanol and 7% glacial acetic 
acid for 15 minutes shaking and lOminutes with Amplify™ Fluorographic reagent 
(Amersham). The gel was transferred onto filter paper, dried and exposed for 
autoradiography at -70°C overnight.
GST pull-down assay were performed as follows: pGEX, pGEX-L2 and pGEX-L2 
deletion mutants were used to transform competent E  coli BL21 cells. GST fusion 
proteins were expressed and purified as described in section 2.2.4.7. The proteins 
immobilised on beads were pre-washed three times in pull-down buffer (PDB: 50mM Tris 
pH 7.9, lOOmMNaCl, ImM DTT, 0.5mM EGTA, 0.5% NP-40, ImMPMSF). The NaCl 
concentration in PDB can be changed to assess the specificity of binding. 7.5pl ^^ S labelled 
in vitro translated protein was then incubated with approximately Ipl immobilised fusion 
protein (approximately lOpl protein on beads) in a total volume of 200ql fresh PDB for 30 
minutes at 4°C with rotation. The beads were pelleted in a microfuge (14000 rpm, lOsec) 
washed four times in PDB. Bound proteins were separated by 10% SDS-PAGE, fixed, the 
gel was dried and exposed for autoradiography at ~ l(fC  overnight. Bands were then 
analysed by densitometry using a UMAX Powerlook III Flatbed scanner and ImageQuant 
v5.2 software.
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2.2.4.9. Pulse-chase Methionine labelling for protein Half-Life
Cells were plated out at 1.2x10*' cells/100mm dishes (to give -80%  confluency when
labelling). Culture medium was aspirated from dishes and cells washed once with PBS and 
once with 5ml Ix short term labelling (STL) medium. Cells were then incubated with 
STLM (STL, 5% DFCS, 4mM L-Glutamine) for 15 minutes. The STLM was aspirated 
and STLM with [^^S] methionine (0.2pCi/ml) was added to cells for 1 hour at 37®C, 5% 
CO2  to pulse cells. To chase, the dishes were washed with Ix chase medium (10% FCS in 
DIMEM) then incubated with 10ml chase medium. For protein half-life studies, cells were 
harvested over a described time course. To harvest cells, chase medium was removed and 
washed Ix with 5ml PBS. 1ml of trypsin was added per dish. Once detached, 4ml of chase 
medium was added and aspirated and centrifuged at 14000rpm at 4°C for 10 minutes. NP- 
40 lysis buffer was used to harvest the cells as described in section 2.2.4.1. To analyse for 
protein half-life, cell lysates were immunoprecipitated with required antibody as described 
in section 2.2.4.6. The gel was dried and exposed for autoradiography at -70°C overnight. 
Bands were then analysed by densitometry using a UMAX Powerlook III Flatbed scanner 
and ImageQuant v5.2 software.
2.2.4.10. Cydoheximide treatment for protein Half-Life
Cells were plated out at 1.2x10^ cells in 100mm dishes then left for 24 hours before being
treated with cydoheximide (CHX). CHX (Sigma-Aldrich) in DMSO was added to a final 
concentration of lOOpg/ml to each plate and DMSO only was used as a negative control. 
Cells were harvested in SDS lysis buffer at regular time intervals after CHX/DMSG 
addition. Lysates were then run on Nu PAGE™ pre cast gel system (Invitrogen), before 
being transferred to a nitrocellulose membrane for probing. Bands were then analysed by
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densitometry using a UMAX Powerlook III Flatbed scanner and ImageQuant v5.2 
software.
2.2.5. Immunofluorescence
Round cover slips were first washed in distilled water, air-dried and put into a beaker for 
autoclaving. The cover slips were placed in 16 well tissue culture plates and cells seeded 
1x10^ cells per well. All transfections for immunofluorescence studies were performed 
using LIPOFECTAMINE™ according to the manufacturer’s instructions. Twenty-four 
hours after transfection, the cells were washed twice with PBS and fixed by 10 minute 
incubation at room temperature with 1.85% formaldehyde (Sigma) diluted in PBS 
containing 2% sucrose and washed three times with PBS. They were permeablilsed by 10 
minute incubation at room temperature with 0.5% NP40 in PBS containing 10% sucrose 
and washed three times with 1% FCS in PBS After washes with 1% FCS in PBS, 
coverslips were mounted in AFl (Citifluor, UK). Fluorescence was analysed using a Leica 
TCS SP2 true confocal scanner (Leica-microsystems, Heidelberg Germany) with three 
lasers giving excitation lines at 488nm.
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CHAPTER 3: EFFECT OF THE HUMAN 
PAPILLOMA VIRUS TYPE 16 L2 PROTEIN ON THE 
FUNCTIONS OF THE E2 PROTEIN
3.1. The Viral Regulatory Protein E2
The viral E2 protein regulates viral transcription through binding as a dimer to its specific 
recognition sequences (binding sites) contained within the viral long control region 
(LCR). The LCR of mucosal papillomavimses has four E2 binding sites (E2BS1-4) (Fig 
1.3) (Desaintes and Demeret, 1996). Two of these sites are immediately upstream from 
the TATA box (E2BS 1,2), separated from each other and from the TATA box by 3 or 4 
base pairs. For the other two sites, one is beside the El DNA binding site involved in the 
regulation of viral DNA replication, and one is a further 300-400 bp upstream (Fig 1.3). 
In general, binding of E2 to E2BS 1, 2 and 3 causes transcriptional repression, while E2 
binding to E2BS 4 leads to activation (Demeret et al., 1997). The full-length E2 protein is 
essential for efficient viral DNA replication. The El protein has DNA binding, DNA 
helicase and ATPase activities and plays a key role in viral DNA replication. Both El and 
E2 proteins bind to sites located within the LCR called the origin of DNA replication 
(on) (Chiang et al., 1992), and are the only viral proteins necessary to initiate replication 
from the ori (Chow and Broker, 1994). The ability of E2 to form a complex with El is 
mediated by the amino-terminal portion of E2.
In BPV-1, CO-expression of L2 and E2 causes the redistribution of E2 into PODs, leading 
to the suggestion that a major redistribution of viral components occurs during virion
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assembly (Day et al., 1998; Heino et al., 2000). Despite the obseived co-localisation of 
E2 and L2 to PODs, little is known about the effect of this interaction on E2 function in 
viral transcription regulation or replication. As such the effect of the interaction of HPV- 
16 E2 and HPV-16 L2 on the transcription transactivation and replication function of E2 
was investigated.
3.1.1. Down-regulation of the transcription transactivation function of 
HPV-16 E2 by HPV-16 L2
In order to determine the effect of L2 on E2 function in transcription transactivation, the
role of E2 in enhancing transcription from the HPV-18 LCR was investigated. The BPV- 
4 LCR was also used to obseive activation of transcription transactivation from a 
different promoter. C33a and U20S cells were transfected with wild type HPV-18 LCR 
or BPV-4 LCR luciferase reporter constmcts and pCMV-E2,6. In both cell lines, E2 
activated transcription from the HPV-18 and BPV-4 promoters as described previously 
(Jackson and Campo, 1995; Morgan et al., 1998; Steger and Corbach, 1997). This 
activation was approximately one and a half fold to two fold at low and inteiinediate 
levels of E2 while high levels of E2 results in down-regulation of transcription 
transactivation (Fig 3.1) indicating that over expression of E2 résultés in the down- 
regulation of transcription transactivation from the wild type HPV-18 and BPV-4 LCR 
promoters. This down-regulation has been shown to occur as a result of E2 binding to 
E2BS 1 interfering with TBP binding to the TATA-box (Steger et al., 1995) or by 
competing with the cellular transcription factor Spl, which binds to a site overlapping 
E2BS 3 (Demeret et al., 1994; Demeret et al., 1997; Tan et al., 1994). This is further
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elucidated with the observation that overexpression of E2 increases transcription 
activation of an SV40 promoter (Morgan et al., 1998) and mutations in the E2BS 1-3 
have been shown to lead to an increase in transcription activation eliminating trans­
repression (Morgan et al., 1998; Phelps and Howley, 1987; Vance et al., 1999), 
indicating that down-regulation is mediated tlii'ough E2 binding to its E2BS. E2BS 4 has 
been shown to be the major site for E2 activation on the LCR with which it has its highest 
binding affinity (Steger and Corbach, 1997).
In this study, E2 responsive reporter constmcts derived from the HPV-18 LCR with 
mutations in E2BS 1 (pl8LCR~BSl) or E2BS 1-3 (pl8LCR-BSl-3) to prevent E2 
binding these sites (Fig 3.2) and two synthetic promoters consisting of six multimerized 
E2BS 4 fused to the HPV-18 TATA (pl8-6E2) or tk promoter (ptk6E2) were used. These 
reporter constmcts were chosen, as transcription is not repressed by E2 as obseived with 
wild type LCR. Any activity difference between these plasmids in a reporter assay is 
attributed to the binding of E2 to the E2BS, inducing transcription of the reporter gene. 
HaCaT and C33a cells were transfected with each plasmid and increasing amounts of 
pCMV-E2|6. The results indicated that luciferase expression increased with increasing 
amounts of E2 in both cell lines and no trans-repression was obseiwed even at the highest 
amounts of E2 used. In HaCaT cells, the LCR was five to ten times more 
transcriptionally active when the E2BS 1 was mutated. Mutation of E2BS 1-3 similarly 
activated transcription about 12 fold. The use of synthetic promoters further increased 
transcription, with ptk6E2 showing the highest activation (Fig 3.3). In C33a cells, 
mutation of E2BS 1 or 1-3 gave activations of three to six fold while pi 8-6E2 and ptk6E2 
gave 15 and 35 fold aetivation respectively (Fig 3.4). In summary, overexpression of E2
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increased the transcription transactivation of all reporter constmcts in a dose dependent 
manner with complete abrogation of down-regulation. Although the kinetics of activation 
differed slightly between promoters and between different cell lines, a similar pattern of 
activation was observed for all promoters.
As the down-regulation of E2 transcription transactivation is abrogated using the E2 
responsive reporter constmcts described above, it provided a system to study any change 
in E2 function in the activation of transcription. To study the effect of HPV-16 L2 on the 
transactivation function of HPV-16 E2, HaCaT and C33a cells were transfected with 
pl8LCR-BSl, pl8LCR-BSl-3, pl8-6E2, ptk6E2, pCMV-E2i6 and increasing amounts of 
pl6-HAL2, a HPV-16 L2 expressing plasmid. The amount of E2 was kept sub-optimal 
for E2-mediated transactivation to allow for detection of any effect of L2. The addition of 
L2 led to an inliibition of E2-mediated transactivation in a dose-dependent manner in 
both cell lines (Fig. 3.5 and Fig. 3.6). This was obseiwed for all reporter plasmids used 
although the kinetics of inhibition varied slightly from reporter to reporter. All reporters 
were however fully inhibited at the highest amounts of L2 used in both cell lines. The 
addition of L2 in the absence of E2 did not affect the constitutive activity of reporters 
(Fig 3.5 and Fig 3.6). To determine if L2 had any effect on a promoter not responsive to 
E2, C33a cells were transfeeted with ptkluc (the tk promoter reporter plasmid with no E2 
binding sites), and increasing amounts of pl6-HAL2. The results indicate that L2 and E2 
co-expression has no effect on the tk promoter activity (Fig. 3.7).
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3.1.2. HPV-16 L2 does not affect the replication function of HPV-16 E2
E2 binds to El and promotes origin-dependent viral replication. The effect of HPV-16 L2
on the ability of HPV-16 E2 to co-operate with HPV-16 El in a transient DNA 
replication assay was investigated. The DNA replication assays were performed in C33a 
cells, because replication assays did not work in HaCaT cells, perhaps due to a decrease 
in cdk2/cyclin E activity as described for HeLa cells (Lin et al., 2000). C33a cells were 
transfected with pl6ori-m (a plasmid which contains the HPV16 origin of replication 
cloned into pSKII(-), with a point mutation at 115 from C to A to create a Dpnl 
restriction enzyme site), pCMV-El i6, and pCMV-E2i6 with or without pl6-HAL2 and 
assayed for E2 mediated DNA replication. DNA replication was dependent on the 
presence of pl6ori-m, El and E2. Forty-eight hours post transfection, low molecular 
weight DNA was extracted using the Hiit protocol (Hirt, 1967) and linearised by 
digestion with Xmnl. The linearised plasmid was further digested with Dpnl, which 
cleaves only when its reeognition site is methylated. Xmnl linearises pl6ori-m while 
Dpnl digests only dam methylated unreplicated DNA. Replication was assayed after 
Xmnl and Dpnl digestion by detection of an undigested but linearised pl6ori-m band. In 
the absence of E2, no replication took place, while at lOng of E2, a replieated band was 
detected, increasing with E2 concentrations (Fig. 3.8a). There was no replication in the 
presence of L2 and absence of E2. The results indicate that L2 had little effect on the 
replication activity of E2 (Fig. 3.8a and b). Altogether, these results indicate that L2 has a 
selective effect on the functions of E2. L2 drastically inhibits the transcriptional function 
of E2 but has little effect on replication.
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Figure 3.1. Transactivation of HPV-18 LCR and BPV-4 LCR luciferase reporter 
constructs by HPV-16 E2 in C33a and U20S cells respectively. C33a and U20S cells 
were transiently transfected with 0.1 pg of each luciferase reporter construct and with 
increasing amounts of the E2 expression plasmid pCMV-E2i6, (0.01 pg, 0.1 pg and Ipg). 
The total amount of DNA was kept constant by adding appropriate amounts of the 
parental plasmid pCMV. Each experiment was performed in triplicate. Transactivation is 
shown as fold activation of luciferase expression over that of the reporter plasmids 
without E2, taken arbitarily as 1.
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Figure 3.2. Schematic representation of luciferase reporter plasmids. The first three 
plasmids contain respectively the wild type LCR of HPV-18 (pHPV18-LCR), the LCR 
with four point mutations in the E2 binding site 1 (pHPV18-LCR-BS1 ) or four point 
mutations in each of sites 1 to 3 (pHPVl 8-LCR-BS 1-3). The other two plasmids are p i8- 
6E2 containing six E2 binding sites upstream of the HPV-18 TATA and the E2-minimal 
promoter constiuets ptk6E2, containing six E2 binding sites upstream of the tk promoter.
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Figure 3.3. Transactivation of HPV-18 LCR BS mutants and E2 minimal promoter 
constructs by HPV-16 E2 in HaCaT cells. HaCaT cells were transiently transfected 
with 0.1 |ig of each luciferase reporter construct (BSl, BS 1,2,3, pl8-6E2, and ptk6E2) 
and with increasing amounts of the E2 expression plasmid pCMV-E2]6 (O.Olng, 0.1 ng, 
Ing and lOng). Shown are representative results from each promoter in HaCaT cells. The 
total amount of DNA was kept constant by adding appropriate amounts of the parental 
plasmid pCMV, Each experiment was performed in triplicate. Transactivation is shown 
as fold activation of luciferase expression over that of the reporter plasmids without E2, 
taken arbitarily as 1.
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Figure 3.4. Transactivation of HPV-18 LCR BS mutants and E2 minimal promoter 
constructs by HPV-16 E2 in C33a cells. C33a cells were transiently transfected with 
O.lpg of each luciferase reporter construct (BSl, BSl,2,3, pl8-6E2, and ptk6E2) and 
with increasing amounts of the E2 expression plasmid pCMV-E2i6, (O.Olng, O.lng, Ing 
and lOng). Shown are representative results from each promoter in C33a cells. The total 
amount of DNA was kept constant by adding appropriate amounts of the parental plasmid 
pCMV. Each experiment was performed in triplicate. Transactivation is shown as fold 
activation of luciferase expression over that of the reporter plasmids without E2, taken 
arbitarily as 1.
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Figure 3.5. HPV-16 L2 down-regulates the transcription transactivation function of 
E2 in HaCaT cells. HaCaT cells were transiently co-transfected with O.lpg of each 
luciferase reporter construct and Ing pCMV-E2i6 with increasing amounts of pl6~HAL2, 
(O.OSpg, O.lpg, 0.5pg and Ipg). Each experiment was adjusted for total DNA by co­
transfecting with the parental plasmid pCMV. Shown are representative experiments for 
each promoter (a) BSl, (b) BS1,2,3, (c) pl8-6E2 and (d) ptk6E2 in HaCaT cells. Each 
experiment was performed in triplicate. Transactivation is shown as fold activation of 
luciferase expression over that of the reporter plasmids without E2, taken arbitrarily as 1.
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Figure 3.6. HPV-16 L2 down-regulates the transcription transactivation function of 
E2 in C33a cells. C33a cells were transiently co-transfected with O.lpg of each luciferase 
reporter construct and Ing pCMV-E2i6 with increasing amounts of pl6-HAL2, (0.05pg,
O.lpg, 0.5pg and Ipg). Each experiment was adjusted for total DNA by co-transfecting 
with the parental plasmid pCMV. Shown are representative experiments for each 
promoter (a) BSl, (b) BS1,2,3, (c) pl8-6E2 and (d) ptk6E2 in C33a cells. Each 
experiment was performed in triplicate. Transactivation is shown as fold activation of 
luciferase expression over that of the reporter plasmids without E2, taken arbitrarily as 1.
122
HPV-16 L2 down-regulates the transcription
transactivation function of HPV-16 E2 in C33a cells
f loG
>G
<
BSl
E2 Ing
No L2
B S l,2,3
E2 Ing
0.5pg No L2
■  promoter 
m E2 O.Olug
□  E2+L2 O.OSug
□  E2+L2 0.1ug
□  E2+L2 O.Sug
□  E2+L21ug
0.5pg
25
pl8-6E2
E2 Ing
■>
No E2
No L2 0.5pg No L2
ptk6E2
E2 Ing
No E2
0.5pg
123
Chapter Three_________________________________________________________ Results
Figure 3.7. Effect of HPV-16 L2 on the transactivation of tk and tk6E2 promoters 
by HPV-16 E2 in C33a cells. Cells were transiently co-transfected with O.lpg of each 
luciferase reporter construct and Ing pCMV-E2]6 with increasing amounts of pl6-HAL2, 
(O.lpg, 0.5pg and Ipg). The total amount of DNA was kept constant by adding 
appropriate amounts of the parental plasmid pCMV. Each experiment was performed in 
triplicate. Transactivation is shown as fold activation of luciferase expression over that of 
the reporter plasmids without E2, taken arbitarily as 1.
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Figure 3.8. Effect of HPV-16 L2 on the transient replication function of HPV-16 E2 
in C33a cells. (A) Phosphoimage of Southern blot hybridised with ^^P-labelled HPV-16 
ori plasmid. Cells were transfected with Ipg of pl6ori-m, +/- 5pg pCMV-Eli6, +/- lOng 
or lOOng pCMV-E2i6 and +/- Ipg or 2pg p 16-HAL2. For each reaction, Xnml was used 
to linearise p 16ori-m (odd-numbered lanes), and then Dpnl was used to digest replicated 
DNA (even-numbered lanes). The open arrow on the left indicates unreplicated plasmid 
and the closed arrow on the right indicates replicated plasmid. Replication occurred in the 
presence of lOng or lOOng of pCMV-E2,6 co-transfected with Ipg pl6ori-m and 5pg 
pCMV-El 1 6 (lanes 6 and 12). The absence of either El (lane 4) or E2 (lane 2) resulted in 
no detectable replication. The experiment was carried out three times with essentially the 
same results. (B) Quantification of DNA replication. Southern blots were scanned and 
extent of DNA replication was calculated by measuring the ratio of double cut/single cut 
bands, thus controlling for variations between experiments. The graph represents a 
summary of three independent experiments +/- standard deviation.
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CHAPTER 4: THE EFFECT OF L2 ON E2 PROTEIN 
EXPRESSION AND STABILITY
4.1. E2 expression and stability
Proteins utilize a variety of protease pathways for their destmction. These include non­
specific lysosymal protease; proteases involved with apoptosis such as caspase and 
calpains; and the ubiquitin-dependent proteasome pathway. The degradation of BPV-1 
E2 is regulated by phosphoiylation, which is required for efficient ubiquitination and 
subsequent degradation of E2 by the ubiquitin-proteasome pathway (Penrose and 
McBride, 2000). The ubiquitin-proteasome degradation pathway also controls the 
stability of HPV-18 E2 mediated thi’ough its amino-terminal transactivation domain 
(Bellanger et al., 2001). The full-length or transactivation domain of E2 is efficiently 
ubiquinated and proteasome inhibition in cells expressing E2 increases its half-life about 
sevenfold. As the transcription transactivation function of E2 is down regulated in the 
presence of L2, the effect of L2 on E2 expression was investigated.
4.1.1. Down-regiilation of HPV-16E2 protein expression by HPV-16 L2 
in HaCaT and U 20S  but not C33a cells
HPV-16 L2 down regulates HPV-16 E2-mediated transcription transactivation in a dose 
dependent manner. To deteimine whether the effect of L2 on E2 function in transcription 
transactivation was due to the degradation of E2, HaCaT, U20S and C33a cell lines were 
transfected with 4pg pCMV-E2i6 alone or 4pg of pCMV-E2]6 and 4pg p 16-HAL2 
expression plasmids and detection of E2 levels was accomplished by Western blotting. In
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HaCaT cells, the presence of L2 lead to a marked reduction in the level of the E2 protein 
(Fig 4.1a). In U20S cells, the level of E2 expression in the presence of L2 was also 
drastically reduced when compared to cells expressing E2 alone (Fig 4.1c). In contrast, 
co-expression of E2 and L2 in 03 3a cells resulted in no marked reduction in the level of 
the E2 protein (Fig 4.Id). The effect of L2 on E2 protein levels in HaCaT cells was 
further investigated using a stable E2 expression system established in HaCaT cells. This 
system provided a functional and detectable level of E2 in HaCaT cells. Transfection of 
HaCaT-E2 cells with 4pg pl6-HAL2 lead to a marked reduction in the level of the E2 
with actin levels remaining unchanged (Fig 4.1b). These results indicate that the effect of 
L2 on E2 levels is a cell type dependent effect.
As the degradation of E2 is proteasome mediated (Bellanger et al., 2001; Pem'ose and 
McBride, 2000), the down-regulation of E2 protein expression by L2 was further 
investigated to deteimine whether this effect was proteasome dependent. A variety of 
proteasome inliibitors were used, which have been shown to inhibit proteasome-mediated 
degradation of E2 (Penrose and McBride, 2000). HaCaT and C33a cells were transfected 
with 4pg pCMV-E2i6 alone or 4|ig of pCMV-E2i6 and 4|u.g pl6-HAL2. The cells were 
then treated 24h post transfection with each proteasome inliibitor for 8h. The inhibitors 
used were 5pM MG132, 12.5pM Lactacystin, lOOpM ALLN (calpain inhibitor 1) and 
lOOpM ALLM (calpain inhibitor 11) and detection of E2 levels was accomplished by 
Western blotting. In untreated HaCaT cells, the presence of L2 lead to an -75% reduction 
in E2 level while no reduction was obseiwed in C33a cells. Treatment with all proteaome 
inhibitors led a 30% increase in E2 protein levels in both cell lines transfected with E2
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alone. In the presence of L2, treatment with all proteasome inhibitors did not restore the 
level of E2 in HaCaT cells expressing both E2 and L2 (Fig 4.2). In contrast, in C33a 
cells, the inhibitors increased the amount of E2 present in cells expressing both E2 and 
L2 to similar levels as cells expressing E2 alone (Fig 4.2). These results conclude that the 
proteasome degradation pathway is not involved in L2 mediated decrease in E2 protein 
levels as proteasome inhibition fails to restore E2 levels in the presence of L2. This leads 
to the possibility that the effect of L2 could be acting at the level of protein transcription.
4.1.2 L2 does not alter E2 mRNA transcription.
To ascertain whether the decrease in E2 protein in HaCaT cells expressing L2 was due at 
least in part to inhibition of E2 mRNA sysnthesis, HaCaT cells were transfected with 4pg 
pCMV-E2]6 +/- 4pg pl6-HAL2 and total RNA isolated. The RNA preparations were 
analysed by comparing RNA extracted from cells expressing E2 or co-expressing E2 and 
L2 after RT-PCR. The results indicated that there was no difference in the level of E2 in 
cells expressing E2 alone compared with cells expressing both E2 and L2 indicating that 
L2-induced decrease in E2 protein level is a post-transcriptional process (Fig 4.3a).
A Real Time Quantitative PCR was also used to investigate differences in E2 mRNA 
synthesis due to co-expression of E2 with L2. HaCaT cells were seeded and transfected 
with 4pg pCMV-E2i6 +/- 4pg pl6-HAL2, and total RNA was isolated and resuspended 
in RNase-free water. The results indicated that there were no differences in E2 mRNA 
levels in cells transfected with pCMV-E2,6 or pCMV-E2i6 and pl6-HAL2, as all the 
amplification cmwes were coincident (Fig 4.3b). As E2 mRNA levels remain the same in
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the presence or absence of L2, these results indicate that the effect of L2 on E2 protein 
expression is not mediated by transcription inhibition.
4.1.3. L2 down-regulation of the transcriptional activity of E2 is 
proteasome independent
To further investigate if the effect of L2 on the transcription transactivation function of 
E2 could be overcome by inhibition of E2 degradation mediated thiough the proteasome, 
C33a cells were transfected with pl8-6E2, ptk6E2, pCMV-E2i6 and increasing amounts 
of p l6 “HAL2 and treated with the proteasome inhibitor MG 132. The amount of pCMV- 
E2i6 was kept sub-optimal for E2-mediated transactivation. For both promoters used, 
inhibition of E2 degradation had no effect on the down-regulation of E2 transcription 
transactivation by L2 as the presence or absence of MG 132 resulted in similar kinetics of 
inhibition of transcription transactivation (Fig 4.4). This further confinns that the down 
regulation of transcription transactivation function of E2 by L2 is not due to E2 protein 
degradation.
4.2. L2 does not affect E2 half-life/stability
Biosynthetic labelling teclmiques are commonly used in the study of biochemical 
properties, synthesis, processing, intracellular transport, secretion and degradation of 
proteins. To investigate the effect of L2 on E2 protein turnover, the half-life of E2 was 
measured by pulse-chase analysis in HaCaT cells. HaCaT cells were transfected with 
pCMV-E2i6, +/- pl6-HAL2 and labelled with [^^Sjmethionine for Ihi'. The labelling 
medium was removed and samples extracted at hourly time points up to 6h. E2 was 
immunoprecipitated and analysed by SDS PAGE and autoradiography. A graphical
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representation of the experiment shown in Fig 4.5, illustrates that E2 had a half-life of 
-75 minutes with -60% degradation observed after 2 hour. In HaCaT cells co-transfected 
with both pCMV-E2i6 and pl6-HAL2, the level of residual E2 was lower than in cells 
transfected with only pCMV-E2i6 but the half-life remained similar (Fig 4.5). The use of 
pulse-chase analysis to obseiwe E2 half-life in the presence of L2, results in labelled 
E2 being affected by a continuous expression of L2. The presence of L2 did not affect the 
level of E2 in cells expressing both E2 and L2 when compared to cells expressing E2 
alone.
To further investigate the effect of L2 on E2 half-life, cycloheximide (CHX), which shuts 
down protein translation, was used to treat HaCaT cells. As CHX shuts down protein 
translation, the effect of L2 on E2 will be as a result of the presence of residual L2 left 
after protein translation has been shut off. HaCaT cells were transfected with pCMV-E2i6 
or pCMV-E2i6 and pl6-HAL2. CHX was added and cells were haiwested over an hourly 
time course up to 8 hours. The E2 protein was detected using Western blotting analysed 
by SDS PAGE. Dimethyl sulfoxide (DMSO) tlie solvent for CHX was used as a control. 
A graphical representation of the experiment shown in Fig 4.6, illustrates that E2 had a 
half-life of -110 minutes with -60% degradation also obseiwed after 2 hour (Fig 4.6). 
The half-life of E2 was slightly longer than the half-life seen with the pulse-chase 
experiment. In both experiments, the results also did not indicate a difference in E2 half- 
life in the presence of L2.
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Although there were slight differences in the measurement of protein turnover, both 
experiments indicated that L2 had no effect on the half-life of E2 in HaCaT cells. The 
reason why no difference in E2 half-life was detected is unclear. In both experiments L2 
reduced the level of E2 expressed and although less E2 was present, this residual E2 had 
no change in its half-life. These results suggest that L2 may act on E2 mRNA translation.
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Figure 4.1. HPV-16 L2 down-regulates E2 in HaCaT but not in C33a cells. (A), 
HaCaT cells were transfected with 4|ig pCMV-E2i6 (lane 1), or 4pg pCMV-E2i6 plus 
4|ig pl6-HAL2 (lane 2), or with 4pg pl6-HAL2 alone (lane 3). (B), HaCaT cells stably 
expressing E2 (lane 1) were transfected with 4pg pl6-HAL2 (lane 2). (C) U20S cells 
were transfected with 4pg pCMV-E2i6 (lane 1), or 4pg pCMV-E2i6 plus 4pg pl6-HAL2 
(lane 2). (D), C33a cells were transfected with 4pg pCMV-E2i6 (lane 1), or 4|ig pCMV- 
E2i6 plus 4pg pl6-HAL2 (lane 2). Cell were harvested using SDS-PAGE lysis buffer and 
extracts were analysed in independent Western blots with mouse anti-HA monoclonal 
antibody (HA.l 1) to probe for HA-L2, anti-E2 mouse monoclonal antibody TVG261 and 
mouse anti-actin antibodies.
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Figure 4.2. HPV-16 L2 decreases the level of E2 in HaCaT cells in a proteasome 
independent manner. HaCaT cells or C33a cells were transiently transfected with 4pg 
pCMV“E2i6 alone lanes) or with 4pg pCMV-E2i6 and 4pg pl6-HAL2 (“+” lanes). 
After 24 hours the transfected cells were either treated for 8 h with the indicated 
proteasome inhibitors or kept untreated. All cells were harvested using SDS-PAGE lysis 
buffer and the different cell extracts were analysed by Western blot and revealed by anti- 
E2 mouse monoclonal antibody TVG261 and mouse anti-actin antibodies.
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Figure 4.3. HPV-16 L2 does not alter E2 mRNA transcription. (A) Total RNA from 
HaCaT cells transfected with pCMV-E2i6 alone or with pCMV-E2i6 and pl6-HAL2 
After RNA extraction and DNase treament, the extracted RNA was reverse transcribed to 
cDNA and PCR was performed using E2 and L2 primers. Lanes 1 and 2 show RNA from 
HaCaT transfected with E2 alone, and actin control respectively. Lanes 3 and 4 show 
RNA from cells transfected with L2 alone and actin control respectively. Lanes 5, 6 and 7 
show RNA from cells transfected with E2 and L2 as well as the actin control 
respectively. Lanes 8 and 9 show RNA from cells transfected with pCMV, which did not 
yield cDNA using the E2 and L2 primers. The actin control in lanes 2, 4 and 7 show the 
three actin isotypes (alpha, beta and gamma). All three isotypes were detected with the 
actin primers used. (B) Total RNA from HaCaT cells transfected with pCMV-E2i6 alone 
or with pCMV-E2i6 and pl6-HAL2 was digested with DNAse and reverse transcribed 
with random primers. Real time PCR was performed in triplicate with primers and probes 
for E2 and actin. There was no difference in E2 transcription in the presence or absence 
of L2, and all the amplification curves were coincident.
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Figure 4.4. HPV-16 L2 down-regulates the transcription transactivation function of 
E2 in cells is independent of E2 degradation. C33a cells were transiently co-transfected 
with 0.1 ng of luciferase reporter construct and Ing pCMV-E2i6 with increasing amounts 
of pl6-HAL2, (O.OSpg, 0.1 pg, 0.5pg and Ipg). Each experiment was adjusted for total 
DNA by co-transfecting with the parental plasmid pCMV. The experiment was 
conducted in the presence or absence of MG 132 treatment for 8 hours post-transfection. 
Shown are representative experiments for each promoter (a) pl8-6E2 (b) ptk6E2 in C33a 
cells. Transactivation is shown as fold activation of luciferase expression over that of the 
reporter plasmids without E2, taken arbitrarily as 1.
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Figure 4.5. The effect of HPV-16 L2 on the stability of HPV-16 E2 using 
methionine labelling in HaCaT cells. HaCaT cells were transiently co-transfected with 
4pg of pCMV-E2i6 or 4pg of pCMV-E2,6 and 4pg of pl6-HAL2. Twenty-four hours post 
transfection, the cells were incubated with [^ ^S] methionine (0.2pCi/ml) for 1 hour at 
37°C, 5% CO2  to pulse cells. To detect protein half-life, cells were harvested using NP- 
40 lysis buffer over a six-hour time course. Detection of ^ ^S-labelled E2 was achieved by 
immunoprécipitation with anti-E2 polyclonal antibody and exposed by autoradiography 
(a). Densitometry was carried out on bands and shown by graphical representation (b).
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Figure 4.6. The effect of HPV-16 L2 on the stability of HPV-16 E2 after 
cycloheximide treatment in HaCaT cells. HaCaT cells were transiently co-transfected 
with 4jig of pCMV-E2j6 or 4fig of pCMV-E2i6 and 4pg of pl6-HAL2. Twenty four 
hours post transfection, cells were treated with lOOpg/ml CHX in DMSO and DMSO 
only used as a negative control. Cells were harvested using SDS-PAGE lysis buffer at 
regular time intervals after CHX/DMSO addition for up to 8h. Samples were 
immunoblotted and samples probed for E2 by anti-E2 mouse monoclonal antibody 
TVG261 (a). Densitometry was carried out on bands and shown by graphical 
representation (b).
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CHAPTER 5: ANALYSIS OF HPV-16 L2 DELETION 
MUTANTS
5.1 Introduction
The interaction of HPV-16 L2 with HPV-16 E2 has been shown to result in the down 
regulation of the transcription transactivation function of E2 as well as a proteasome 
independent down-regulation of E2 expression in a cell dependent manner, with no effect 
on E2 mRNA synthesis. To detennine the domain or domains of L2 responsible for the 
alteration of E2 transcription transactivation or expression, deletion mutants of L2 (Fig 
5.1) were constructed. An in vitro protein-protein association assay was used to 
determine the ability of L2 and L2 deletion mutants to bind with E2. GPP fusion foims of 
each L2 deletion mutant were also constmcted to determine cellular localisation and 
luciferase transcription assays were performed to identify domain or domains of L2 
responsible for the down-regulation of E2 transcription transactivation.
5.2. Identification of E2-binding domains of L2
5.2.1. GST Gene Fusion System
Glutathione S-transferase is a naturally occumng enzyme that can be expressed in E. coli 
with full enzymatic activity. The system has been widely used for the expression, 
purification and detection of fusion proteins expressed in bacteria. Fusion proteins with 
the GST moiety at the amino teiminus and the protein of interest at the carboxyl terminus 
are expressed in bacteria. The protein accumulates within the cytoplasm and can be 
purified by affinity chromatography using immobilised glutathione. The HPV-16 L2 N-
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and C- tenninus deletion mutants were constmcted by inserting the deleted L2 sequences 
as a BamHI-EcoRl insert within the multiple cloning site of the pGEX-4T-2 vector. 
Expression of the fused protein is under the control of the tac promoter which can be 
induced by the addition of isopropyl (3-D thiogalactosidase (IPTG). The bacterial host 
strain used was E. coli BL21, a strain defective in OmpT and Lon protease production, 
designed to maximize expression of full-length fusion proteins by minimizing the effects 
of proteolytic degradation.
5.2.2. Construction of GST-L2 deletion mutants
The PCR amplified inserts from HPV-16 L2 deletion mutants were cloned into pGEX- 
4T-2 expression plasmid (Fig 5.2). L2 was amplified by PCR as a BamFIl-EcoRl 
fiagment and inserted into pGEX-4T-2. The restriction sites chosen ensured that all 
proteins would be inserted in frame. All mutants were expressed as fusion proteins with 
the GST moiety at the amino terminus and L2 or its deletion mutants at the carboxyl 
teiminus. For the C-teiminus L2 deletion mutants, the primer HPV-16 L2 BamHl 
forward was used for all forward reactions while the primers GST L2 1-50 (or 1-100, 1- 
200,1-300,1-400) reverse (Table 2.1) were used for the reverse reaction. For cloning of 
the amino teiminus deletion mutants, the primer HPV-16 L2 EcoRl reverse was used for 
all reverse reactions while the primers GST-L2 25-473 (or 50-473,150-473,250-473,350- 
473,390-473) forward (Table 2.1) were used for all fbiwaid reactions. For sequencing of 
GST-L2 deletion mutants, the following sequencing primers 5’- 
GGGCTGGCAAGCCACGTTTGGTG-3’ foiward corresponding to position 869-891 on 
the pGEX-4T-2 plasmid and 5 '-CCGGGAGCTGCATGTGTCAGAGG-3 ' reverse 
coiTesponding to position 1042-1020 were designed. Sequencing showed L2 and the L2
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deletion mutants all fused in frame with the GST protein. Restriction digest were also 
perfoimed to confiim that all L2 deletion inserts were of the conect size (Fig 5.3). The 
amino acid sequences of each L2 deletion mutant (Fig 5.1) were as follows:-
1. HPV-16 L2 amino acids 1-50
2. HPV-16 L2 amino acids 1-100
3. HPV-16 L2 amino acids 1-200
4. HPV-16 L2 amino acids 1-300
5. HPV-16 L2 amino acids 1-400
6. HPV-16 L2 amino acids 25-473
7. HPV-16 L2 amino acids 50-473
8. HPV-16 L2 amino acids 150-473
9. HPV-16 L2 amino acids 250-473
10. HPV-16 L2 amino acids 350-473
11. HPV-16 L2 amino acids 390-473
5.2.3. The amino terminus of L2 mediates binding with E2
GST pull-down assays were perfoimed to determine the domain or domains of L2 that 
mediate binding to E2. L2 and L2 deletion mutants were cloned into pGEX-4T-2 as 
described above. Bacteria were transformed with GST-L2 and each GST-L2 deletion 
mutants and grown at 37°C for 5 hours after induction with 0.5mM IPTG. Bacteria were 
haiwested, lysed and cell extracts were incubated with glutathione beads, which 
immobilises GST fusion proteins. Expression of GST-L2 and GST-L2 deletion mutants 
was analysed by SDS-PAGE and Western blotting. Immunoblotting with anti-GST
148
Chapter Five ____________________________________________________ Results
antibody to detect expression levels of the GST-L2 deletion mutants showed that GST-L2 
and GST-L2 C-terminal deletion mutants all gave the expected migration on 
polyacrylamide gels (Fig 5.4). N-tenninal deletion mutants were also detected and the 
expected migration was also obseived, although with multiple banding indicating 
increased instability of mutants with deletions in the N teiminus.
Bacterially expressed GST-L2 and GST-L2 deletion mutants were immobilised onto 
glutathione beads and incubated with -methionine labelled HPV-16 E2, The result 
indicated that E2 interacts with GST-L2, with approximately 5% of input E2 bound to 
GST-L2 (Fig 5.4). The binding observed between E2 and GST alone was negligible when 
compared to binding of E2 with GST-L2. GST-L2 N-tenninal and C-teiminal deletion 
mutants were also bacterially expressed, immobilised on glutathione beads and incubated 
with labelled E2. The mutant GST-L2 1-50 showed strong binding with E2 (Fig 5.4a), 
all C-terminal mutants also showed binding with E2. The N-terminal deletion mutants all 
showed weak interaction with E2 indicating the loss of possible binding domains in the 
amino terminal portion of L2. The specificity of the interaction between E2 and L2 was 
confirmed the binding of labelled L2 with GST-E2 immobilised on beads. ^^S-L2 did 
not bind to bead immobilised GST. An umelated protein ^^ S labelled luciferase did not 
bind to bead immobilised GST-E2 (Fig 5.4c).
To quantify the binding of GST-L2 and its deletion mutants with E2, the amount of ^^ -S 
E2 bound to each fusion protein immobilised onto beads was measured by 
autoradiography. These values were then normalised by dividing them by the mount of
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GST-L2 proteins immobilised on beads. The latter was measured with the use of image 
analysis software by measuring bands of each ftision protein after SDS-PAGE and 
immunoblotting. The results indicated that binding of the first 50 N-terminal amino acids 
of L2 with E2 gave binding at levels observed for ftill-length L2. Mutant GST-L2 1-300 
showed a weak interaction with E2 probably as a result of confoimational changes in the 
protein (Fig 5.5). The GST-L2 C-teiminal deletion mutants did not bind E2 to levels 
obseiwed with binding with the ftill-length or N-terminal deletion mutants possibly as a 
result of loss of E2 binding domains.
The analysis of the expression of GST-L2 deletion mutants by SDS-PAGE western 
blotting with anti-GST antibody showed that GST-L2 and GST-L2 deletion mutants had 
undergone degradation, as several bands were present, in addition to the expected bands. 
This degradation prevents accurate quantification of the amount of E2 bound by the L2 
mutants, as the quantification method used does not take into consideration any E2 
binding by the GST-L2 breakdown product. Therefore the amount of E2 bound by L2 in 
fig 5.5 may be an underestimate. Nevertheless, the use of GST-pull down assays does 
give an indication of HPV-16 E2-L2 interaction in vitro as has previously been observed 
for BPV-1 (Heino et al., 2000). The results lead us to conclude that the interaction of L2 
with E2 is mediated through the amino terminus of L2.
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Figure 5.1. Schematic representation of HPV-16 L2 deletion mutants. L2 N-terminus 
and C-temiinus deletion mutants were generated by PGR from a HPV-16 genome 
containing plasmid.
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Figure 5.2. Graphical representation of pGEX-4T-2. The gene of interest is inserted 
into the multiple cloning site (MCS) of the vector and expressed as a fusion to the 
carboxyl tenninus of GST. Expression of the fused protein is under the control of the tac 
promoter which can be induced by the addition of IPTG.
153
Graphical representation of pGEX-4T-2 
vector and multiple cloning site.
p6E X -4T -2  (27-4581-01)_ _ _ _ _ _ Thrombin_____I  Leu Val Pro Arg’^ Gty S eri Pro Giy lie Pro Gly Ser Thr Arg Ala Ala Ala Ser GIG m  COG CGT.G6A TCG.CCA GpA ATT CGG 6 6 p  TGG ACT GGA GCG GGG GOA TGG TGA
BamH I EcoR I* gm a I * Xho I N oll ' Stop codon
m ill 1 Aat IIBal I
BspM I pSjl 0ABam7Stop7
pGEX
-4 900  bp
EcoRV
BssH I
BstE IIMlu 1 pBR322on
154
Chapter Five___________________________________________________________Results
Figure 5.3. Digestion of GST-L2 N-terminal and C-terminal deletion mutants. Ijig of 
each plasmid was digested for Ih with BamHl-EcoRl and analysed using agarose gel 
electrophoresis and observed under UV light. All inserts gave bands at the expected 
mobility when compared with Ikb and lOObp ladders.
155
pgo0
M1
as(Q
JS
%
•PNs%
f if i
f iS
f i0
"oS
fN
1HC/5
O
o
f io
c/!}0>54
BBOS- I
BBOOI-I
BBoor-I
BBooe-i
BBOOt'- l
jappBi dqool
JoppBi q^ i \
JsppBi dqoOl
z-if-xaod
BB[6t-06E
BBEAt-OSE
BBEAt-OSZ
BBEAt-OSl
BBEAt-OS
BBEAt-SZ
J3PPBI qN \
oLT)
Chapter Five__________________________________________________________ Results
Figure 5.4. The N-terminal domain of L2 mediates binding with E2. Bacterially 
expressed GST and GST-L2 (a) C-tenninal or (a) N-terminal deletion mutants 
immobilised on glutathione beads. lOpl of immobilised beads was incubated with 5pi 
labelled in vitro translated E2. (c) Bacterially expressed GST and GST-E2 were 
immobilised on glutathione beads. lOpl of immobilised beads was incubated with 5pi ^^ S 
labelled in vitro translated L2 or lOpl ^^ S labelled in vitro translated luciferase. Bounds 
proteins were separated by SDS-PAGE and visualised by autoradigraphy.
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Figure 5.5. Then N-terminal domain of L2 mediates binding with E2. Bacterially 
expressed GST and GST-L2 carboxyl terminal or amino terminal deletion mutants 
immobilised on glutathione beads were incubated with ^^ S labelled in vitro translated E2. 
Bounds proteins were separated by SDS-PAGE and visualised by autoradigraphy. Graph 
represents binding of ^^S-methionine labelled E2 to immobilised GST or GST-L2 
deletion mutants normalised for amount of GST-L2 protein.
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5.3. Visualisation of GFP-L2 deletion mutants 
5.3.1. The Green Fluorescent Protein
The green fluorescent protein, GFP (Fig 5.6a), is a spontaneously fluorescent protein 
isolated from the Pacific jellyfish, Aeqtioria Victoria which transduces, by energy 
transfer, the blue chemiluminescence of another protein, aequorin, into green fluorescent 
light. The molecular cloning of GFP cDNA and the demonstration by Chalfie et al (1994) 
that GFP can be expressed as a functional transgene has opened exciting new avenues of 
investigation in cell, developmental and molecular biology. Fluorescent GFP has been 
expressed in bacteria, yeast, plants, Drosophila, and mammalian cells. GFP can Fmction 
as a protein tag, as it tolerates N- and C-terminal fusion to a broad variety of proteins 
many of which have been shown to retain native function. When expressed in mammalian 
cells, fluorescence from wild type GFP is typically distributed tluoughout the cytoplasm 
and nucleus. The flexibility of GFP as a non-invasive marker in living cells allows for its 
use as a reporter of gene expression. The cDNA of GFP encodes a protein of 238 amino 
acids with the molecular weight of 26.9kDa. Only three amino acids serine 65,tyrosine 66 
and glycine 67 that make up the chi'omophore are responsible for the fluorescence. Its 
wild-type absorbance/ excitation peak is at 395 nm with a minor peak at 475 nm with 
extinction coefficients of roughly 30,000 and 7,000 M'‘ cm"’, respectively. The emission 
peak is at 508 nm.
5.3.2. Construction of GFP-L2 deletion mutants
To obtain a fusion form of HPV-16 L2 with GFP (Fig 5.6b), the L2 sequence was cloned 
into pEGFP-Cl vector (Fig 5.7) at the C-terminus of GFP using PCR. L2 cDNA was
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PCR amplified as a BamHl-EcoRl fragment from HPV-16 genome. The resulting 
plasmid was sequenced to confiiTn its identity and called pGFP-L2. A series of L2 N- 
terminus and C- terminus deletions of HPV-16 L2 were also designed and cloned into 
pEGFP-Cl vector at the C-tenninus of GFP. Primers were designed with BamHl-EcoRl 
restriction sites. For cloning into the pEGFP-Cl vector, the restriction sites Bgl II-EcoRl 
were used to clone each insert into the pEGFP-Cl plasmid.
5.3.3. Primer design and cloning
For the C-terminus L2 deletion mutants, the p r i m e r L2 BamHl forward was used 
for all forward reactions while the primers GFP L2 1-50 (or 1-100, 1-200,1-300,1-400) 
reverse (Table 2.1) were used for the reverse reaction. For cloning of the N-terminus 
deletion mutants, the primer HPV-16 L2 EcoRl reverse was used for all reverse reactions 
while the primers GFP-L2 25-473 (or 50-473,150-473,250-473,350-473,390-473) 
foi'ward (Table 2.1) were used for all forward reactions. For sequencing GFP-L2 and its 
deletion mutants, the sequencing primer 5’-CCTAGGAGCACTAAGCGA-3’ 
corresponding to position 679-658 of the pEGFP-Cl plasmid was used. All plasmids 
sequences had the L2 deletion fused to the GFP protein as a Bgl 11 (BamHl)-EcoRl 
insert. Sequences showed HPV-16 L2 inserts all fused in frame with the GFP fusion 
protein and designated pGFP-L2 1-400, pGFP-L2 1-300, pGFP-L2 1-200, pGFP-L2 1- 
100, pGFP-L2 1-50, pGFP-L2 25-473, pGFP-L2 50-473, pGFP-L2 150-473, pGFP-L2 
250-473, pGFP-L2 350-473 and pGFP-L2 390-473. Restriction digest were also 
perfoiuied to confinn that all L2 deletion inserts were of the coiTect size (Fig 5.8).
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5.3.4. Detection of GFP-L2 and its deletion mutants
To determine the localisation of GFP-L2 and its deletion mutants, HaCaT cells were first 
transiently transfected with varying amounts of GFP-L2 and the vector expressing GFP 
alone. Cells were seeded onto iri 01 coverslips in 24-well plates at a density of 10^  
cells/well and cultured overnight. When 80% confluent, cells were transfected with 5ng, 
lOng, 25ng, 50ng lOOng, 0.5pg, Ipg or 5pg of pGFP-L2 or pEGFP (GPF-L2 or GFP 
alone expressing plasmids). A DNA concentration of lOOng was chosen for subsequent 
transfections as it gave best results for efficiency of transfection.
Twenty-four hours after transfection, the cells were washed twice with PBS and fixed by 
10-min incubation at room temperature with 1.85% formaldehyde diluted in PBS 
containing 2% sucrose, and washed three times with PBS. Staining for DNA was done 
using 4’6’-Diamino-2-phenylindole (DAPI) that stains nucleic acids in general and 
fluoresces in the deep blue spectium. Cells were incubated with a DAPI staining solution 
(a 1/100 dilution from a lOpg/ml stock of DAPI in washing buffer) for lOmins, washed in 
PBS-FCS and then distilled water (to remove traces of FCS) and dried before the 
coverslips were mounted in AFl (Citifluor, UK) and visualised using the confocal 
microscope as described in section 2.2.5. Cells transfected with GFP showed a green 
fluorescence uniformly distributed in the whole cell (Fig 5.9a) while GFP-L2 expressing 
cells resulted in a well-defined localisation to the nucleus (Fig 5.9b) suggesting that the 
nuclear localisation of GFP-L2 was exclusively due to L2 sequence. All cells even with 
the weakest fluorescence presented a nuclear localisation of GFP-L2 excluding the 
possibility that the cellular localisation of GFP-L2 was due to its over expression.
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In order to determine the localisation of GFP-L2 C-terminal deletion mutants, HaCaT 
cells were transfected with lOOng pGFP-L2 1-400, pGFP-L2 1-300, pGFP-L2 1-200, 
pGFP-L2 1-100 and pGFP-L2 1-50. Cells were fixed as described above, mounted and 
visualised using the confocal microscope. Cells expressing all C-terminal deletion 
mutants showed clear localisation to the nucleus (Fig 5.9c-g). Nuclear localisation results 
from the presence of an arginine rich DNA binding domain (Zhou et al., 1994) which has 
been shown to function as NLS sequences with N-terminal amino acids 1-60 of HPV-6b 
L2 being able to localise beta-galactosidase to the nucleus (Sun et al., 1995).
Transfection of lOOng of pGFP-L2 25-473, pGFP-L2 50-473, pGFP-L2 150-473, pGFP- 
L2 250-473, pGFP-L2 350-473 and pGFP-L2 390-473 in HaCaT cells all showed 
localisation to both the nucleus and the cytoplasm. In contrast to cells transfected with 
GFP alone with green fluorescence uniformly distributed in the whole cell when 
transfected, with the N-teiminal deletion mutants, clearly defined nucleus and cytoplasm 
could be identified (Fig 5.9h-m). Localisation to the nucleus results from the presence of 
NLS sequences at the C-terminus of L2. Deletion of sequences within the N teiminal 
protein of L2 appears to affect effective translocation or prevent retention of L2 within 
the nucleus. Both the N-teiminal DNA binding domain and the C-terminal NLS of HPV- 
6b L2 have been shown to be functional in protein nuclear transport and contribute to the 
translocation of L2 into the nucleus (Sun et al., 1995). In summaiy, GFP-L2 and GFP-L2 
C-teiminal deletion mutants all gave a localisation to the nucleus while the GFP-L2 N- 
teiminal deletion mutants gave a staining pattern that was both nuclear and cytoplasmic.
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5.3.5, Expression of GFP-L2 deletion mutants
To detect GFP-L2 and GFP-L2 deletion mutants by immunoblotting, HaCaT cells were 
transfected with 4g pGFP-L2 or 4p of each pGFP-L2 deletion mutants. Cells were 
harvested 24 hours post transfection and detection of GFP fusion proteins was 
accomplished by SDS-PAGE and Western blotting. Probing with HPV-16 L2 polyclonal 
rabbit serum detected a high steady state level of expression in cells expressing GFP-L2 
1-400, GFP-L2 1.300 and GFP-L2 1-200 (Fig 5.10a). Cells transfected with pGFP-L2 
showed a lower expression level with multiple banding obseived indicating a high level 
of protein instability. A low level of GFP-L2 1-100 could be detected while GFP-L2 1-50 
could not be detected using the L2 polyclonal rabbit semm possibly due to a loss of the 
L2 epitope. Mutants pGFP-L2 25-473 and pGFP-L2 50-473 showed a lower steady state 
level of expression while mutants pGFP-L2 150-473, 250-473, 350-473 and 390-473 
could not be detected using the L2 semm (Fig 5.10a). Differences in detection between 
the N-terminal and C-terminal deletion mutants could result from deletion of instability 
sequences located within the 3’-end of the L2 mRNA (Sokolowski et al., 1998) leading 
to increased expression of C-tenninal deletion mutants. All GFP-L2 C-terminal deletion 
mutants were also detected using an anti-GFP rabbit polyclonal antibody (Santa Cmz) 
including mutants GFP-L2 1-50 and GFP-L2 1-100, which could not be detected using 
the HPV-16 L2 polyclonal rabbit semm (Fig 5.10b). GFP-L2 as well as all N-terminal 
GFP-L2 deletion mutants could not be detected using the anti-GFP antibody.
Expression of papillomavirus stmctural proteins LI and L2 is tightly regulated resulting 
in difficulties in detection of L2 in mammalian cells by means of DNA transfections. 
This regulation has been linked to the differentiation status of cells, polyadenylation
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signals teiTninating transcripts before reaching the late region (Baker and Howley, 1987; 
Terhune et al., 2001) and mRNA encoding negative regulatory sequences that prevent 
nuclear export or destabilize the message (Kennedy et a l, 1990; Kennedy et al., 1991; 
Sokolowski et al., 1998). Transient expression of L2 in non-differentiated human cells 
has been shown to be highly improved by changing the RNA coding sequences (Leder et 
al., 2001; Zhou et al., 1999). Considering that GFP-L2 and N-terminal GFP-L2 deletion 
mutants could be visualised by immunofluorescence but not by Western blotting 
indicates that the process of protein extraction and SDS-PAGE analysis could contribute 
to the increased instability and reduced detection of L2 by immunoblotting.
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Figure 5,6. Schematic representation of the backbone of the green fluorescent 
protein. (A) GFP consists of eleven anti-parallel beta-sheets, which surround a co-axial 
helix enclosing the chromophor. The structure gives high stability to the protein, making 
it resistant to denaturing chemicals. (B) Schematic representation of HPV-16 L2 fused to 
the carboxyl terminus of GFP.
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Figure 5.7. Graphical representation of pEGFP-Cl. pEGFP-Cl is a GFP expression 
plasmid designed to generate fusion proteins for expression and localization studies, or 
expression of GFP in mammalian cells. The gene of interest is inserted into the multiple 
cloning site (MCS) of the vector and expressed as a fusion to the C-terminus of GFP.
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Figure 5.8. Digestion of pEGFF-L2 N-terminal and C-terminal deletion mutants.
Ifxg of each plasmid was digested for Ih with Nhel-EcoRl, analysed using agarose gel 
electrophoresis and observed under UV light. All inserts gave bands at the expected 
mobility when compared with Ikb and lOObp ladders.
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Figure 5.9. Visualisation of GFP-L2 and GFP-L2 deletion mutants. Confocal images 
of HaCaT cells transfected with lOOng of (a) pEGFP, (b) pGFP~L2 (c) pGFP-L2 1-400, 
(d) pGFP-L2 1-300, (e) pGFP-L2 1-200, (f) pGFP-L2 1-100, (g) pGFP-L2 1-50, (h) 
pGFP-L2 25-473, (i) pGFP-L2 50-473, (j) pGFP-L2 150-473, (k) pGFP-L2 250-473, (1) 
pGFP-L2 350-473 and (m) pGFP-L2 390-473, fixed after 24h and stained for DNA using 
DAPI. GFP alone showed a uniform distribution in the cell. GFP-L2 showed a well- 
defined localisation to the nucleus. The C-terminal deletion mutants also showed well- 
defined localisation to the nucleus. The N-terminal GFP-L2 deletion mutants showed a 
disperse localisation in both the cytoplasm and nucleus.
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Figure 5.10. Expression of GFP-L2 and GFP-L2 deletion mutants. HaCaT cells were 
transfected with 4pg pGFP-L2, or 4pg pGFP-L2 deletion mutants. Cell were harvested 
using SDS-PAGE lysis buffer and extracts were analysed by Western blotting with (A) 
HPV-16 L2 polyclonal rabbit serum (B) Anti-rabbit polyclonal antibody to probe for GFP 
fusion proteins.
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5.4. Analysis of the effect of L2 deletion mutants on E2 function
5.4.1. Construction of L2-deletion mutants in pCDNA expression vector
To investigate the domain or domains of L2 that mediate the down-regulation of E2 
transcription transactivation as well as E2 expression, the series of L2 deletion mutants 
was cloned into pCDNA3.1(+) expression vector. The pCDNA3.1(+) plasmid is a 5.4kb 
vector derived from pCDNA3 and designed for high-level stable and transient expression 
in mammalian hosts. It contains the CMV promoter, neomycin resistance gene and a 
multiple cloning site, which facilitates cloning. A series of primers were designed for 
cloning of both the N-terminal and the C-terminal deletions of HPV-16 L2 (Fig 5.1).
5.4.2 Primer design and cloning
The following primers were used to PGR amplify inserts for cloning into pCDNA 3.1+ 
vector. For the carboxyl terminus L2 deletion mutants, the ^nm.Qx HPV-16 L2atg BamHl 
forward was used for all forward reactions while the primers L2 1-50 (or 1-100, 1-200,1- 
300,1-400) reverse (Table 2.1) were used for the reverse reaction. For cloning of the 
amino terminus deletion mutants, the primer HPV-16 L2 EcoRl reverse was used for all 
reverse reactions while the primers L2 25-473atg (or 50-473atg, 150-473atg, 250-473atg, 
350-473atg, 390-473atg) forward (Table 2.1) were used for all forward reactions. For 
sequencing of pCDNA-L2 deletion mutants, the forward sequencing primer ‘5- 
ATTAATACGACTCACTATAGGGA-3’ corresponding to position 864-882 in 
pCDNA3.1 (+) and the reverse primer 5 ’-CTAGAAGGCACAGTCGAGGC-3 ’ 
corresponding to position 1249-1018 were designed. All plasmid sequences had the L2 
deletion as a BamHl-EcoRl insert with the ATG start site and designated pCDNAL2,
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pCDNAL2 1-400, pCDNAL2 1-300, pCDNAL2 1-200, pCDNAL2 1-100, pCDNAL2 1- 
50, pCDNAL2 25-473, pCDNAL2 50-473, pCDNAL2 150-473, pCDNAL2 250-473, 
pCDNAL2 350-473 and pCDNAL2 390-473. Restriction digests were also performed to 
confimi that all L2 deletion inserts were of the correct size (Fig 5.10).
5.4.3. Effect of L2 and L2 deletion mutants on the transcription 
transactivation function of E2
To determine the domain or domains of L2 that mediate the down regulation of the 
transcription transactivation function of E2, C33a and HaCaT cells were transfected with 
ptk6E2, pCMV-E2i6 and increasing amounts (0.1-lpg) of pl6-HAL2, pCDNAL2 or L2 
deletion mutants (pCDNAl-400, 1-300, 1-200, 1-100, 1-50, 25-473, 50-473, 150-473, 
250-473, 350-473 and 390-473). The amount of E2 was kept sub-optimal for E2- 
mediated transactivation. In C33a cells transfection with pl6-HAL2, pCDNAL2 or 
mutants pCDNAL2 1-400 and pCDNAL2 1-300, down-regulated E2 transcription 
transactivation in a dose dependent manner, completely repressing E2 activation to levels 
obseived with the base promoter in cells transfected with Ipg of plasmid (Fig 5.11a). 
Mutant 1-200 did not inhibit E2 activity while mutants 1-100 and 1-50 inhibited E2 
activity but not to levels observed with full-length L2. For the N-terminus L2 deletion 
mutants, all mutants with the exception of 150-473 were able to fully inhibit E2 
transcription transactivation (Fig 5.11b). In HaCaT cells, mutants 1-200, 1-100 and 1-50 
did not inhibit E2 activity. The N-terminus deletion mutants 25-473, 350-473 and 390- 
473 inhibited E2 transcription transactivation at the highest amount of plasmid 
transfected while mutants 50-473, 150-473 and 250-473 showed no inhibition of E2 
activity (Fig 5.12b). In C33a cells, it appears that sequences between amino acids 150-
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200 inhibits repression of E2 transactivation function. It also appears that deletion of the 
C-tenninus of L2 from amino acid 200 also alleviates repression of E2 transcription 
transactivation which is better elucidated with results observed in HaCaT than in C33a 
cells. In HaCaT cells, transfection of the N-terminal deletion mutants did not give levels 
of repression of E2 transactivation as observed in C33a cells although results with mutant 
150-473 remained similar. Differences in the mode of transfection could contribute to 
differences in results obtained from both cell lines, as calcium phosphate precipitation is 
used to transfect C33a cells while LIPOFECTAMINE is used for transfection with 
HaCaT.
5.4.4. Effect of L2 and L2 deletion mutants on E2 expression
HPV-16 L2 down-regulates the expression level of HPV-16 E2 in HaCaT and U20S but
not C33a cells. To determine the domain or domains of L2 which mediate this down 
regulation of E2 expression, HaCaT cells were transiently transfected with 4pg pCMV- 
E2i6 alone or 4pg of pCMV-E2i6 and 4pg pl6-HAL2, pCDNAL2 or pCDNAL2 deletion 
mutants and detection of E2 levels was accomplished by Western blotting. In HaCaT 
cells, the expression of HA-L2 or wild type L2 lead to a marked reduction in the level of 
the E2 protein (Fig 5.13). In cells expressing E2 and L2 deletion mutants, the level of E2 
did not appear to be inhibited to levels comparable with the full-length L2 protein, 
indicating that the full-length protein is required for the down-regulation of E2 
expression.
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Figure 5.11. Digestion of pCDNA-L2 and pCDNA-L2 N-terminal and C-terminal 
deletion mutants. Ipg of each plasmid was digested for Ih with BamHl-EcoRl and 
analysed using agarose gel electrophoresis and observed under a UV light. All inserts 
gave bands at the expected mobility when compared with Ikb and lOObp ladders.
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Figure 5.12. Effect of L2 and L2 deletion mutants on the transcription 
transactivation function of E2 in C33a cells. C33a cells were transiently co-transfected 
with 0.1 jig of ptk6E2 luciferase reporter construct and Ing pCMV-E2i5 with increasing 
concentrations (0.1 pg, 0.5pg andlpg) of pCDNA16-L2 or (a) C-terminus and (b) N- 
terminus deletion mutants. Shown is the average of three consecutive experiments. 
Transactivation is shown as fold activation of luciferase expression over that of the 
reporter plasmids without E2, taken arbitrarily as 1.
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Figure 5.13. Effect of L2 and L2 deletion mutants on the transcription 
transactivation function of E2 in HaCaT cells, HaCaT ceils were transiently co­
transfected with 0.1 pg of ptk6E2 luciferase reporter construct and Ing pCMV-E225 with 
increasing concentrations (0.1 pg, 0.5pg andlpg) of pCDNA16-L2 or (a) C-terminus and 
(b) N-terminus deletion mutants. Shown is the average of three consecutive experiments. 
Transactivation is shown as fold activation of luciferase expression over that of the 
reporter plasmids without E2, taken arbitrarily as 1.
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Figure 5.14. Full length HPV-16 L2 is required to down-regulate E2 in HaCaT cells.
HaCaT cells were transfected with 4jag pCMV-E2i6, or 4jag pCMV-E2]6 plus 4pg pl6- 
HAL2, pCDNAL2 or pCDNAL2 (a) C-terminus and (b) N-terminus deletion mutants. 
Cell were harvested using SDS-PAGE lysis buffer and extracts were analysed in 
independent Western blots with anti-E2 mouse monoclonal antibody TVG261 and mouse 
anti-actin antibodies.
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CHAPTER 6: DISCUSSION 
6.1. Introduction
The viral minor structural protein L2 of BPV-1, HPV-16 and HPV-33 has been shown to 
localise to dynamic nuclear substructures associated with the nuclear matiix called PODs 
(Day et al., 1998; Florin et al., 2002; Gomemaim et a l, 2002). Co-expression of BPV-1 
L2 and E2 causes the redistribution of E2 into PODs (Day et at., 1998; Heino et al., 
2000). Besides the co-localisation of E2 and L2 to PODs, little is known about the effect 
of this interaction on E2 function. As a result, the aim of this thesis was to address the 
question of whether L2 plays a role in regulating E2 functions during the viral life cycle. 
The study presents evidence in a HPV-16 system that L2 was able to down regulate the 
transcription transactivation function of L2 in a dose dependent manner but had no effect 
on E2 function in DNA replication. Although no effect of L2 on E2 mRNA levels was 
observed, L2 was able to reduce the level of E2 expression in a cell type dependent 
manner and this reduction was not proteasome dependent. Using L2 deletion mutants, the 
domain of L2 required for binding with E2 was identified. Binding of L2 did not correlate 
with the down regulation of E2 transcription transactivation function or a reduction of E2 
protein expression levels.
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6.2. Functional interaction between HPV-16 E2 and HPV-16 L2
6.2.1. Regulation of transcription
The viral E2 gene product regulates papillomavims gene expression. E2 is a sequence 
specific DNA-binding protein, which interacts directly with E2-dependent enhancer 
elements, located within the viral genomes thiough E2 binding sites (E2BS) and plays an 
essential role in the activation of viral gene expression. There are four E2BS on the LCR, 
which mediate the activity of E2 in transcriptional activation and repression. E2BS 1-3, 
mediate the ability of E2 to repress transcription (Demeret et a l, 1997; Dong et al., 1994; 
Romanczuk et al., 1990; Thierry and Howley, 1991). This is thought to result from the 
ability of E2 to prevent TATA box binding protein (TBP) from binding to the TATA box 
thus preventing transcriptional initiation when E2 is bound to E2BS 1 (Dostatni et al., 
1991). E2BS 3 is thought to mediate E2 repression by competing with the cellular 
transcription factor Spl, which binds to a site overlapping it (Demeret et al., 1997; Tan et 
al., 1994). E2BS 4 mediates activation of transcription by E2, especially under conditions 
where the other binding sites are dismpted (Demeret et al., 1997). During the productive 
stage of the viral life cycle, E2 regulates transcription of the viral E6 and E7 oncogenes. 
Malignant transformation usually occurs as a result of dismption of the E2 gene and 
consequent deregulated expression of E6 and E7 (Fig 1.7). Réintroduction of FlPV-18 E2 
to ceiwical carcinoma cell lines by transient transfection leads to repression of the 
endogenous E6/E7 transcription, inducing cell cycle arrest in G, mediated by the 
stabilization of p53 (Desaintes etal., 1997; Dowhanick a/., 1995).
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The role of E2 in regulating expression of the E6/E7 promoter of HPV-18 has been 
analysed using an in vitro transcription system to deteimine the dose response of E2 on 
the long control region (LCR) (Steger and Corbach, 1997). E2 was shown to activate 
transcription at low concentrations, while increasing the concentration of E2 resulted in 
complete promoter repression. BPV-4 E2 has also been shown to activate transcription 
from the BPV-4 LCR, which was up-regulated at low E2 concentrations while high levels 
of E2 resulted in down regulation of transcriptional activation (Jackson and Campo, 
1995; Morgan et a l, 1998).
The effect of increasing amounts of E2 on the activity of the LCR was further elucidated 
in this study. E2 regulated transcription from the wild type HPV-18 and BPV-4 
promoters in a dose dependent manner with low levels of E2 stimulating transcription. 
Activation of transcription has been shown to result horn E2 binding to E2BS 4 with 
which it has its highest binding efficiency (Steger and Corbach, 1997). An increase in the 
amount of E2 resulted in repression of transcription transactivation. This repression is 
mediated by E2 binding E2BS 1-3 with which it has been shown to bind with lower 
efficiency (Steger and Corbach, 1997). Elimination of repression of E2 transcription 
activation was achieved with the use of a variety of E2 responsive reporter constmcts 
derived from the HPV-18 LCR with mutations in E2BS 1 or E2BS 1-3 to prevent E2 
from binding these sites. Two synthetic promoters consisting of multimerized E2BS 
fused to the HPV-18 TATA or tk promoter were also used. E2 strongly activated 
transcription in a dose dependent manner with no repression observed even at the highest 
amounts of E2, as previously shown (Morgan et ciL, 1998; Phelps and Howley, 1987;
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Vance et al., 1999). The use of HPV-18-derived and synthetic E2 responsive promoters 
showed that the transcriptional transactivation activity of E2 was drastically inhibited by 
L2 in a dose dependent manner. These obseivations are in agreement with obseivations 
using a bovine system that showed repression of BPV-1 E2TA-dependent luciferase 
expression by increasing amounts of BPV-1 L2 in CV-1 3T3 cells (Heino et al., 2000). In 
this study, two human cell lines, HaCaT and C33a were used representing two different 
human models of carcinogenesis. In both cases, similai' results were obtained showing 
repression of HPV-16 E2 dependent luciferase expression by increasing amounts of 
HPV-16 L2. These results suggest that this aspect of the interaction between E2 and L2 
may be a common feature of papillomavimses of different types.
How L2 inhibits E2 transcriptional transactivation activity is not clear. Recruitment of E2 
to PODs by L2 may be the underlying mechanism. PODs are sites of protein modification 
and as a result, post-translational modifications of E2 may interfere with some of its 
activities. PML has been shown to regulate transcription of certain genes in either a 
positive or negative manner. PML interacts with Spl and inhibits Spl-mediated 
transcriptional activity of the epidemial growth factor receptor promoter by dismpting 
Spl-DNA binding (Vallian et a l, 1998). Recmitment of E2 to PODs could result in PML 
interference with Spl binding to the viral LCR, which could result in repression of the 
viral promoter (Tan et al., 1994).
Another possible mechanism for E2 transcription down regulation could result from L2 
acting as a transcription repressor with the ability to actively target E2 transcription
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initiation factors or indirectly by displacing the binding of E2 responsive transcription 
factors by competing for their binding sites. The N-tenninus of L2 binds viral DNA in a 
sequence independent process (Zhou et al., 1994). Binding of L2 to viral DNA could 
interfere with the activity of transcription factors that modulate E2 mediated transcription 
initiation such as TBP, TFIIB or Spl (Li et al., 1991; Rank and Lambert, 1995). E2 binds 
TBP and has been shown to act synergistically with exogenous TBP to facilitate high- 
level transcription from a minimal promoter (Ham et al., 1991; Rank and Lambert, 1995; 
Steger et al., 1995). L2 transcription repression could involve interference with the TBP- 
TATA box interaction affecting E2 mediated transcription initiation.
L2 has been shown to assoeiate with the transcription repressor PATZ (Gomemann et al., 
2002) (Table 1.4). PATZ (POZ-AT hook-zinc finger protein) is a member of the 
BTB/POZ family (for Broad complex, tramtrack, and brie à brae and POZ for poxvims 
and zinc finger), which associates with RNF4 RING finger protein, a mediator of 
androgen receptor activity and acts as a transcription repressor (Fedele et al., 2000). 
POZ/ZF (zinc finger) proteins display a transrepressive activity in a variety of cell types 
and on various promoters (Huynh and Bardwell, 1998). As with other POZ proteins, the 
repressor activity of PATZ is mediated by its POZ domain (Fedele et al., 2000). The 
mechanisms by which transrepression by PATZ occurs still remains unclear but its 
interaction with L2 could be implicated with repression of E2 transcription 
transactivation. PATZ has been shown to localise to nuclear dot and to colocalise with 
L2. The presence of PATZ and the recmitment of E2 to PODs by L2 could result in 
PATZ transrepression of E2 activation.
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The question arises as to why L2 should act to repress the transcription transactivation 
function of E2 during the viral life cycle. Expression of L2 represents a shift from the 
maintenance stage of the viral life cycle to the productive stage as cellular differentiation 
is initiated resulting in expression of the stmctural proteins. At this stage, the expression 
of E6/E7 needs to be down-regulated to enable cellular differentiation to proceed. 
Although over-expression of E2 down-regulates transcription of E6/E7, E2 is also needed 
to enhance genome replication. Expression of L2 could assist in down-regulating E2 
transcription transactivation from the viral LCR with E2 still being able to associate with 
El in genome replication. To further enhance this hypothesis, the effect of L2 on E2 
function in DNA replication was investigated.
6.2.2. DNA replication
Papillomavimses replicate their genomes as episomal DNA using E2 and El (LaPorta 
and Taichman, 1982). E2 binds to El and promotes origin-dependent viral DNA 
replication. In this study, transient replication assays were used to investigate the effect of 
L2 on E2 function in viral replication. These assays allowed for the detection of low-level 
replication eonesponding to the maintenance stage of the viral life cycle. At this stage, 
HPV-16 DNA has been shown to replicate bidirectionally via theta stmctures (Flores and 
Lambert, 1997). With eveiy round of replication, theta stmctures require initiation 
involving E2 tethering E 1 to the origin and allowing for the recmitment of the rest of the 
DNA replication machinery. In differentiated epithelial cells HPV-16 DNA has been 
shown to replicate by a rolling cycle mode of replication which is unidirectional and
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requires one initiation event leading to amplification of PV DNA resulting in multiple 
copies of the genome (Flores and Lambert, 1997) consistent with the productive phase of 
the viral life cycle.
The effect of L2 on the ability of E2 to co-operate with El in a transient DNA replication 
assay was studied. It was shown that expression of L2 had no effect on the ability of E2 
to enhance DNA replication in C33a cells as seen in figure 3.8. This is in agreement with 
previous studies showing that BPV-1 L2 does not interfere with the replication function 
of BPV-1 E2TA (Heino et aL, 2000). These results indicate that L2 preferentially inhibits 
the transcription transactivation function of E2 in both bovine and human papillomavims 
systems with no effect on E2 function in replication. The loss of E2 function in 
transcription transactivation but not replication as a result of expression of L2 during 
productive stage of the viral life cycle is supported by data showing that E2 mutants 
which had no transcription transactivation function but retained replication activity did 
not significantly interfere with the stable maintenance of episomes, the expression of late 
genes, or the differentiation-dependent amplification of the viral genome (Stubenrauch et 
al., 1998). Altogether, these results suggest a novel function for L2 as a possible negative 
regulator of E2 transcription transactivation during cell differentiation and the viral 
genome amplification stage of the viral life cycle.
In this study a transient replication system corresponding to the maintenance stage of the 
viral life cycle was used which requires one initiation event with every round of 
replication possibly requiring more E2. In this system, no effect of L2 on E2 function in
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replication was detected. As one initiation event is expected to occur during the 
productive stage of the viral life cycle, less E2 would be required suggesting that L2 
should not affect viral DNA amplification at this stage.
HPV-11 El, E2 and replicating DNA have been shown to associate with PODs after 
transient co-transfection of the ori plasmid and expression plasmids for El and E2 
(Swindle et aL, 1999), indicating that PODs could be sites of HPV DNA replication as 
observed with Herpes Simplex vims (HSV), which foim replication compartments 
juxtaposed to PODs (Lukonis and Weller, 1997). SV40 DNA replication also occurs in 
similar POD associated foci (Ishov and Maul, 1996) suggesting that recmitment of viral 
proteins to PODs with subsequent association with viral replication could be a common 
feature among DNA vimses. Although L2 does not affect E2 function in replication, L2 
could assist in the translocation of the necessary viral proteins required for replication 
and subsequently packaging.
6.2.3. Protein Expression
E2 degradation is mediated tlii’ough the ubiquitin-proteasome pathway (Bellanger et aL, 
2001; Pem'ose and McBride, 2000). L2 down-regulates the expression of E2 in HaCaT, 
and U20S cells as well as in HaCaT cells stably expressing E2 as shown in figure 4.1. 
This effect did not occur in C33a cells suggesting a cell type dependence for L2 induced 
down-regulation of E2 expression. The presence of proteasome inhibitors failed to restore 
E2 to normal amounts leading to the conclusion that proteasome mediated degradation is 
not the only mechanism implicated in L2-induced decrease of E2 levels. As E2 mRNA 
levels were shown not to change in cells with or without L2 expression (section 4.1.2),
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down-regulation of transcription of the E2 gene by L2 can be discounted. How L2 leads 
to such a decrease in E2 levels remains unclear, particularly as this down-regulation does 
not take place in C33a cells. As E2 gene transcription is not affected by L2, a possible 
mechanism for the down regulation of E2 repression could be the inhibition of E2 protein 
translation.
Interestingly L2 had no effect on E2 protein turnover in HaCaT cells (section 4.2). Even 
though both systems used to analyse E2 stability in the presence of L2 differed with 
respect to the measurement of protein turnover, the half-life of E2 remained unchanged. 
In pulse chase experiments, the degradation of E2 results from a continuous expression of 
L2 as protein translation is not switched off. Treatment of cells with cycloheximide 
(CHX) on the other hand efficiently shuts down protein translation. As a result, the 
observed E2 half-life is due to the effect of any residual L2 present.
In both systems, L2 did not appear to change the half-life of E2. The reason why no 
change in E2 half-life in the presence of L2 was obseived even though L2 is capable of 
reducing E2 levels is unclear. The experimental protocol used allows for the 
measurement of E2 half-life only after the effect of L2 on E2 protein levels has taken 
place. As a result, residual E2 protein not affected by L2 expression has similar kinetics 
of half-life with the wild type E2. A system whereby L2 could be induced instead of co­
transfecting with E2 could result in an improved analysis of the effect of L2 on E2 half- 
life.
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The down regulation of E2 protein expression by L2 is interesting as this effect occurs in 
HaCaT and U20S cells but not in C33a cells. HaCaT aie spontaneously immortalised 
kératinocytes (Boukamp et aL, 1988) while U20S are osteosarcoma cell lines. C33a are 
cervical caicinoma derived cells, which have no HPV DNA. The difference in E2 
expression in the presence of L2 could represent differences in the model of 
carcinogenesis represented by the different cell lines used. HaCaT cells represent an in 
vitro carcinogenesis model of human skin kératinocytes while U20S cells represent a 
model for carcinogenesis of human osteocytes. C33a cells represent an in vitro model for 
ceiwical carcinogenesis. The mechanism for L2 down regulation of E2 expression in one 
cell line but not the other requires further investigation.
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6.3. HPV-16 L2 deletion mutants and E2 function
The role of L2 during the life cycle of papillomavimses is still unclear, particularly as it 
has been shown that the major stmctmal protein LI can self assemble into capsid-like 
particles (Kirnbauer et aL, 1993; Zhou et aL, 1993), suggesting that L2 is not required in 
the assembly of the viral capsid. Recent studies have begun to enhance our understanding 
of the function of L2 with reports that L2 is able to increase the efficiency of DNA 
encapsidation (Zhao et aL, 1998) and infectivity of HPV-33 peudovirions generated in 
COS-7 cells (Unckell et aL, 1997). The obseiwation that co-expression of BPV-1 L2 and 
E2 causes the redistribution of E2 into PODs (Day et aL, 1998; Heino et aL, 2000) opens 
up the possibility that L2 could posses non-stmctural functions.
To further characterise the effect of L2 on E2 function, deletion mutants of L2 were 
constructed to identify domain or domains of L2 responsible for regulating E2 function in 
transcription transactivation and the modulation of E2 expression. The domain or 
domains responsible for direct physical interaction between E2 and L2 was also 
investigated.
6.3.1. L2-E2 Association
L2 is able to affect the transcription transactivation but not replication function of E2 as 
well as reduce the level of E2 expression, as a result, the ability of L2 to physically 
interact with E2 was investigated to determine if binding of L2 with E2 correlated with 
an effect on transcription transactivation and E2 protein expression levels. In this study
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Glutathione S-transferase (GST) pull-down assays were performed using GST-L2 and 
GST-L2 deletion mutants.
To generate GST-L2 deletion mutants, both N-terminal and C-terminal deletions of HPV- 
16 L2 were constructed to yield fusion proteins with the GST moiety at the amino 
teiminus. All mutants were cloned as BamHI-EcoRl inserts into the multiple cloning site 
of the pGEX-4T-2 plasmid (Amersham) in which, expression of GST is under the control 
of the tac promoter which can be induced using isopropyl p-D thiogalactoside (IPTG). 
All mutants were subsequently expressed in BL21 E. coli, which are protease deficient 
and designed to maximize expression of full-length fusion proteins. Once all mutants 
were sequenced to confirm that the inserts were in the correct orientation, expression 
studies were perfonned to optimise fusion protein expression for each mutant. 
Optimisation of expression involved growing bacteria transformed with GST-L2 or GST- 
L2 deletion mutants at various temperatures (30-37”C), for different times (3-24 hours) 
and induction with different amounts of IPTG (0.1-ImM) in order to determine the best 
growth conditions for each mutant. Expression of full-length GST-L2 and its deletion 
mutants proved quite difficult, as L2 appeared to be very unstable. As a result, when 
bacteria were lysed and the GST fusions were analysed by SDS-PAGE and Western 
blotting, multiple bands were often seen. With subsequent manipulation of the growth 
conditions, a temperature of 37“C and an incubation time of 5-6 hours after induction 
with 0.5mM IPTG was chosen as the best expected migration of each fusion protein 
analysed after SDS-PAGE and Western blotting was obseiwed in these conditions.
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GST pull-down assays were perfonned by incubating beads bound to GST-L2 or each 
GST-L2 deletion mutant with in vitro translated ^^S-methionine labelled HPV-16 E2. The 
results indicated that GST L2 deletion mutants expressing 1-50 and 1-100 amino acids of 
L2 fused to GST showed strong binding to E2, compamble to binding with full length L2. 
This indicated that the N-teiminus of L2 mediates binding with E2. BPV-1 E2 contains 
two BPV-1 L2 interaction domains (Heino et aL, 2000). No E2 interaction domains on 
L2 have previously been identified. A 30 amino acid sequence of HPV-33 L2 between 
amino acids 390-420 is required for localisation of L2 to PODs (Becker et aL, 2003). As 
a result, we could hypothesise that L2 localises to PODs via its C-terminal portion and 
binds E2 via its N-terminus recmiting it to PODs. Recmitment of E2 subsequently results 
in the down regulation of E2 transcription transactivation leading to the down regulation 
of E6/E7 expression. Recruitment of E2 to PODs by L2 also allows for the recmitment of 
the viral replication machinery facilitating genome amplification and subsequent 
packaging and release of the mature virion (Fig 6.1). This is confiimed by studies, which 
have shown that E2 enhances packaging of full-length plasmid DNA in BPV-1 
pseudovirions (Zhao et aL, 2000). E2 increased the number of VLPs incorporating a 
circular plasmid supporting the role of L2 and E2 interaction in facilitating packaging of 
the circular PV genome in to the viral capsid.
6.3.2. Cellular localisation of GFP-L2 and GFP-L2 deletion mutants
Papillomavims late genes are inefficiently expressed in undifferentiated cells possibly 
due to the presence of codons that are rarely used in mammalian cells. This could help in 
restricting late gene expression to teiminally differentiating cells. Consequently, 
detection of L2 with eucaryotic expression plasmids designed to produce L2 in
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mammalian cells is not very efficient. L2 mRNA has negative regulatory sequences in the 
3’ end, which reduces protein levels approximately 10 fold (Sokolowski et aL, 1998). In 
an attempt to obtain an efficient detection system for visualising L2 expressed from 
transiently transfected expression plasmids, fusion foims of L2 and L2 N-terminal and C- 
teiminal deletion mutants fused to the green florescent protein (GFP) were constmcted.
Fluorescence microscopy revealed HPV-16 GFP-L2 localised to the nucleus (Fig 5.5b). 
In this study no localisation to PODs was observed, in contrast to HPV-33 GFP L2, HPV- 
6b L2 or BPV-1 L2, which have all been shown to localise to PODs (Becker et aL, 2003; 
Roden et aL, 2001; Sun et aL, 1995). Differences in localisation could be a result of 
differences in the mode of transfection. The use of recombinant vaccinia virases or 
baculoviruses is commonly used (Xi and Banks, 1991; Zhou et aL, 1991) which appears 
to result in expression levels of L2, which permit visualisation of L2 localisation to PODs 
(Becker et aL, 2003; Roden et aL, 2001; Sun et aL, 1995). Codon modification of L2 has 
also been used to detect localisation by immunofluorescence (Heino et aL, 2000). In this 
study, transient transfections with plasmids expressing wild type L2 or L2 deletion 
mutants were used resulting in high levels of protein expression not permitting 
visualisation of co-localisation of L2 with PODs although localisation to the nucleus was 
obseiwed.
The C-terminal deletion mutants all localised specifically to the nucleus with their 
distribution not differing from wild type GFP-L2. Expression of the first 50 amino acids 
of L2 fused to GFP was sufficient for localisation to the nucleus suggesting the presence
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of a nuclear localisation signal (NLS) at the N-tenninus of HPV-16 L2. In contrast, the 
N-terminal deletion mutants localised to both tlie nucleus and the cytoplasm. As the 
mutant GFP-L2 1-50 localised to the nucleus and N-teiminal deletion mutants with 
sequences either completely or partially lacking the first 50 amino acids of L2 localised 
to both the nucleus and the cytoplasm, these results indicate that the sequences contained 
within the first 50 amino acids of L2 are sufficient to localise and retain GFP in the 
nucleus. Dismption of this sequence inhibits the effective retention of GFP to the nucleus 
as obseiwed with the N-teiminal deletion mutants. HPV-6b L2 contains tlnee potential 
NLS, localised at the N-tenninus, the C-tenninus and around amino acids 286 to 306 
(Sun et aL, 1995). HPV-33 L2 also has two NLS located within the central and C- 
teiminal part of L2, homologous to HPV-6b L2 NLS (Becker et aL, 2003). From this 
study, HPV-16 L2 has been shown to have an NLS at both the N and C-terminus.
6.3.3. Expression of L2 and L2 deletion mutants in HaCaT
GFP-L2 and GFP-L2 deletion mutant expression plasmids were transfected into HaCaT 
cells and protein extracts were analysed by SDS-PAGE and Western blotting to 
deteimine the levels of expression of each mutant. Detection of GFP-L2 and its deletion 
mutants was perfoiuied using an anti-HPV-16 L2 polyclonal rabbit serum and anti-GFP 
polyclonal antibody. GFP-L2 was detected at the expected migration but multiple bands 
were also detected indicating breakdown of the fusion protein. GFP-L2 mutants 1-400, 1- 
300 and 1-200 all gave quite a high steady state levels of expression. The L2 semm could 
not efficiently detect GFP-mutants 1-100 and 1-50 possibly due to loss of the L2 epitope. 
This is confirmed by the obseiwation that both could be detected using an anti-GFP 
antibody. Detection of the GFP-L2 N-temiinal deletion mutants 25-473 and 50-473 could
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be achieved with the L2 semm but a lower steady state of expression was obseiwed. The 
L2 semm could not detect mutants 150-473, 350-473 and 390-473. This loss of detection 
could be as a result of the presence of negative regulatoiy sequences present at the C- 
tenninus of L2 mRNA, which has been shown to reduce protein levels (Sokolowski et 
aL, 1998). No detection of bands at the expected migration for all N-terminus deletion 
mutants was obseiwed using an anti-GFP antibody. Although the GFP-L2 N-terminus 
deletion mutants could not be obseiwed by Western blotting, they could be efficiently 
detected by immunofluorescence. As such it is possible that the process of cell extraction 
and SDS polyacrylamide gel electrophoresis significantly reduces the ability to detect the 
mutants by immunoblotting
6.3.4. E2 function and L2 deletion mutants
The domain or domains of L2 that mediate the down-regulation of the transcription 
transactivation function of E2 were investigated. HPV-16 L2 and L2 deletion mutants 
were cloned into pCDNA 3.1 expression plasmid. All plasmids were sequenced to 
determine that all inserts were in the correct orientation and subsequently transfected into 
HaCaT and C33a cells to deteimine the effect of each deletion mutant on the transcription 
transactivation function of E2 in order to coiielate binding of L2 and E2 with the down- 
regulation of E2 mediated transcription transactivation. In C33a cells, most mutants lead 
to a down regulation of transcription transactivation at the highest amount of L2 used 
except for mutants 1-200 and 150-473, suggesting the presence of an overlapping 
sequence between amino acids 150-200 which seems to alleviate L2 induced inhibition of 
E2 transcription transactivation. Mutants 1-50 and 1-100 had less of an effect on E2 
transcription transactivation than full length L2. Plasmids expressing 350-473 and 390-
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473 amino acids of L2 gave strong repression of transcription transactivation at the 
highest amount of L2 transfected. In HaCaT cells, mutant 1-200 did not repress 
transcription as obseiwed with C33a cells. Mutants 1-100 and 1-50 also did not repress 
transcription transactivation at least not to levels comparable with full length L2. This 
appears to indicate that in HaCaT cells, deletion of the C-terminus of L2 alleviates the 
repression of E2 mediated transcription transactivation. The N-terminal deletion mutants 
of L2 in HaCaT cells gave slightly less repression of E2 transcription transactivation, 
with mutants 50-473 and 150-473 showing no repression even at the highest level of L2.
The difficulty in using deletion mutants for such studies is the role of the protein thi'ee- 
dimensional stmcture to deteimine protein function. As a result, linear deletions could 
provide results difficult to inteipret with regard to the full-length protein although it may 
give us an understanding of the role of certain sequences within the protein. An 
alternative method would be to use site directed mutagenesis to construct mutants of L2 
which retain their three dimensional structure but with mutations in sites implicated in 
protein-DNA or protein-protein interaction.
6.3.5. L2 deletion mutants and E2 protein expression
Following on from studies examining the effect of L2 deletion mutants on the 
transcription transactivation function of L2, the effect on E2 protein expression levels 
was also examined to deteimine a correlation between binding and inhibition of 
transcription transactivation and reduction of protein level. Full-length L2 and all L2 
deletion mutants cloned into pCDNA 3.1 were co-expressed with E2 in HaCaT cells.
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Using SDS-PAGE and Western blotting, the levels of E2 after co-expression of L2 or 
each deletion mutant were analysed. It was obseiwed that the full length L2 is required for 
the down regulation of E2 expression as seen in figure 5.8. In cells co-expressing E2 and 
L2 deletion mutants, the level of E2 was not inliibited indicating that the thiee 
dimensional stmcture of the protein is required for this effect.
6.4, Summary
In summaiy, this thesis has been able to elucidate that HPV-16 L2 has a selective effect 
on the functions of HPV-16 E2. L2 is able to down regulate the transcription 
transactivation function of E2 in a cell line independent manner. No effect of L2 on E2 
mediated DNA replication was obseiwed. L2 was also able to reduce the level of E2 
expression in HaCaT and U20S cells but not in C33a cells indicating that the down- 
regulation of transcription transactivation is not due to the reduction in E2 expression 
levels. The effect of L2 on E2 expression in HaCaT cells was further investigated by 
examining the effect of L2 on E2 mRNA levels and protein half-life. No difference in E2 
mRNA or protein half-life was detected indicating that the effect of L2 on E2 protein 
expression could be an effect on E2 protein translation and not transcription.
To further investigate the effect of L2 on E2 function, a series of L2 deletion mutants 
were constmcted and GST binding assays were perfoimed to deteimine the domains of 
L2 required for direct physical interaction with E2. The first 50 amino acids of L2 was 
shown to bind in vitro translated E2 comparable to binding with full-length L2 indicating 
that the N-terminus of L2 mediates the binding of L2 with E2. To deteimine the cellular
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localisation of L2 and its deletion mutants, GFP fusion proteins were constructed and 
detected by immunofluorescence. GFP-L2 and all C-terminal deletion mutants localised 
and were retained in the nucleus. All N-terminus deletion mutants localised to both the 
nucleus and the cytoplasm indicating the presence of two NLS in the C-tenninus and N- 
terminus of HPV-16 L2. Each mutant was analysed for expression by immunoblotting 
which showed the detection of GFP-L2 and all C-terminal deletion mutants with either 
anti-L2 serum or anti-GFP antibodies. Detection of N-tenninal deletion mutants was 
difficult although mutants 25-473 and 50-473 could be detected with anti-L2 semm.
The effect of L2 deletion mutants on the transcription transactivation function of E2 was 
investigated and mutants 1-200 and 150-473 did not inhibit the transcription 
transactivation function of E2. In HaCaT cells, mutants 1-100 and 1-50 also did not 
inhibit E2 transcription transactivation indicating that the C-terminal domain of L2 could 
be responsible for the down regulation of E2 function in transcription transactivation. 
Deletion of the carboxyl and amino temiinus of L2 did not result in the reduction of E2 
expression levels, only full length L2 was able to reduce the level of E2 expression 
indicating the requirement of the secondary stmcture of the protein for this effect.
The full-length L2 protein, which localises to the nucleus binds E2, down regulates its 
transcription transactivation function but not replication and is able to reduce the level of 
E2 protein expression as summarised in Table 6.1. Binding with E2 does not correlate 
with the down regulation of transcription transactivation as L2 mutants 1-50, 1-100 and 
1-200 all bind E2 but do not (especially in the case of HaCaT cells) down regulate E2
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transcription transactivation. Binding also does not correlate with down-regulation of E2 
expression as only full length L2 is able to reduce E2 expression levels while mutants 1 - 
50, 1-100, 1-200 and 1-400 which all bind E2 do not affect E2 protein expression.
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Table 6.1. Summary of the characterisation of L2 deletion mutants. Table shows the 
summary of the characterisation of L2 and the L2 deletion mutants indicating domains 
involved with binding of L2 with E2, cellular localisation, mutants involved with down- 
regulating E2 transcription transactivation and the effect of each mutant on E2 protein 
expression levels.
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Summary of L2 deletion mutants
HPV-16 L2 
amino acid 
sequence
Binding 
with E2
Cellular
Localisation
Down
regulation of 
HPV-16 E2 
transcription 
transactivation
Down
regulation of 
HPV-16 E2 
expression
L2 Yes Nuclear Yes Yes
l “50aa Yes Nuclear Yes/No No
l"100aa Yes Nuclear Yes/No No
l-200aa Yes Nuclear No No
l-300aa Yes (Low) Nuclear Yes No
l-400aa Yes Nuclear Yes No
25-473aa No Nuclear/cytoplasmic Yes No
50-473 aa No Nuclear/cytoplasmic Yes No
150-473aa No Nuclear/cytoplasmic No No
250-473aa No Nucl ear/cytoplasmic Yes No
350-473aa No Nuclear/cytoplasmic Yes No
390-473aa No Nuclear/cytopl asmi c Yes No
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6.5. E2, L2, PODs and the viral life cycle
The life cycle of papillomavims is intimately tied to the differentiation of the 
keratinocyte (Fig 1.4). The early stages of the vims life cycle take place in the lower 
layers of the epithelium and, according to a widely accepted paradigm, include 
maintenance of the viral DNA as an episome. This requires the expression of low levels 
of El and E2. In addition to its involvement in episomal DNA maintenance, E2 
transactivates the early viral transcriptional promoter (Bouvard et aL, 1994) and initiates 
the expression of the transfoiming genes E6/E7, responsible for the induction of 
unscheduled cell proliferation (Fig 1.7). No L2 is expressed in these epithelial layers, as 
teiminal differentiation is not initiated. The inhibition of teiminal differentiation of 
promyleocytes has been obseiwed to be associated with the dismption of PODs as a result 
of the fusion of PME with the retinoic acid receptor a (Grignani et aL, 1993). A similar 
dismption of PODs in papillomavims infected kératinocytes would, in conjunction with 
the expression of the transforming proteins, delay cell differentiation and favour cell 
proliferation, as in myeloid cells (Wang et aL, 1998a), thus helping the vims replicate its 
DNA.
As the infected kératinocytes progress from the lower layers to the more superficial ones, 
the expression levels of E2 increase up to the stratum spinosum, above which E2 is no 
longer detected (Pemose and McBride, 2000). Fligh levels of E2 repress the early 
promoter (Bouvard et aL, 1994; Steger and Corbach, 1997), thus down-regulating 
expression of the transforming genes and favouring cell differentiation and expression of 
the stmctural proteins. In the differentiating superficial layers, L2 is expressed and
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contributes to the reduction in E2 transcriptional control function while the maintenance 
of its replication functions would help the production of mature virus. The recmitment of 
E2 to PODs by L2 could represent a switch in the vims life cycle from the non­
productive to the virion productive phase as suggested by Heino et aL, (2000). E2 has a 
high affinity for the viral DNA, and it has been proposed that the recmitment of E2 into 
PODs directs the viral genomes into regions of high concentrations of stmctural proteins, 
so helping DNA encapsidation and virion assembly (Day et aL, 1998). The set of 
hypotheses outlined above requires that, although believed to function at different stages 
of the viral life cycle and in different layers of the epithelium, E2 and L2 are co­
expressed and interacting during keratinocyte differentiation. The proposed outcome of 
the L2-E2 interaction is shown diagrammatic ally in Fig 6.1. In conclusion, the interaction 
between E2 and L2 obseiwed for BPV-1 and now for HPV-16 elucidating the effect of L2 
on E2 function in transcription transactivation and replication, suggests that this may be 
part of a common function or phase in papillomavims life cycle, and therefore not merely 
a peculiarity of cultured cells
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Figure 6.1. Cartoon showing the possible role for L2-E2 interaction during the viral 
life cycle. Recruitment of E2 to PODs by L2 leads to a down regulation of transcription 
of E6 and E7 and the possible recruitment of the cellular DNA replication machinery as 
E2 mediated DNA replication is not affected. Subsequently recruitment of LI to PODs by 
L2 would allow for packaging of replicated viral DNA resulting in the release of mature 
vims.
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6.6. Future Work
The effect of L2 on the functions of E2 raises some interesting questions that would be of 
immense interest for future experiments. Firstly, the ability of L2 to down regulate the 
transcription transactivation function of E2 in transient transcription assays requires 
further investigation to elucidate the mechanism of action of L2 in this process. As L2 
has been shown to associate with a known transcription repressor PATZ, the effect of 
PATZ in this process is of interest. Transient transcription assays would be used, co­
transfecting E2 with PATZ to study the effect of PATZ on E2 transcription 
transactivation. This has been observed for co-expression of PATZ and RNF4 resulting in 
a strong repression of RNF4-mediated activation (Fedele et aL, 2000). The effect of 
PATZ on the activity of the LCR would also be of interest. The association of PATZ with 
L2 may be flirther investigated to deteimine if an increase in L2 expression results in a 
subsequent rise in PATZ levels. As L2 associates with PATZ at PODs (Gomemann et aL, 
2002), the correlation between L2 localisation to PODs and down-regulation of 
transcription transactivation would also be examined to determine if the effect of a 
possible L2-PATZ interaction is dependent on localisation to PODs.
In this study, deletion mutants of L2 were used to analyse the domain or domains of L2 
required for the modulation of E2 function or for mapping sites required for the physical 
interaction of L2 with E2. Although this provided useful infoimation for understanding 
L2 effect on E2 function, it failed to provide a full-length mutant of L2 that does not bind 
E2. Such a mutant would provide a useful tool to further understand the role of L2 on E2 
function in transcription transactivation, replication and E2 protein expression. This could
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be achieved by site directed mutagenesis of the N-terminal domain of L2 responsible for 
binding to E2.
In this study, the effect of L2 on E2 function was observed in monolayers with the use of 
HaCaT, C33a and U20S cell lines, a system which will facilitate the study of the effect 
of L2-E2 localisation to PODs on viral transcription during cell differentiation will 
provide an effective tool to obseiwe this interaction in an in vivo situation. W12, which 
are, immortalised kératinocytes derived from low-grade ceiwical intraepithélial neoplasia 
biopsy, containing episomal HPV-16 genomes (Sterling et aL, 1990) will be used to 
establish organotypic raft cultures. W12 cells can differentiate and foim ordered layers of 
differentiating cells in organotypic raft cultures which can be assessed by production of 
differentiation markers, late viral proteins and viral capsids (Sterling et aL, 1990). In raft 
cultures, kératinocytes are grown submerged on a bed of collagen containing fibroblasts 
and when the culture is raised to the liquid-air interface, the kératinocytes undergo 
differentiation. This will provide the possibility to follow events in the individual layers 
of a differentiating epithelium by histological teclmiques
To study the effect of L2 on E2 activity during differentiation, cells expressing E2 and L2 
will be transfected with the LCR reporter constructs driving expression of green 
fluorescent protein (GFP) or P-galactosidase markers and grown on raft cultures. The use 
of a GFP reporter will allow analysis by confocal microscopy of regulated viral gene 
expression in the layers of the raft culture. These studies will be complemented by 
analysis of transactivation of the LCR by staining sections of raft cultures for (3-
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galactosidase. Serial sections will be analysed for expression of the differentiation 
markers keratin 1, involucrin and filaggrin. The results should establish if an interaction 
between an early and a late protein changes LCR activity. This would suggest that in vivo 
the interplay between early and late proteins could change the viral gene expression 
program, perhaps helping to sustain the switch from early promoter transcription to late 
promoter transcription during keratinocyte differentiation.
The loss of PML from PODs leads to loss of PML functions (Zhong et aL, 2000) and 
possibly preventing differentiation of kératinocytes in analogy to maturation aiTcst of 
myeloid cells in acute promyelocytic leukaemia (APL). In APL cells, the PML gene is 
disabled by a translocation with the gene for the retinoic acid receptor (Stemsdorf et aL, 
1997). It has been shown that fibroblasts from PML' '^ mice lacking PODs exhibit an 
increased proportion of cells in S phase and display a marked growth advantage 
compared to PML^^  ^ cells (Wang et aL, 1998b). The loss of PML will be of immense 
benefit to certain viruses such as papillomavimses, which require a delay in cell 
differentiation supporting the maintenance stage of the viral life cycle. To deteiTnine the 
role of PML in the effect of L2 on E2 function in transcription transactivation, PML' '^ and 
PML’^ ’^^ cells will be used in E2 dependent transient transcription assays, co-transfecting 
E2 with increasing concentrations of L2. PML has been shown to be a tumour suppressor 
with PML" '^ mice giving rise to more papillomas than PML'*"'^  ^ mice, with papillomas 
occasionally progressing to carcinomas after several months (Wang et aL, 1998b). The 
level of E2 expression in PML' '^ and PML"^ "^^  cells co-expressing E2 and L2 will be 
examined to deteimine if PML is required for L2 mediated reduction in E2 protein
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expression levels. Also transient DNA replication assays will be performed in PM Y' and 
cells, which will be able to further elucidate the role of PML and PODs to 
papillomavims DNA replication with the hypothesis that the presence of PML and hence 
PODs will enhance the level of viral DNA replication.
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